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General introduction  





…‘’steep increase human Q fever in The Netherlands’’ 
‘’it is possible that Q fever is endemic in Brabant; other regions should also be 
alert’’ 
‘’an association has been found between the human Q fever cases and 
intensive goat farming in this region’’ 
 ‘’this situation raises the question whether the government can and should 
take preventive measures to prevent human disease’’ 
‘’questions raise about the need to screen asymptomatic pregnant women’’ 
 ‘’knowledge is lacking, but the Dutch situation is an opportunity to provide 
answers to a wide range of questions’’… 
 
…some statements selected from the advice written by the Health Council of 
The Netherlands to the Ministry of Health, Welfare and Sport at the end of 
2008.1 What kind of disease is threatening us? And what are the risks and 
implications for pregnant women in specific? 
 
Query fever 
Query (Q) fever is a zoonosis, caused by the bacterium Coxiella burnetii. It was 
first investigated by Derrick and colleagues after an outbreak in abattoir 
workers in Brisbane, Queensland, Australia in 1935. Derrick proposed the term 
‘’Q fever’’ (for query fever) to describe this febrile illness caused by an 
unknown microorganism.2 He attempted to isolate the etiological agent of the 
disease, but did not succeed. Derrick sent some infectious material to his 
college Burnet, who continued the quest. Independently of the group of 
Burnet, Cox and colleagues were investigating the ecology of Rocky Mountain 
spotted fever in Montana, USA. The connection between the groups in 
Montana and Brisbane arose when a laboratory-acquired Q fever infection 
occurred in the Rocky Mountain Laboratory in 1938. Cox and Burnet were the 
first who identified the etiological agent of Q fever as a new rickettsial species, 
which from then on was named Rickettsia burnetii. Later this was changed to 
Coxiella burnetii, a name that honours both researchers.3 
 
Coxiella burnetii 
C. burnetii is a small gram-negative intracellular living bacterium that is 
prevalent throughout the world.3 Domestic ruminants are considered to be the 
main reservoir for Q fever in humans, although other animal species, including 
pet animals, birds and reptiles may also be responsible for human cases.3 The 
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role of vectors, especially tics is unclear (Fig. 1).4 Human-to-human transmission 
is very rare. There are a few cases described in the literature on maternal-foetal 
transmission across the placenta5, transmission by amniotic fluid and placental 
tissue6, trough breastfeeding7, blood transfusion8, or sperm.9 The main route for 
transmission is the respiratory route, in which alveolar macrophages in the lungs 
are likely the first cells to be infected. A small part of people with Q fever is 
infected by the digestive route with Kupffer cells in the liver as the target cells.3 
After passive entry in the host cells using specific receptors like integrins, C. 
burnetii enters phagocytic vesicles which fuse rapidly to phagolysosomes. The 
phagolysosomes fuse progressively to form a large acidic vacuole. C. burnetii’s 
metabolism and multiplication is enhanced by the acidic pH in this vacuole 
and will be stopped with increasing the phagolysosomal pH.10 
C. burnetii is characterised by antigenetic phase variation, which is 
mainly caused by mutational variation in the lipopolysaccharide (LPS).11 Phase 
I is highly infectious and is the natural phase found in infected animals and 
humans. Phase II is less infectious and is obtained only in laboratories after serial 
passages in cell or embryonated egg cultures.3 In humans this antigenetic 
phase variations is especially important in serodiagnosis, which will be 
discussed later in this introduction.  
Encysted ‘’spores’’ of C. burnetii have the ability to survive for 
prolonged periods in dry environmental dust and are highly resistant to 
disinfectants. Together with the low infective dose, airborne transmission, easily 
accessible sources and the ability to cause serious illness in large groups of 
people, C. burnetii has been considered a potential weapon for bioterrorism.4  
 










Reprinted from Cutler SJ, 
Paiba GA, Howells J, Morgan 
KL. Q fever – a forgotten 
disease? Lancet. 2002;2:717-
718. Copyright (2002), with 
permission from Elsevier. 
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Clinical signs and symptoms 
Following exposure to C. burnetii, after an incubation time ranging from 1 to 3 
weeks12, non-immune persons may develop an acute primary infection that is 
asymptomatic in 60% of the cases. A majority of symptomatic patients 
experience a mild self-limiting flu-like illness or isolated fever. Others present 
with atypical pneumonia or hepatitis.13 Meningitis, meningioencephalitis, 
myocarditis and pericarditis have also sporadically been described.14 Besides 
acute infections C. burnetii also has the ability to induce chronic infections, 
characterised by endocarditis in 78% of the cases.13 The severity of disease 
largely varies between hosts. Younger age and female sex seem to be 
protective factors for symptomatic disease15,16, whereas immunocompromised 
patients, patients with cardiac valve or vascular diseases and pregnant 
women have been reported to have an increased risk to develop chronic Q 
fever.3  
 
Diagnosis of Q fever 
There are several methods to diagnose Q fever including culture, DNA 
amplification and several serological assays. There is a great difference in 
simplicity and safety between these methods.17 Since C. burnetii is very 
infectious, isolation of the bacterium should only be performed in biosafety 
level 3 laboratories. Under these cicumstances, the process of inoculation and 
isolation is laborious and therefore not part of the standard diagnostic work up. 
Polymerase chain reaction (PCR) has successfully been used to detect C. 
burnetii DNA in clinical samples.18 PCR results are only positive in a short period 
after the primary infection and during certain phases of chronic Q fever. PCR is 
therefore especially useful in early diagnosis of both acute and chronic Q 
fever, but can not be used in the setting of screening.19 
 Because of its simplicity and safety, in most instances the diagnosis of Q 
fever relies upon serology. There are several serological assays, including micro-
agglutination, complement fixation, enzyme-linked immunosorbent assay 
(ELISA) and indirect immunofluorescence assay (IFA).17 Currently, IFA is the 
reference method.20 Since one of the characteristics of C. burnetii is 
antigenetic phase variation, antibodies against the two phases can be 
distinguished.20 In acute Q fever IgM antibodies against phase II antigens are 
the first to appear, followed by IgM phase I and IgG phase II in one to two 
weeks. Finally, weeks to months after the primary infection IgG phase I will 
appear. All antibodies may persist for many months to even years (Fig. 2).21,22 
Persisting high levels of IgG phase I, mostly in combination with high IgG phase 
II antibodies, are suggestive for chronic Q fever infection.20,23 Due to this 
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timeframe distinguishing  previous, acute and chronic infections is possible. 
 
Figure 2. Idealised antibody responses measured by indirect 
immunofluorescence assay. 
 
PCR, polymerase chain reaction. Adapted from: Marmion BP. Q fever: Your Questions 
answered. St Leonards, N.S.W, MediMedia Communications, 1999. 
 
Treatment 
Since C. burnetii is an intracellular living bacterium treatment is challenging. In 
the general population the first choice treatment for symptomatic acute Q 
fever consists of doxycycline 100mg twice a day for at least 14 days.3,24 In a 
randomised controlled trial25 and in retrospective studies, doxycycline 
outperformed other antibiotics including erythromycin.26,27 Research on newer 
macrolides and fluoroquinolones looks promising but has not ended yet.26,28,29 
In case of chronic Q fever with endocarditis antibiotic treatment 
recommendations vary from 18 months to life-long. Doxycycline should be 
combined with the lysosomotropic agent hydroxychloroquine to increase the 
efficacy of doxycycline bij increasing the phagolysosomal pH.3,30 Whether 
asymptomatic serological profiles suggesting chronic Q fever, without 
cardiovascular or other physical complications, should be treated, is not clear.     
 
Human vaccine prophylaxis 
Despite that there are several animal vaccines available, there is only one Q 
fever vaccine (Q-Vax, Commonwealth Serum Laboratories Limited) available 
for humans. This vaccine is registered in Australia and is given to the Australian 
population with the highest occupational exposure to C. burnetii (mainly 
abattoir workers).3 Although highly immunogenic, this vaccine may induce 
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adverse effects, especially when administered in previously infected persons.31 
Since efficacy and safety have predominantly been investigated in the 
specific group of abattoir workers32,33, this crucial information is lacking for the 
general population and for specific groups at risk, including pregnant women. 
 
Q fever during pregnancy 
Both symptomatic and asymptomatic C. burnetii infection during pregnancy 
have been associated with adverse pregnancy outcomes.5,34,35 A milestone 
hospital-based study from France showed that 81% of the pregnant women 
with untreated Q fever had a miscarriage, premature delivery, intrauterine 
growth restriction or foetal death. Furthermore, 50% of the maternal infections 
were followed by a chronic infection, in 10% with C. burnetii endocarditis. 
These complications seemed to be related to placental infection with C. 
burnetii. Both obstetric and maternal complications were found to occur more 
often in pregnant women infected during their first trimester of pregnancy than 
in those infected later.34 In another study from Canada C. burnetii seropositive 
parturient women had a twice as high risk for adverse pregnancy outcome 
including premature delivery and prior or current neonatal death.35 These 
figures are alarming and emphasise that C. burnetii infection is a potential 
threat to pregnant women and their foetus. Long-term antibiotic treatment 
during pregnancy has been shown to deminish C. burnetii related 
complications.34 Cotrimoxazole for at least five weeks has been put forward as 
the first choice treatment during pregnancy, since doxycycline and 
hydroxychloroquine are contraindicated from the second trimester of 
pregnancy.34 
 Since most of the pregnant women with a C. burnetii infection remain 
asymptomatic (up to 90% compared to 60% in the general population13,36) and 
infections during as well as prior to pregnancy may lead to complications, 
preventive policies based on clinical symptoms are not useful. Instead, routine 
serological screening during pregnancy in endemic areas for Q fever could be 
of great value to prevent complications in this potential high-risk group, but 
evidence from randomised trials is lacking. 
 
The Dutch Q fever epidemic 
In The Netherlands Q fever became a notifiable disease in 1978. However, prior 
to 2007 the number of notifications of symptomatic (fever, pneumonia or 
hepatitis), laboratory confirmed cases was low; between 10 and 20 cases 
each year.37 In 2007 these numbers briskly increased many-fold to 168.38 A 
human outbreak around an infected goat farm in the Southeast was held 
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responsible for this increase.39,40 In the following years there was a steep 
increase in notified cases to over 2300 in 2009 and the high-risk area in the 
South-eastern part of The Netherlands expanded to adjacent regions (Fig. 3).41 
Because of an increased awareness of Q fever among general practitioners, 
diagnostic bias may in part have led to the high number of notified cases in 
2008 and 2009. However the major cause of the increase seems to be the 
increasing numbers of infected dairy goat and sheep farms causing both 
symptomatic and asymptomatic human cases.42 Other European countries, 
such as Belgium, Cyprus and Germany also reported an increasing number of 
Q fever cases since 2007, although to a much smaller extent.43 
The enormous magnitude of the Dutch outbreak led to several 
meetings of the Dutch Outbreak Management Team (OMT) and the Health 
Council of The Netherlands. Preventive measures in general and for risk groups, 
like pregnant women, in specific were discussed to curb the epidemic. At the 
end of 2008 the Health Council advised the Ministry of Health, Welfare and 
Sport to facilitate studies to inform decision makers about the possible value of 
screening pregnant women for C. burnetii infection. They considered the results 
of previous studies on C. burnetii associated risks to be alarming, but 
information on the prevalence in, and the potential benefits and harms 
associated with screening of this potential high-risk group, were lacking.1  
This thesis will focus on the topic of screening for C. burnetii infection 
during pregnancy. The main objective was to assess the effectiveness of large-
scale routine serological screening for C. burnetii infection during pregnancy in 
Q fever high-risk areas. 
 
Figure 3. Human Q fever incidence/100,000 inhabitants per municipality in The 










The dark line shows the dairy goat and 
dairy sheep mandatory vaccination 
area in 2009. (Compiled by the National 




OUTLINE OF THE THESIS 
 
The studies in this thesis will discuss the lessons we can learn from the Dutch Q 
fever epidemic between 2007 and 2010, focusing on infection during 
pregnancy. It starts in Chapter 2 at the level of the consulting room, with one 
pregnant woman with chronic Q fever. We describe the problems of this 
individual patient and discuss the challenges for here caregivers, substantiated 
with theoretical background. The thesis will continue with the large regional Q 
fever outbreak and the emerging questions concerning this infection during 
pregnancy. What are the risks? Is there evidence to promote routine screening 
of asymptomatic pregnant women? And are tests and treatment available? In 
Chapter 3 we try to give answers based on a literature search. Subsequently, 
the study protocol and results of our clustered randomised controlled trial on 
the effectiveness of routine screening for Q fever during pregnancy are 
presented (Chapter 4 and Chapter 5). In Chapter 6 the focus is on the role of 
positive Coxiella burnetii serology in the prediction of adverse pregnancy 
outcomes. After these epidemiological based studies, Chapter 7 and Chapter 
8 concern more basic research on placental histopathology after C. burnetii 
infection and specificity of the indirect immunofluorescence assay, 
respectively. Since the success of a screening program will not only be based 
on medical effectiveness, Chapter 9 focuses on risk perception and the 
psychological aspect concerning Q fever during pregnancy. We aim to 
identify determinants which are crucial in the decision of pregnant women to 
participate in a (fictional) Q fever screening program. Finally, in Chapter 10 a 
meta-analysis on the effectiveness of human Q fever vaccination, a more 
preventive strategy to curb the epidemic, is presented. The thesis will end with 
a general discussion (Chapter 11).  
  
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS 
17 
 
  1  
REFERENCES 
 
1. Health Council of The Netherlands [http://www.gezondheidsraad.nl/nl/adviezen/ 
briefadvies-bijeenkomst-over-q-koorts-nederland]. 
2. Derrick EH. “Q” fever, new fever entity: clinical features, diagnosis and laboratory 
investigation. Med J Aust. 1937;2:281–299. 
3. Maurin M, Raoult D. Q fever. Clin Microbiol Rev. 1999;12:518-553. 
4. Cutler SJ, Paiba GA, Howells J, et al. Q fever – a forgotten disease? Lancet Infect Dis. 
2002;2:717–718. 
5. Stein A, Raoult D. Q fever during pregnancy: a public health problem in Southern 
France. Clin Infect Dis. 1998;27:592-596. 
6. Raoult D, Stein A. Q fever during pregnancy – a risk for women, fetuses, and 
obstetricians. N Engl J Med. 1994;330:371. 
7. Kumar A, Yadav MP, Kakkar S. Human milk as a source of Q fever infection in breast-
fed babies. Indian J Med Res. 1981;73:510-512. 
8. Canadian Diseases Weekly Report. Comment on Q fever transmitted by blood 
transfusion-United States. Can Dis Wkly Rep. 1977;3:210. 
9. Milazzo A, Hall R, Storm PA, et al. Sexually transmitted Q fever. Clin Infect Dis. 
2001;33:399-402. 
10. Hackstadt T, Williams JC. Biochemical stratagem for obligate parasitism of eukaryotic 
cells by Coxiella burnetii. Proc Natl Acad Sci USA. 1981;78:3240–3244. 
11. Hackstadt T, Peacock MG, Hitchcock PJ, et al. Lipopolysaccharide variation in 
Coxiella burnetii: intrastrain heterogeneity in structure and antigenicity. Infect. 
Immun. 1985;48:359–365. 
12. Marrie TJ. Acute Q fever, p. 125–160. In: Marrie TJ, editor. Q fever, vol. 1. The disease. 
CRC Press, Inc., Boca Raton, Fla. 1990. 
13. Raoult D, Marrie TJ, Mege JL. Natural history and pathophysiology of Q fever. Lancet 
Infect Dis. 2005;5:219-226. 
14. Raoult D, Tissot-Dupont H, Foucault C, et al. Q fever 1985–1998—clinical and 
epidemiologic features of 1,383 infections. Medicine (Baltimore). 2000;79:109–123. 
15. Maltezou HC, Raoult D. Q fever in children. Lancet Infect Dis. 2002;2:686–691. 
16. Leone M, Honstettre A, Lepidi H, et al. Effect of sex on Coxiella burnetii infection: 
protective role of 17beta-estradiol. J Infect Dis. 2004;189:339–345. 
17. Fournier P, Marrie TJ, Raoult D. Diagnosis of Q fever. J Clin Microbiol. 1998:36;1823-
1834. 
18. Stein A, Raoult D. Detection of Coxiella burnetii by DNA amplification using 
polymerase chain reaction. J Clin Microbiol. 1992;30:2462–2466. 
19. Schneebergen PM, Hermans MHA, Van Hannen EJ, et al. Real-Time PCR with serum 
samples is indispensable for early diagnosis of acute Q fever. Clin Vaccin Immunol. 
2010;17:286–290. 
20. Tissot-Dupont H, Thirion X, Raoult D. Q fever serology: cutoff determination for 
microimmunofluorescence. Clin Diagn Lab Immunol. 1994;1:189-196. 
21. Dupuis G, Péter O, Peacock M, et al. Immunoglobulin responses in acute Q fever. J 
Clin Microbiol. 1985;22:484-487. 
 18 
 
22. Marmion BP. Q fever: Your Questions answered. St Leonards, N.S.W, MediMedia 
Communications, 1999. 
23. Wagner-Wiening C, Brockmann S, Kimmig P. Serological diagnosis and follow-up of 
asymptomatic and acute Q fever infections. Int J Med Microbiol. 2006;296:294-296.  
24. Parker NR, Barralet JH, Bell AM. Q fever. Lancet. 2006;367:679-688. 
25. Sobradillo V, Zalacain R, Capelastegui A, et al. Antibiotic treatment in pneumonia 
due to Q fever. Thorax. 1992;47:276–278. 
26. Gikas A, Kofteridis DP, Manios A, et al. Newer macrolides as empiric treatment for 
acute Q fever infection. Antimicrob Agents Chemother. 2001;45:3644–3646. 
27. Domingo P, Munoz C, Franquet T, et al. Acute Q fever in adult patients: report on 63 
sporadic cases in an urban area. Clin Infect Dis. 1999;29: 874–879. 
28. Dumler SJ. Q fever. Curr Treat Options Infect Dis. 2002;4:437–445. 
29. Rolain JM, Maurin M, Raoult D. Bacteriostatic and bactericidal activities of 
moxifloxacin against Coxiella burnetii. Antimicrob Agents Chemother. 2001;45:301–
302. 
30. Raoult D, Houpikian P, Tissot-Dupont H, et al. Treatment of Q fever endocarditis: 
comparison of 2 regimens containing doxycycline and ofloxacin or 
hydroxychloroquine. Arch Intern Med. 1999;159:167–73. 
31. Bell JF, Lackman DB, Meis A, et al. Recurrent reaction at site of Q fever vaccination 
in a sensitized person. Mil Med. 1964;129:591–595. 
32. Chiu CK, Durrheim DN. A review of the efficacy of human Q fever vaccine registered 
in Australia, N S W Public Health Bull. 2007;18:133–136. 
33. Gilroy N, Formica N, Beers M, et al. Abattoir-associated Q fever: a Q fever outbreak 
during a Q fever vaccination program. Aust N Z J Public Health. 2001;25:362–367. 
34. Carcopino X, Raoult D, Bretelle F, et al. Managing Q fever during pregnancy: the 
benefits of long-term cotrimoxazole therapy. Clin Infect Dis. 2007;45:548-555. 
35. Langley JM, Marrie TJ, Le Blanc JC, et al. Coxiella Burnetii seropositivity in parturient 
women is associated with adverse pregnancy outcomes. Am J Obstet Gynecol. 
2003;189:228-232. 
36. Tissot-Dupont H, Vaillant V, Rey S, et al. Role of sex, age, previous valve lesion and 
pregnancy in the clinical expression and outcome of Q fever after a large outbreak. 
Clin Infect Dis. 2007;44:232-237. 
37. Van Lier EA, Rahamat-Langendoen JC, van Vliet JA. State of infectious diseases in 
The Netherlands 2006 [in Dutch]. RIVM Rapport 210211002/2007. 
38. Van der Hoek W, Dijkstra F, Schimmer B, et al. Q fever in the Netherlands: an update 
on the epidemiology and control measures. Euro Surveill. 2010;15:12. 
39. Karagiannis I, Schimmer B, Van Lier A, et al. Investigation of a Q fever outbreak in a 
rural area of The Netherlands. Epidemiol Infect. 2009;137:1283–1294. 
40. Van Steenbergen JE, Morroy G, Groot CAR, et al. An outbreak of Q fever in The 
Netherlands - possible link to goats. Ned Tijdschr Geneeskd. 2007;151:1998-2003. 
41. Roest HI, Tilburg JJ, Van der Hoek W, et al. The Q fever epidemic in The Netherlands: 
history, onset, response and reflection. Epidemiol Infect. 2011;139:1-12. 
42. Dijkstra F, Hoek W, Wijers N, et al. The 2007-2010 Q fever epidemic in the Netherlands: 
characteristics of notified acute Q fever patients and the association with dairy goat 
farming. FEMS Immunol Med Microbiol. 2012;64:3-12. 
GENERAL INTRODUCTION AND OUTLINE OF THE THESIS 
19 
 
  1  
43. European Centre for Disease Prevention and Control (ECDC). Annual 












Chronische Q-koorts tijdens de 
zwangerschap (casuїstiek)  
 
























Janna M. Munster 
Carl J.C.M. Hamilton 
Alexander C.A.P. Leenders 





Een 42-jarige vrouw werd ter controle van een doorgemaakte pneumonie 
gezien door de longarts. Die constateerde dat de pneumonie een uiting was 
geweest van een acute Q-koortsinfectie. Enkele weken later bleek patiënte 
onverwacht zwanger te zijn. Bij de reguliere serologische follow-up 6 maanden 
na de primaire infectie werd de diagnose ‘chronische Q-koorts’ gesteld. Voor 
behandeling met doxycycline en hydroxychloroquine was er een contra-
indicatie vanwege de zwangerschap en patiënte bleek allergisch te zijn voor 
co-trimoxazol. Op empirische gronden werd daarom gekozen voor 
behandeling met erytromycine. Patiënte ervoer veel klachten tijdens de 
zwangerschap. Op maternale indicatie werd de bevalling bij een 
amenorroeduur van 38 weken en 2 dagen ingeleid. Patiënte beviel uiteindelijk 
middels sectio caesarea van een gezonde zoon van 3850 g. In verband met 
een verhoogd risico op chronische Q-koorts tijdens de zwangerschap, 
adviseren wij ook na een acute infectie vlak vóór de zwangerschap de 
serologische controles te intensiveren. 




  2 
INTRODUCTIE 
 
Sinds 2007 kampt Nederland met een Q-koortsuitbraak van ongekende 
omvang.1 Acute Q-koorts wordt gekenmerkt door koorts, hepatitis of 
pneumonie, maar kan ook asymptomatisch verlopen. De ziekte wordt 
veroorzaakt door de bacterie Coxiella burnetii. Q-koorts kan leiden tot een 
chronisch ziektebeeld, waarbij endocarditis of infecties van vasculaire 
structuren ontstaan. De kans op het ontwikkelen van chronische Q-koorts is 
groter bij immuungecompromitteerden, patiënten met pre-existent klep- of 
vaatlijden en zwangeren.2 Eerder verscheen in het Tijdschrift een artikel over 
een vaatpatiënt met chronische Q-koorts.3 Naast het verhoogde risico op 
chronische Q-koorts zijn er bij zwangeren met Q-koorts mogelijk ook risico’s 
voor de foetus, voornamelijk bij infecties vroeg in de zwangerschap.4 Als deze 
zwangeren niet worden behandeld, bestaat er een verhoogde kans op 
abortus, vroeggeboorte, groeirestrictie en intra-uteriene vruchtdood.5 In dit 






Patiënt A, een 42-jarige vrouw, bezocht ter controle de longarts na het 
doormaken van een pneumonie. De arts vond geen bijzonderheden, behalve 
positieve serologische uitslagen voor C. burnetii. Patiënte vertelde daarop 
inderdaad in contact te zijn geweest met geiten in een gebied waar Q-koorts 
voorkwam. De antibiotische therapie die zij inmiddels had voltooid, was niet 
optimaal voor de behandeling van Q-koorts, maar patiënte ervoer op dat 
moment geen klachten meer. Er werd een afspraak gemaakt voor de 
standaard serologische follow-up na 3, 6 en 12 maanden om een chronische 
infectie uit te sluiten (zie uitlegkader). 
Enkele weken laten bleek patiënte onverwacht zwanger te zijn. Bij 15 weken 
amenorroeduur werd er vanwege haar leeftijd een vruchtwaterpunctie 
verricht. Er waren geen aanwijzingen voor chromosomale afwijkingen en de 
PCR op C. burnetii in het vruchtwater was negatief. Serologisch onderzoek na 
3 maanden toonde geen aanwijzingen voor een chronische infectie. Zes 
maanden na de primaire infectie (25 weken amenorroe) waren de 
antilichamen echter fors gestegen (IgG fase I van 1:256 naar 1:4096 en IgG 
fase II van 1:4096 naar 1:16.384; zie uitlegkader). Daarnaast was de PCR op C. 
burnetii in het serum positief, wat de diagnose ‘chronische Q-koorts’ 
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bevestigde.6 De patiënte kreeg co-trimoxazol, maar reageerde daar allergisch 
op met roodheid en koorts. Op empirische gronden werd co-trimoxazol 
vervangen door erytromycine, waarna de serologische waarden niet verder 
doorstegen. Wel had patiënte in het derde trimester klachten zoals moeheid, 
dyspneu en gewichtsverlies, die duidelijk ernstiger waren dan in haar 
voorgaande 2 zwangerschappen. De groei van de foetus was conform de 
zwangerschapstermijn. Bij een amenorroeduur van 38 weken en 2 dagen werd 
patiënte op maternale indicatie ingeleid. Bij 3 cm ontsluiting besloot de 
gynaecoloog op verdenking van foetale nood een secundaire sectio 
caesarea te verrichten. In verband met mogelijke infectiositeit van de 
placenta en het vruchtwater gebeurde dit onder strikte hygiënische 
maatregelen.5 Het jongentje dat geboren werd woog 3850 g (P90) en maakte 
een goede start. PCR liet zien dat placenta en vruchtwater positief waren voor 
C. burnetii; navelstrengbloed en perifeer bloed van de pasgeborene waren 
negatief. Bij het verlosteam werd geen Q-koorts vastgesteld. 
Post partum begon patiënte met doxycycline en hydroxychloroquine. Het 
geven van borstvoeding werd haar afgeraden vanwege mogelijke verticale 
transmissie van C. burnetii.7 Echoscopie toonde geen endocarditis en 
vasculaire problematiek aan en een PET-scan toonde geen traceractiviteit in 
de uterus, wat er op wees dat ook daar geen infectie speelde. Desondanks 
bleven de antistofuitslagen hoog. Omdat patiënte ernstige dermatologische 
en gastro-intestinale bijwerkingen had van de combinatietherapie, vervingen 
wij deze 18 weken post partum door ciprofloxacine. Hierop ontwikkelde 
patiënte echter ernstige artropathie, waarna besloten werd de behandeling 
volledig te staken. De serologische waarden bleven onverminderd hoog 
(1:1064 voor IgG fase I en II), maar er werd geen positieve PCR meer 
gevonden. 
De pasgeborene ontwikkelde zich goed en serologische controles tot 6 
maanden post partum toonden slechts dalend maternaal IgG, maar geen 





Het te voeren beleid bij chronische Q-koorts is nog onvoldoende evidence 
based. Bij onze casus kwam het beleid tot stand na overleg tussen 
verschillende disciplines in een centrum waar relatief veel ervaring is met Q-
koorts. 
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Zwangerschap als risicofactor voor chronische Q-koorts 
Tijdens een zwangerschap past het immuunsysteem zich aan om tolerantie 
voor foetale antigenen van vaderlijke origine te bewerkstelligen. Onder 
invloed van oestrogenen en progestagenen wordt de celgemedieerde 
immuunrespons onderdrukt.8 C. burnetii is een intracellulair levende bacterie; 
klaring van de infectie zal daarom voornamelijk afhankelijk zijn van de 
celgemedieerde immuunrespons,2 waardoor tijdens de zwangerschap de kans 
op persisteren van de infectie groter is. Daarnaast is de placenta één van de 
doelwitorganen van C. burnetii. In de veterinaire geneeskunde is bekend dat 
er bij geïnfecteerde drachtige dieren veelal sprake is van vroeg- en 
doodgeboorte van jongen wat samengaat met een beeld van placentitis. 
Placenta en vruchtwater zijn dan zeer infectieus.9 Ook bij de mens is deze 
placentitis aangetoond.5  
 
Follow-up 
Het Jeroen Bosch Ziekenhuis heeft een lokale richtlijn voor de follow-up van alle 
patiënten die een acute Q-koortsinfectie hebben doorgemaakt. Deze richtlijn 
adviseerde tot 2010 om 3, 6 en 12 maanden na de primaire infectie 
serologisch onderzoek te verrichten om chroniciteit van de infectie uit te 
sluiten.10 Na evaluatie van de resultaten hiervan, wordt sinds 2010 eenmalig na 
9 maanden gecontroleerd. Met de wetenschap dat zwangeren een 
verhoogd risico hebben op chronische Q-koorts, is het te rechtvaardigen om 
hen vaker serologisch te vervolgen, ook als zij vlak voor de zwangerschap 
acute Q-koorts hadden. Zo nodig kan dan behandeling plaatsvinden. 
 
Behandeling 
De therapie van eerste keus bij patiënten met chronische Q-koorts is een 
combinatie van doxycycline en hydroxychloroquine voor minimaal 1 jaar.2 Er is 
echter een contra-indicatie voor doxycycline vanaf het tweede trimester van 
de zwangerschap in verband met vertraging van de osteogenese bij de 
foetus. Op dit moment is er voor de behandeling van Q-koorts tijdens de 
zwangerschap de meeste ervaring met het combinatiepreparaat co-
trimoxazol. Aanbevolen wordt om minimaal 5 weken te behandelen. Deze 
aanbeveling is echter gebaseerd op een retrospectieve studie waarbij 
mogelijke vertekening is van de resultaten door selectiebias.5 Onze patiënte 
bleek overigens allergisch te zijn voor co-trimoxazol. Wat het beste middel is als 
tweede keus voor Q-koorts tijdens de zwangerschap is niet aan te geven. 
Meerdere middelen die in aanmerking zouden kunnen komen, zijn relatief 
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Zwangeren die vlak voor de zwangerschap een acute Q-koorts infectie 
doormaken, hebben mogelijk meer kans op het ontwikkelen van chronische 
Q-koorts, net als zwangeren die tijdens de zwangerschap een infectie 
doormaken. Intensievere serologische follow-up tijdens de zwangerschap lijkt 
ook bij deze vrouwen aangewezen. De behandeling is niet eenvoudig, temeer 
omdat er voor de behandeling van eerste keus met doxycycline en 
hydroxychloroquine een contra-indicatie bestaat vanaf het tweede trimester 
van de zwangerschap.  
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Uitleg diagnostiek chronische Q-koorts  
De diagnostiek van chronische Q-koorts is gebaseerd op serologisch 
onderzoek eventueel gevolgd door PCR. Coxiella burnetii heeft 2 antigene 
fasen. Antistoffen tegen fase II-antigenen ontstaan kort na blootstelling aan de 
bacterie en zijn kenmerkend voor een acute Q-koortsinfectie. Chronische Q-
koorts gaat juist gepaard met hogere titers van IgG fase I, meestal samen met 
hoge titers van IgG fase II. Er is nog geen consensus over de afkapwaarden 
voor de titers die hierbij gehanteerd dienen te worden, mede omdat deze 
afhankelijk zijn van de gebruikte test. Om een chronische infectie op te sporen 
is het dus nodig zowel IgG-antistoffen tegen fase I-antigenen als tegen fase II-
antigenen te bepalen.10 De diagnose wordt bevestigd door een passend 
klinisch beeld of het aantonen van C. burnetii-DNA in bloed of weefsel door 





• Zwangeren met acute Q-koorts hebben meer kans op een chronische  
Q-koortsinfectie. 
• Het is raadzaam ook zwangeren die kort voor hun zwangerschap een 
acute Q-koortsinfectie doormaken intensief op een chronische infectie te 
screenen. 
• Vanaf het tweede trimester van de zwangerschap is er een contra-
indicatie voor behandeling met doxycycline en hydroxychloroquine, de 
therapie van eerste keus bij chronische Q-koorts; eventuele alternatieven 
zijn co-trimoxazol en erytromycine 
• De angst voor nadelige effecten van een Q-koortsinfectie op de 
zwangerschapsduur en op het geboortegewicht van de neonaat en voor 







Since 2007 The Netherlands is suffering from an outbreak of Q fever, caused by 
Coxiella burnetii, with more than 2300 patients in 2009. Besides an acute form, 
which is characterised by pneumonia, hepatitis or fever, a chronic infection 
may develop. Immunocompromised patients, patients with underlying cardiac 
valve- or vessel disease and pregnant women have a higher risk to develop 
chronic Q fever. The increased risk for pregnant women might be explained by 
the knowledge that the T-cell response of the immune system is suppressed by 
high levels of female hormones. Furthermore, the placenta seems to be one of 
the target organs, since C. burnetii causes placentitis in both animals and 
humans. Besides the risk for chronic Q fever infection, obstetric complications, 
like miscarriage, intrauterine growth restriction and intrauterine foetal death, 
have been described. In this article we discuss the difficulties concerning 
diagnose and treatment of chronic Q fever during pregnancy. 
 
Case description 
A 42 years old lady suffered from an acute Q fever infection shortly before her 
third pregnancy. Regular serological follow-up at 3, 6, and 12 months is 
arranged. At 15 weeks of gestation (GA) an amniocentesis is performed. There 
are no chromosomal abnormalities and PCR on C. burnetii is negative. 
Serology at three months shows low antibody titres, however six months after 
the primary infection (GA 25 weeks) there is a steep increase of IgG phase I 
(from 1:256 to 1:4096) and IgG phase II (from 1:4096 to 1:16,384) and PCR in 
serum is positive. Chronic Q fever is diagnosed and treatment with 
cotrimoxazole is started. However, the patient develops an allergy and 
cotrimoxazole is empirically switched to erythromycin. Antibody titres do not 
further increase, but the patient experiences many complaints. Therefore at 38 
weeks and two days of gestation labour is induced. Finally, a healthy boy with 
normal birth weight of 3850 grams is born with a secondary caesarean section. 
PCR C. burnetii on placenta and amniotic fluid are positive. PCR on umbilical 
cord blood and peripheral blood of the newborn are negative. Erythromycin is 
switched to doxycycline and hydroxychloroquine. Endocarditis, vascular 
abnormalities and retentio placentae are excluded with ultrasound and PET 
scan. However, antibody levels remain high with a negative PCR and the 
patient experiences many side effects of her treatment. Eighteen weeks post 
partum combination therapy is therefore switched to ciprofloxacin. 
Unfortunately, the patient develops ciprofloxacin-related arthropathy. 




  2 
Therefore, complete cessation of antibiotic therapy is decided. Patients’ 
complaints decrease, however serology remains high.  
The newborn develops without any problems and serology shows, besides 
maternal IgG, no signs of active Q fever infection. 
 
Conclusion 
Like an acute Q fever infection during pregnancy an acute infection shortly 
before pregnancy should be considered as a risk factor for developing chronic 
Q fever. We advise to intensivate serological follow-up in these cases. 
Treatment is challenging because first choice treatment with doxycycline and 
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In Europe the incidence of human Q fever has dramatically increased over the 
previous years. Untreated infections with Coxiella burnetii, the causal agent of 
Q fever, have been associated with both obstetric and maternal 
complications. The majority of pregnant women with a C. burnetii infection 
remain asymptomatic, hence screening could be of value to prevent 
unwanted outcomes in this high-risk group. We applied the updated Wilson 
and Jungner criteria to review the evidence for routine screening for C. burnetii 
infection during pregnancy. Since much uncertainty remains about the 
incidence, clinical consequences, diagnostics and treatment of C. burnetii 
infection during pregnancy, routine screening for C. burnetii infection during 
pregnancy should not be recommended. Rigorous studies to assess the 
effectiveness of C. burnetii screening are warranted. 
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INTRODUCTION 
 
Infections during pregnancy may cause a threat to both maternal and foetal 
health, even if the infected pregnant woman herself remains asymptomatic.1 
Therefore, routine screening at 12 weeks of gestation is being offered to all 
Dutch pregnant women for human immunodeficiency virus (HIV), Treponema 
pallidum and hepatitis B virus (HBV). The incidence of human Q fever, a 
zoonosis caused by Coxiella burnetii, showed an enormous increase in The 
Netherlands and other European countries over the past few years.2 Since 
there is evidence for infection-associated obstetric and maternal 
complications, C. burnetii infection poses a potential risk to pregnant women 
and their (unborn) children.3 Most of the pregnant women with a C. burnetii 
infection remain asymptomatic.4 Therefore routine screening has been put 
forward for early detection and treatment in this group, but scientific evidence 
about the usefulness of such an intensive program is lacking. In this review we 
applied the Wilson and Jungner criteria according to the World Health 
Organization to scrutinise the available evidence for routine screening for C. 
burnetii infection during pregnancy. These criteria were developed over 40 
years ago but are still of great value in decision making around screening 
policies.5 The criteria centre on the problem caused by the infection or disease, 
the screening population, the test and the treatment, and the costs. As newer 
policy tools, especially concerning genetic screening, have been suggested6, 
we also integrated the emerging criteria which are applicable to our research 
question. A review of the literature was done by searching PubMed and the 
references of included papers. Our search was limited to studies in English or 
Dutch. The search strategy included the keywords ’Q fever’ or ‘Coxiella 
burnetii’ and keywords related to the criteria (‘incidence’ or ‘prevalence’ or 
‘pregnancy’ or ‘risk factors’ or ‘diagnosis’ or ‘treatment’ or ‘costs’). Our overall 
aim was to examine the evidence base for routine C. burnetii screening 





Terminology used in the scientific literature concerning ’Q fever‘ is diverse and 
therefore direct comparisons of epidemiological studies should be performed 
with caution. ‘Q fever’ is commonly referred to the symptomatic disease, 
including symptoms such as fever, hepatitis or pneumonia in combination with 
positive antibody titres or polymerase chain reaction (PCR). The terms ‘C. 
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burnetii infection’ and ‘presence of antibodies’ are more often used in the 
context of asymptomatic disease, for example, in prevalence studies. 
 
Is Coxiella burnetii infection during pregnancy an important health problem? 
Prior to 2007 Q fever was uncommon in Europe2, except from some local 
outbreaks such as the outbreak in Germany in spring 2005, causing 331 cases.7 
In The Netherlands around 10 to 30 cases have been notified each year since 
1977. Between 2007 and 2009 the numbers briskly increased to over 2300 cases 
in 2009, the highest number ever reported in the literature.8 Veterinary 
outbreaks on several dairy goat and sheep farms in the southern parts of The 
Netherlands are held responsible for this increase. In 2009 and 2010 it was 
decided to implement extensive measures such as vaccinating and culling of 
thousands of animals.8 As a result, the number of human Q fever cases 
decreased rapidly to around 500 cases by the end of 2010, which is still 
considerable and may indicate an endemic stage.9 Also other European 
countries, such as Belgium, Cyprus and Germany have reported an increasing 
number of cases since 2007, albeit to a smaller extent.2 
 
The prevalence of Q fever among pregnant women is unknown. Recently 
published data from The Netherlands showed a prevalence of immunoglobulin 
(Ig)M, suggesting recent infection with C. burnetii, in 3.4% of 1646 tested serum 
samples from pregnant women in Q fever high-risk areas.10 In a cohort study 
from Canada, 3.8% of parturient women had evidence of previous exposure to 
C. burnetii (presence of IgG phase I and/or II). These women had, in contrast 
to the Dutch seropositive women10, a higher risk for adverse pregnancy 
outcomes, in terms of premature delivery and prior or current neonatal death, 
compared with seronegative women.11 A milestone hospital-based study from 
France showed that 81% of the pregnant women with untreated Q fever had a 
miscarriage, premature delivery, intrauterine growth restriction or foetal death. 
Furthermore, chronic Q fever occurred in 50% of the cases, of whom 10% 
developed C. burnetii endocarditis.3 These figures are alarming, but need to 
be cautiously interpreted as the retrospective design covering many years 
may have led to some overestimation of risks. Certainly, this study together with 
the prevalence studies emphasise that C. burnetii infection is a potential threat 
to pregnant women. 
 
Is there a latent or early symptomatic stage? 
Up to 90% of infected pregnant women remain asymptomatic.4 Therefore, 
early detection, before obstetric complications and maternal chronic Q fever 
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have occurred, enables treatment that may prevent complications due to C. 
burnetii infection.3  
 
Is the natural history of Coxiella burnetii infection adequately understood? 
C. burnetii is a small gram-negative intracellular living bacterium. The main 
route of transmission is the respiratory route, in which alveolar macrophages in 
the lungs are the first cells to be infected.12 Furthermore, the placenta seems to 
be a target organ since placentitis has been described in both animals and 
humans.3,13 After the primary infection, C. burnetii has the ability to induce 
chronic infections. It is hypothesised that, besides the liver, bone, heart valves 
and mural endocardium14, the uterus could be a site of latent infection, hence 
reactivation during pregnancy can occur.3,11 
 
The pathogenesis of obstetric complications following infection is not 
completely understood; immune complexes may cause vasculitis and vascular 
thrombosis, which in turn may lead to the placental insufficiency and 
subsequent obstetric complications.15 Also, direct transplacental transmission 
by C. burnetii may cause foetal death.16 Obstetric complications occur 
significantly more often in patients who are infected during the first trimester of 
pregnancy than in those infected later.3  
 
Not only acute infections have been associated with obstetric complications, 
also previous infections seem to increase the risk.11 There is no good 
explanation for this association besides the hypothesis of intrauterine latency of 
the infection.11 In all, the natural history of C. burnetii infection among 
pregnant women is not completely understood. 
 
 
THE SCREENING POPULATION 
 
Since the Q fever incidence largely varies between regions (see for example 
the situation in The Netherlands, Fig. 1), the population for routine screening 
should be limited to pregnant women living in high-risk Q fever areas. Women 
living within a five-kilometre zone around a dairy goat or dairy sheep farm 
affected by C. burnetii-related abortion waves have the highest risk of 
contracting an infection, however, still 41% of the Dutch cases in 2009 lived 
outside of these areas.8 Whether these cases visited the five-kilometre zones is 
unclear. Therefore, if introduced, routine screening of all pregnant women 
would be advisable in areas with a high incidence (e.g. >50/100,000 
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inhabitants). So, with a good surveillance system, the screening population can 
be accurately defined. Screening of specific groups at risk, e.g. pregnant 
women with occupational hazard for Q fever or with complicated 
pregnancies can also be considered, but is beyond the scope of this study 
discussing routine screening of a total population.  
 
Similar to other screening programs during pregnancy, eligible women have to 
be counselled about the benefits and possible consequences of the screening 
(i.e. long-term antibiotic treatment and hospital birth instead of home birth in 
case of an acute infection, stress induced by awareness of infectious diseases 




Figure 1. Human Q fever incidence per 100,000 inhabitants per municipality in 
















Incidences are based on 
symptomatic(fever, pneumo-
nia and/or hepatitis), labora-
tory-confirmed Q fever cases. 
Source: National Institute for 
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Is there an agreed policy on whom to treat as patients? 
All phases of C. burnetii infection during pregnancy have been associated with 
adverse pregnancy outcome. However, evidence for the benefits of antibiotic 
treatment is only available in patients with acute and chronic Q fever.3 
Whether antibiotic treatment prevents complications in women with 
asymptomatic seropositivity needs to be investigated. 
 
Is case finding a continuing process and not a “once and for all” project? 
If introduced, screening for C. burnetii infection should be performed during 
each pregnancy since the infection can be contracted at any moment and 
reactivation during pregnancy of a previous infection may occur.3,11 Therefore 
case finding is a continuing process. 
 
 
THE TEST AND THE TREATMENT 
 
Is there a suitable test? 
There are several accurate methods to diagnose C. burnetii infection, 
including culture, PCR and serology, of which serology is most suitable for 
screening.17 However, the performance of these tests during pregnancy is 
unknown. In the general population, indirect immunofluorescence assay (IFA) is 
the reference method.17,18 Since one of the characteristics of C. burnetii is 
antigenetic phase variation, antibodies against two phases of antigens can be 
detected. All types of antibodies have their own timeframe of appearance, 
therefore distinguishing previous, acute and chronic infections is possible.12,18 As 
already mentioned, test characteristics during pregnancy are unknown. From 
other infectious diseases we know that false-positive serological results occur 
quite often during pregnancy.19 Furthermore, with respect to sensitivity and 
specificity, there is an ongoing debate about which cut-off values to use, 
especially because there are many different commercial and in-house 
methods. In all, more research needs to be performed with respect to 
serological screening for C. burnetii during pregnancy before routine screening 
can be implemented.  
 
Is the test acceptable to the population? 
Acceptance of the test can be expected since only one blood sample is 
necessary, which can be obtained by venepuncture combined with the 
screening for other infectious diseases around 12 weeks of pregnancy. An 
advantage of testing in the first trimester is the possibility of early counselling 
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and treatment during the most vulnerable phase of pregnancy.3 However, with 
early screening, infections later in pregnancy would be missed. Timing of the 
screening needs to be further investigated, also taking into account a seasonal 
variation in C. burnetii spreading.9  
 
Is there an accepted treatment for patients with recognised disease? 
First choice treatment for Q fever among the general population is a 14-day 
antibiotic treatment with doxycycline or fluoroquinolone.12 However, both 
agents are contraindicated during pregnancy. Long-term treatment with 
cotrimoxazole has been suggested to be the treatment of choice during 
pregnancy.3 However, use of cotrimoxazole during pregnancy has not been 
fully investigated yet. Pharmacological activity of this drug could cause folic 
acid depletion in the foetus.20 Furthermore, neonatal hyperbilirubinemia has 
been described when used prior to delivery. However, these risks turned out to 
be small in large groups of pregnant women with HIV who received 
prophylactic cotrimoxazole therapy during pregnancy.21 In all, more evidence 
for the best treatment option during pregnancy is needed. 
 
Are there facilities for diagnosis and treatment available? 
Since screening for other infectious diseases during pregnancy is already 
routinely performed, adding C. burnetii screening will be relatively 
straightforward. In The Netherlands, as in other Western countries, several 
laboratories have facilities to perform C. burnetii serology. Quality assessments 
should be performed on a regular basis. Treatment and follow-up of positively 
screened women should be performed by obstetricians, infectious disease 
specialists and medical microbiologist, who should receive additional training 





Are the costs of case finding economically balanced in relation to possible 
expenditure on medical care as a whole? 
Outcomes of cost-effectiveness models are not available yet and input data 
are required. Screening with IFA and antibiotic treatment are relatively cheap, 
though referral for treatment and hospital birth may induce high costs since 
around 25% of the deliveries in The Netherlands normally take place at home.22  
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The adapted Wilson and Jungner criteria, addressed in this study are 





According to the adapted Wilson and Jungner criteria (Table 1), the currently 
available evidence is insufficient to promote routine screening for C. burnetii 
infection during pregnancy in high-risk Q fever areas. Because of potential bias 
in the studies reported so far, there is too much uncertainty about the 
consequences of untreated C. burnetii infection during pregnancy. There is 
also no consensus about the screening method and treatment. Furthermore, Q 
fever incidence rates highly affect the effectiveness of screening. Therefore the 
candidate populations for screening are not static and should be identified 
based on epidemiological criteria. Finally, besides screening, there are other 
methods to prevent C. burnetii related complications, for example human 
vaccination.23 Overall, more evidence about the effectiveness of a C. burnetii 
screening program, in addition to other Q fever prevention and control 
measures taken by the European countries, is needed before this infection will 
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Table 1. Wilson and Jungner criteria and emerging criteria (Italic) for disease screening. 
Wilson and Jungner criteria and emerging criteria for disease screening Criteria fulfilled? 
The problem 
The condition sought should be an important health problem. 
There should be a latent or early symptomatic stage. 
The natural history of the condition should be adequately understood. 
The screening program should respond to a recognised need. 
The objectives of screening should be defined at the outset. 
The screening population 
There should be an agreed policy on whom to treat as patients. 
Case finding should be a continuing process and not a “once and for all” project. 
There should be a defined target population. 
The program should ensure informed choice, confidentiality and respect for autonomy. 
The program should promote equity and access to screening for the entire target population. 
The test and the treatment 
There should be an accepted treatment for patients with recognised disease. 
Facilities for diagnosis and treatment should be available. 
There should be a suitable test or examination. 
The test should be acceptable to the population. 
There should be quality assurance, with mechanisms to minimise potential risks of screening.  
The costs 
The costs of case finding should be economically balanced in relation to possible expenditure on medical care as a 
whole. 
Overall 
There should be scientific evidence of screening program effectiveness. 
The program should integrate education, testing, clinical services and program management. 
        Program evaluation should be planned from the outset. 
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Introduction In The Netherlands the largest human Q fever outbreak ever 
reported in the literature is currently ongoing with more than 2300 notified 
cases in 2009. Pregnant women are particularly at risk as Q fever during 
pregnancy may cause maternal and obstetric complications. Since the 
majority of infected pregnant women are asymptomatic, a screening strategy 
might be of great value to reduce Q fever related complications. We 
designed a trial to assess the (cost-)effectiveness of a screening program for Q 
fever in pregnant women living in risks areas in The Netherlands. 
Methods/design We will conduct a clustered randomised controlled trial in 
which primary care midwife centres in Q fever risk areas are randomised to 
recruit pregnant women for either the control group or the intervention group. 
In both groups a blood sample is taken around 20 weeks postmenstrual age. In 
the intervention group, this sample is immediately analysed by indirect 
immunofluorescence assay for detection of IgG and IgM antibodies using a 
sensitive cut-off level of 1:32. In case of an active Q fever infection, antibiotic 
treatment is recommended and serological follow up is performed. In the 
control group, serum is frozen for analysis after delivery. The primary endpoint is 
a maternal (chronic Q fever or reactivation) or obstetric complication (low 
birth weight, preterm delivery or foetal death) in Q fever positive women. 
Secondary aims pertain to the course of infection in pregnant women, 
diagnostic accuracy of laboratory tests used for screening, histo-pathological 
abnormalities of the placenta of Q fever positive women, side effects of 
therapy, and costs. The analysis will be according to the intention-to-screen 
principle, and cost-effectiveness analysis will be performed by comparing the 
direct and indirect costs between the intervention and control group. 
Discussion With this study we aim to provide insight into the balance of risks of 
undetected and detected Q fever during pregnancy. 
 
Trial registration ClinicalTrials.gov, protocol record NL30340.042.09. 
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INTRODUCTION 
 
Q fever, a zoonosis caused by Coxiella burnetii (C. burnetii), primarily infects 
ruminants and rodents.1 Especially pregnancy products of infected animals like 
placentas and amniotic fluid can contain high numbers of bacteria. After 
drying, the organism spreads in aerosols and remains virulent for months. 
Humans are infected by inhalation of these contaminated aerosols. Most of 
the infected patients are either asymptomatic or present with a mild flu-like 
illness. However, Q fever may pose a serious threat to certain groups at risk, 
including pregnant women, immune compromised hosts and individuals with 
pre-existing cardiac valve or vascular defects.1,2 In The Netherlands, the 
number of human cases of Q fever has dramatically increased from around 12 
cases each year before 2007 to more than 2300 cases in 2009.3-5 This 
observation has led to several meetings of the Dutch Outbreak Management 
Team (OMT) of the Ministry of Health to curb the epidemic. Studies revealed 
that the epidemic among Dutch inhabitants was a result of Q fever outbreaks 
on dairy goat farms.6 
 
Pregnant women are by far the largest risk group in size. When infected by C. 
burnetii, most pregnant women will remain asymptomatic: percentages up to 
90% have been described compared to 60% in the general population.7,8 
Notably, serious complications due to Q fever seem to occur more frequently 
during pregnancy if the infection is undetected and untreated. Pregnant 
women have an increased risk to develop chronic Q fever or to reactivate a 
past infection.9,10 Furthermore, obstetric complications related to C. burnetii 
infection have been described. A landmark study from France showed 
obstetric complications including spontaneous abortion, preterm delivery, 
intrauterine growth restriction, oligohydramnios and foetal death in 81% of the 
53 women who were positive for Q fever and not sufficiently treated with 
antibiotics.10 However, because of the retrospective design selection bias 
might have led to overestimation of the complication prevalence. In a 
Canadian cohort study in an affected area, 3.8% of parturient women had 
evidence of previous exposure to C. burnetii. These women had higher risks for 
adverse obstetrical outcome in terms of premature delivery and prior or 
current neonatal death.11 Little is known about the chances of vertical 
transmission from mother to child. Transmission across the placenta, 
transmission by inhalation of infected amniotic fluid or by ingestion of infected 




Because most infected pregnant women remain asymptomatic, one of the 
suggested measures to prevent obstetric complications and maternal 
chronicity concerns a screening strategy. However, because of lack of 
information on the prevalence during pregnancy and lack of randomised 
controlled trials weighing potential benefits and risks associated with screening, 
evidence for its potential impact is scarce. The Health Council of The 
Netherlands therefore advised the Ministry of Health in 2008 to facilitate studies 
to inform decision makers. We therefore designed a trial to assess the effects of 
a screening policy for Q fever in pregnant women from areas with large 
numbers of Q fever cases on the pregnancy outcome and cost-effectiveness 
from a societal and health care perspective. The study will primarily provide 






Since ethical issues surrounding randomisation of the individual pregnant 
woman for a Q fever screening or non-screening strategy could seriously 
threaten approval by an ethics committee, we designed a clustered 
randomised controlled trial in which primary care midwife centres are 
randomised to recruit either pregnant women for the control group or for the 
intervention group. In this way, the choice for either strategy by individual 
eligible women was avoided. Timing and phasing after eligibility checks are 
shown in Figure 1. The study will be conducted according to the principles of 
the Declaration of Helsinki. The study protocol is approved by the Medical 
Ethical Review Board of the University Medical Center Groningen. The study 
protocol is registered at http://ClinicalTrials.gov, protocol record 
NL30340.042.09. The inclusion of participants started in April 2010.  
 
The conduct of the trial is currently supported by the Royal Dutch Society for 
Midwifery (KNOV), the professional organisation of midwives. Midwife centres in 
risk areas for Q fever (incidence in 2009 of more than 50:100,000 inhabitants 
according to the National Institute for Public Health and the Environment 
(RIVM)), were primarily invited to facilitate inclusion of participants. During 
spring 2010 we expanded the area based on the incidence of 2010. All 
obstetricians, paediatricians, medical microbiologists and pathologists in these 
areas were informed about the study. 
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EDD, estimated date of delivery; IC, informed consent; IFA, indirect immunofluorescence 
assay; QoL, Quality of life. *Antibiotic treatment will be given according to the local 
hospital protocol. First choice treatment during pregnancy consists of cotrimoxazole 
160/800mg b.i.d. for at least 5 weeks. After pregnancy doxycycline 100mg b.i.d. for at 
least two weeks is the preferred treatment for an active Q fever infection. 
 
Inclusion criteria 
Pregnant women, 18 years of age or older, with an estimated date of delivery 
between June 1st and December 31st 2010, and under supervision of a 
midwife in primary health care are eligible for inclusion. In The Netherlands, 
midwives working in primary health care are allowed to only supervise 
uncomplicated, singleton pregnancies. It is estimated that approximately 
10,000 eligible pregnant women live in the Q fever affected areas. 
 
 
Midwife centres in 
high- risk Q fever areas 
Randomisation 
Intervention group Control group 
Invite pregnant women with 
EDD  June 1
st
 – Dec 31
st
 2010                    
IC procedure  by researchers 
Blood sample between 20 and   
32 weeks postmenstrual age  
Q fever negative Q fever positive 
Evaluation of clinical outcome, costs, QoL, Q fever risk factors 




Serum frozen at – 20 ⁰ C for 
analysis after delivery  
Exclusion criteria:                            
- < 18 years                                   
- Doesn’t understand Dutch      
- Previously Q fever positive    
- No internet / email                                              
Analysed immediately with 
IFA: IgM and IgG phase I and II 
  
Blood sample between 20 and   
32 weeks postmenstrual age  
Invite pregnant women with 
EDD  June 1
st
 – Dec 31
st
 2010                    




Women who do not have access to internet and/or an email address are 
excluded because data collection is web-based. In addition, women who are 
unable to understand Dutch or to give informed consent, or who have 





Participants who are recruited by a midwife centre randomised for the 
intervention group are asked for a blood sample around 20 weeks 
postmenstrual age. If possible the visit is combined with the routine structural 
ultrasound scan around that time. If the participant is included after 20 weeks, 
the blood sample will be taken as soon as possible after inclusion. The sample 
will immediately be tested for antibodies against C. burnetii in the laboratory of 
the Jeroen Bosch Hospital which has analysed most samples during the 
epidemic in 2007, 2008, and 2009. Serologic diagnosis of Q fever will be made 
by indirect immunofluorescence assay (IFA), the reference method for 
serodiagnosis of Q fever.12 Both IgM and IgG antibodies against phase I and 
phase II antigens are measured according to the manufacturer's instructions 
(Focus Diagnostics, Cypress, CA, USA). Titres ≥ 1:32 are considered positive. All 
positive samples will be fully titrated to reduce the chance of treatment in false 
positives. In general, the first antibody to appear in acute Q fever patients is 
IgM phase II, followed by a more or less simultaneous IgG phase II and IgM 
phase I response and subsequent appearance of IgG phase I antibodies (see 
Fig. 2).13 This time-dependent serologic profile allows us to discriminate 
between a recent acute infection, a past infection, and a chronic infection.  
 
Figure 2. Idealised antibody responses in acute Q fever as measured by IFA.13 
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If the pregnant woman does not have evidence for an acute, past or chronic 
Q fever infection, standard care will be provided. In case of acute Q fever, the 
participant will be referred to an obstetrician, and treatment will be advised 
according to the local hospital protocol. In the literature, the first choice 
treatment of Q fever during pregnancy is oral cotrimoxazole (sulfamethoxazole 
/trimethoprim) for at least 5 weeks.10 Antibiotic treatment, further obstetrical 
care and serological follow up will be supervised by the obstetrician in 
collaboration with the medical microbiologist. The current routine for pregnant 
women being treated for acute Q fever is to perform monthly blood analyses 
to detect the development of chronic Q fever. If the titres decline, the 
frequency of these controls is scaled down to once every two months during 
pregnancy, and at 3, 6 and 12 months after delivery. If chronic Q fever 
develops, treatment will be continued until the end of pregnancy followed by 
bactericidal treatment with doxycycline and hydroxychloroquine after 
delivery. In Q fever cases placentas will be collected for polymerase chain 
reaction (PCR) and histo-pathology. If there is evidence for a past infection, no 
treatment is started. However, midwives will be advised to perform an extra 
serological analysis later in pregnancy to exclude reactivation. 
 
Control group 
Participants who are recruited by a midwife centre randomly allocated to the 
control group will also be asked for a blood sample around 20 weeks 
postmenstrual age. These blood samples will be stored at -20°C, and analysed 
for C. burnetii after delivery. In case of a positive test, the participant's general 
practitioner will be advised to perform an extra serological analysis to exclude 




All neonates born to Q fever positive mothers will receive care according to 
the local hospital protocols. The Section for Paediatric Infectious Diseases and 
Immunology of the Dutch Paediatric Society has formulated a consensus 
guideline for neonates born to Q fever positive women during pregnancy.14 
The guideline advices PCR at birth and one month of age, and serological 
follow up until 18 months of age in case of active maternal Q fever during 
pregnancy to diagnose and treat potential mother-to-child transmission. 
Preventive antibiotic treatment is not advised. Breastfeeding is contraindicated 
if maternal serum or milk is C. burnetii PCR positive. Breastfeeding might also be 




Participating midwife centres are randomised to include either pregnant 
women for the control group or for the intervention group. Randomisation is 
stratified according to the risk of contracting a C. burnetii infection as 
determined by the number of goat farms in the neighborhood (registration by 
Statistics Netherlands (CBS)), and by the size of the midwife centre. 
 
Inclusion of participants 
Pregnant women are invited by their midwife to participate in the study. The 
informed consent procedure will be performed by the researchers. 
 
Data collection 
Data will be collected in four ways using a structured case record file: 
1. Serological samples will be collected at the time points described in the 
section Experimental procedure, and will be analysed in the laboratory of 
the Jeroen Bosch Hospital. 
2. Questionnaires; two questionnaires will be filled out by the participant and 
one will be filled out by the midwife/obstetrician. 
At baseline, when the participant is included in the trial, a questionnaire is 
completed by all participants including questions about the current 
pregnancy, outcome of previous pregnancies, smoking and alcohol 
habits, co-morbidities, medication use and demographic characteristics. 
With this questionnaire risk factors are assessed for complicated 
pregnancy outcome. After delivery all relevant outcome data on obstetric 
complications are collected by a questionnaire completed by the 
midwife. Questionnaires for participants who are referred to a hospital 
during pregnancy or delivery, are filled out by the obstetrician. During 
follow up, all health care and potential cost data will be measured by a 
third questionnaire completed by the participant one month after delivery. 
With this questionnaire we will also verify symptoms during pregnancy, 
health-related quality-of-life (using EQ5D15), depressive symptoms and 
fatigue (using the Shortened Fatigue Questionnaire16), potential long-term 
consequences of Q fever, tolerance to antibiotic treatment and problems 
and development of the newborn. Furthermore, the risk for Q fever 
infection will be assessed. 
3. PCR and histo-pathology of the placenta will be performed by the local 
microbiologists and pathologists. Re-evaluation of the histological slides will 
be performed by one pathologist at the University Medical Center 
Groningen. 
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4. Medical data in primary care; data on the health status of the participant 
or the newborn is collected from medical files of the general practitioner. 
 
Outcome measures 
The primary endpoint is a maternal (chronic Q fever or reactivation) or 
obstetric complication (low birth weight, preterm delivery or foetal death) after 
the first trimester of pregnancy in Q fever positive women. 
The secondary endpoints are direct and indirect costs of the screening 
program compared to costs of complications which could be prevented by 
screening. Furthermore, we aim to assess the course of infection in pregnant 
women, the accuracy of the diagnostic tests used for screening, histo-
pathological abnormalities of the placenta of Q fever infected women, and 
side effects associated with treatment. 
 
Withdrawal of individual participants 
Participants are informed that they can withdraw from the study at any time 
point, without giving a reason for withdrawal. If the blood sample has already 
been taken, participants will be asked to give permission for collecting data on 
obstetric outcome. Participants who withdraw will receive regular health care 
according to the local protocols. 
 
Sample size calculation and statistics 
Based on the literature and pilot data from The Netherlands, we expect that 
12% of pregnant women in the high-risk areas will have serological evidence 
for a Q fever infection.17,18 Of these women, we conservatively estimate that 
25% will develop complications, so 3% of women will have the primary 
outcome. Assuming a reduction of the complication rate of 50% by early 
detection with screening during pregnancy, we will need a participation of at 
least 3400 participants with complete follow up (statistical power of 80 percent, 
P ≤ 0.05). Assuming a loss to follow up of 10% and to allow for a small clustering 
effect, we aim to include 4000 participants. Data will be analysed according 
to intention-to-screen principles. A two-sided P-value of 0.05 or less will be 
considered to indicate statistically significant. Descriptive statistics concerning 
the distributions of the predictor variables and outcome variables will be 
performed using the software SPSS for windows (version 16). For univariate 
analysis the chi-square test and Fischer's exact test will be used to compare 
proportions. For variables with a normal distribution, differences will be 
analysed with Student's t-test. In case of non-parametric distribution, 
differences between populations will either be evaluated using the Mann-
 56 
 
Whitney-U test or the data will be log-transformed to obtain a normal 
distribution. Relative risks as well as absolute risk reductions and numbers 
needed to treat will be estimated with their corresponding 95% confidence 
intervals. Possible clustering of outcome data will be taken into account using 
generalised estimating equations (GEE) modelling. 
 
Economic evaluation 
The study will primarily provide insights into the economical balance of 
undetected and detected Q fever during pregnancy. The economic 
evaluation will be performed from a societal and health care perspective. 
Direct medical and non-medical costs (laboratory costs, costs of health care 
following positive screening, time, and travel costs) as well as indirect costs (loss 
of productivity) will be taken into account. The time horizon will be from taking 
the blood sample until one month after delivery for measured and calculated 
costs and until one year after delivery for estimated costs. Data on health care 
use and productivity loss will be collected by questionnaires. Unit costs will be 
based on the Dutch 2004 guidelines for costing in health care research and 





Right at the beginning of the first Q fever outbreak in The Netherlands in 2007, 
the government and health care providers assessed the risk of Q fever related 
to the outcome of pregnancies.20 In all, only research from France is currently 
available on the risks of Q fever during pregnancy and the benefits of long-
term antibiotic treatment.10 There is, however, a lack of data on the 
prevalence and the risk of Q fever infection and the impact of antibiotic 
treatment during pregnancy in other countries such as The Netherlands. 
Therefore, in December 2008 the Dutch Health Council advised the Ministry of 
Health not to screen for Q fever during pregnancy until additional scientific 
data would be available to support screening.20 The Dutch outbreak is an 
opportunity to gain more knowledge in this field. Therefore we will conduct the 
study described previously, to provide insights into the balance of risks of 
undetected and detected Q fever during pregnancy. By the end of February 
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Background Since asymptomatic Coxiella burnetii infection has been 
associated with maternal and obstetric complications and outbreaks of 
human Q fever are reported more often in Europe since 2007, evidence about 
the effectiveness of routine screening for Coxiella burnetii infection during 
pregnancy in Q fever high-risk areas is needed.  
Methods During the recent Dutch Q fever outbreak we performed a clustered 
randomised controlled trial in which 55 midwife centres were randomised to 
recruit pregnant women for an intervention or control strategy. In both groups 
a serum sample was taken between 20 and 32 weeks of gestation. In the 
intervention group (n=536) the samples were analysed immediately by indirect 
immunofluorescence assay and antibiotic treatment was given during 
pregnancy in case of an acute or chronic infection. In the control group 
(n=693), sera were frozen for analysis after delivery. For all participants data on 
pregnancy outcome were collected. 
Results In both groups 15% of the women were seropositive. In the intervention 
group 2.2% of the women were seropositive and had an obstetric 
complication, compared with 1.4% in the control group (odds ratio 1.54 (95% 
confidence interval 0.60-3.96)).  
Conclusion Routine Coxiella burnetii screening during pregnancy starting at 20 
weeks of gestation seems not to be associated with a relevant reduction in 
obstetric complications. 
 
Trial registration: ClinicalTrials.gov, identifier NCT01095328 
[http://clinicaltrials.gov/ct2/show/NCT01095328?term=q+fever+pregnancy& 
rank=1]
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WHAT IS ALREADY KNOWN ON THIS TOPIC? 
Several outbreaks of human Q fever have taken place in Europe since 2007.  
 
Pregnant women with a Coxiella burnetii infection are more often 
asymptomatic than the general population.  
 
Undetected and untreated Coxiella burnetii infection during pregnancy was 
reported to be associated with both maternal complications (mainly chronic Q 
fever) and obstetric complications (miscarriage, preterm delivery, a child small 
for gestational age and foetal death). 
WHAT THIS STUDY ADDS? 
Fifteen percent of pregnant women living in Q fever high risk areas in The 
Netherlands have serological evidence for a previous or acute Coxiella 
burnetii infection. 
 
Asymptomatic seropositivity is not associated with adverse pregnancy 
outcome. 
 
Routine Coxiella burnetii screening during pregnancy starting at 20 weeks of 






Infections such as human immunodeficiency virus, syphilis and hepatitis B virus 
during pregnancy cause a threat to both maternal and foetal health, even if 
the infection is asymptomatic. Routine screening for infectious diseases is 
therefore recommended for millions of pregnant women worldwide.1 Due to 
several outbreaks the incidence of Q fever, a zoonosis caused by the 
bacterium Coxiella burnetii, has been increasing in The Netherlands and other 
European countries since 2007.2,3 Most of the infected individuals are either 
asymptomatic or present with a mild flu-like illness. However, C. burnetii may 
pose a serious threat to pregnant women because of the increased risk of 
chronic Q fever which is often complicated by endocarditis.4-6 In addition, 
both symptomatic and asymptomatic C. burnetii infection during pregnancy 
have been associated with obstetric complications due to placentitis, 
including preterm delivery, intrauterine growth restriction and foetal death.7,8 
Because most infected pregnant women remain asymptomatic9, routine 
serological screening could be of great value to prevent chronic maternal 
infections and obstetric complications, but evidence from randomised trials is 
lacking. Since the Dutch Q fever outbreak was with over 3500 cases in three 
years of time unique in its size10, we had the opportunity to perform this 
clustered randomised controlled trial (RCT).  The objective of this study was to 
assess the effectiveness of large-scale routine serological screening for C. 






We conducted a clustered RCT in which primary care midwife centres were 
randomised to recruit pregnant women either for the intervention or for the 
control group (Fig. 1). The study was conducted according to the principles of 
the Declaration of Helsinki, and the study protocol was approved by the 
Medical Ethical Review Board of the University Medical Center Groningen. All 
participants gave written informed consent. 
 
Setting 
The study was set in Q fever high-risk areas in The Netherlands defined as 
municipalities with a Q fever incidence of more than 50 cases per 100,000 
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inhabitants in 2009 or more than 20 cases per 100,000 inhabitants in 2010 
according to the official Dutch surveillance data.11 
 
Randomisation procedure 
Participating midwife centres in these high-risk areas were randomly allocated 
(ratio 1:1) using a computer-generated list of random numbers, containing 
random block sizes of 4 and 6 prepared by an investigator with no clinical 
involvement in the trial. Randomisation was stratified according to the risk-
factor associated with contracting a C. burnetii infection by the number of 
goat farms in the municipality (up to 7 or >7)12 and by the size of the midwife 
centre (up to 300 or >300 pregnant women under care per year). Since this 
was an open-label study, midwives, other health care workers, participants 




Pregnant women, 18 years of age or older, with an estimated date of delivery 
between June 1st and December 31st 2010, who were under supervision of a 
midwife in primary health care were eligible for inclusion. In The Netherlands, 
midwives working in primary health care are only allowed to supervise low-risk, 
singleton pregnancies. Using this criterion, women with an increased risk for 
complicated pregnancy outcome on forehand (i.g. twin pregnancies or 
pregnant women with chronic illnesses) were excluded. 
 
Exclusion criteria 
Women who did not have access to Internet or an email address were 
excluded because data collection was web-based. In The Netherlands, only 
9% of the households do not have Internet access.13 These households mainly 
consist of elderly or singles, so very little exclusion from this restriction was 
expected. In addition, women who were unable to understand Dutch, unable 
to give informed consent, or were already known as being Q fever positive 




Participants in the intervention group were asked for a serum sample between 
20 and 32 weeks of gestation. The samples were analysed immediately by 
indirect immunofluorescence assay (IFA) in the laboratory of the Jeroen Bosch 
Hospital, ‘s-Hertogenbosch, The Netherlands. Both immunoglobulin (Ig)M and 
 64 
 
IgG against phase I and phase II antigens (Nine Mile strain) were measured 
according to the manufacturer's instructions (Focus Diagnostics, Cypress, CA, 
USA). Each run included a positive and a negative control. In line with the cut-
off values used in the clinical setting for the diagnosis of Q fever in 
symptomatic patients, titres ≥ 1:32 were considered positive.14 Of every positive 
sample the titre was determined to reduce the chance of false positivity. A 
probable acute infection was defined as the presence of positive titres of IgM 
(phase I and/or II) in the first screening sample. A proven acute infection was 
defined as positive titres for IgM accompanied with (rising) titres of IgG phase I 
and/or II during follow-up, two to four weeks after the screening sample. A 
previous infection was defined as the presence of only IgG (phase I and/or II) 
in the screening sample. A chronic C. burnetii infection was defined as an 
antibody titre of IgG phase I ≥ 1:1024.15  
In seronegative women standard care was provided. In case of a 
(probable) acute or chronic C. burnetii infection, women were referred to an 
obstetrician and intensified serological and obstetric follow-up according to 
the local hospital protocol was given. Antibiotic treatment (cotrimoxazole (960 
mg b.i.d.) or erythromycin (500 mg b.i.d to q.i.d.) depending on the term of 
pregnancy, for at least 5 weeks) was started in collaboration with the local 
medical microbiologist in any case of a proven acute or chronic infection. In 
case of a previous infection, no treatment was started, but serological analysis 
was repeated in the third trimester of pregnancy to exclude reactivation as 
part of a chronic infection.  
 
Control group 
Women in the control group were also asked for a serum sample between 20 
and 32 weeks of gestation. These samples were centrally stored in the 
laboratory of the Jeroen Bosch Hospital at -20⁰C and were analysed for 
antibodies against C. burnetii after delivery similar to the intervention group. In 
this group, distinguishing a probable and proven acute infection was 
impossible since follow-up serology during pregnancy was not performed. In 
case of a positive test, the participant’s general practitioner was advised to 




In case of symptoms compatible with Q fever during pregnancy, all 
participants were free to visit a physician for regular diagnostics. 
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Outcome measures 
The primary endpoint pertained to the individual level and was a composite 
measure of a maternal or obstetric complication in seropositive women. A 
maternal complication was defined as the development of a serological 
profile suggesting chronic infection (IgG phase I ≥ 1:102415). Obstetric 
complications included preterm delivery (defined as delivery <37 weeks of 
gestation), a child small for gestational age (SGA, defined as birth weight <10th 
percentile16), and perinatal mortality (defined as foetal or neonatal death 
between 22 weeks of gestation and one week post partum). Secondary 
endpoints were the separate components of the composite measure and 
fatigue and quality of life one month post partum. Fatigue was assessed using 
the Shortened fatigue questionnaire.17 Quality of life was assessed using the 
validated EQ5D questionnaire.18  
 
Sample size calculation 
Since midwifery in primary health care is very much protocolised and serology 
was performed in one laboratory, the presence of clustering in the infrequent 
primary outcome of the study was expected to be minimal. Therefore the 
sample size calculation was performed on the individual level. Based on the 
literature and pilot data from The Netherlands, we expected that 12% of the 
pregnant women in the Q fever high-risk areas would be seropositive.19,20 Of 
these women we estimated that at least 25% would have a complication. Thus, 
3% of all pregnant women in Q fever high-risk areas would meet the primary 
outcome. A reduction of the complication rate by at least 50% as a 
consequence of early detection with screening during pregnancy was defined 
as clinically relevant. We considered reductions smaller than 50% unlikely to 
trigger a change in practice given the implications on health care resources. 
Based on these expectations, we estimated needing at least 3400 participants 
with complete follow-up (statistical power of 80%, α of 0.05).  
 
Statistical methods 
Data were analysed according to intention-to-screen principle. Baseline 
demographic information was summarised by group using frequencies with 
percentages for categorical variables and means with standard deviations for 
continuous variables. Odds ratio’s (OR) and corresponding 95% confidence 
intervals (CI) were calculated using generalised linear mixed models (GLMM) 
to adjust for possible clustering effects. For continuous variables the mean 
difference with 95% CI was calculated. For the primary endpoint also the crude 
OR with 95% CI was calculated using binary logistic regression analysis, to 
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provide an indication of the extent of clustering. A two-sided P-value of 0.05 or 
less was defined as being statistically significant. Statistical analyses were 
performed using R version 12.1 and PASW Statistics version 18.0 (SPSS inc. 
Chicago, Illinois, USA). 
 
 

























EDD, estimated date of delivery; IC, informed consent; IFA, indirect immunofluorescence 
assay. * For the intervention group intensified serological follow-up and pregnancy 
monitoring with possible antibiotic treatment were performed during pregnancy under 
supervision of secondary health care. For the control group serological follow-up was 





Midwife centres in 
high- risk Q fever areas 
Randomisation 
Intervention group Control group 
Invite pregnant women with 
EDD  June 1
st
 – Dec 31
st
 2010                    
IC procedure  by researchers 
Blood sample between 20 and   
32 weeks of gestation  
Seronegative Seropositive 
Evaluation of clinical outcome, quality of life, fatigue 
Intensified follow up*  
Serum frozen at – 20 ⁰ C for 
analysis after delivery  
Exclusion criteria:                            
- < 18 years                                   
- Doesn’t understand Dutch      
- Previously Q fever positive    
- No internet / email                                              
Analysed immediately with 
IFA: IgM and IgG phase I and II 
  
Blood sample between 20 and   
32 weeks of gestation  
Invite pregnant women with 
EDD  June 1
st
 – Dec 31
st
 2010                    
IC procedure  by researchers 
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RESULTS 
 
Between March 16 and July 17, 2010, 55 of the 99 eligible midwife centres were 
willing to participate and were randomised (27 to the intervention and 28 to 
the control strategy, Fig. 2). In total, these centres supervised 6860 eligible 
pregnant women of whom 1348 (20%) signed informed consent. Among these 
women a blood sample was collected for 1229 participants (536 participants in 
the intervention group and 693 in the control group). At the moment of 
screening, none of the participants suffered from a pneumonia or hepatitis 
(clinical signs of symptomatic Q fever4). Of 119 participants no blood sample 
was received, either because they forgot to give a sample or the sample was 
lost. These women were excluded from the analysis since the primary outcome 
measure was missing. Of 104 participants in the intervention group and 196 
participants in the control group, the sample was taken outside the protocol 
period, i.e. before 20 weeks of gestation (n=7 and n=5, respectively) or after 32 
weeks of gestation (n=97 and n=191). However, there was no difference in the 
baseline and outcome variables between the participants with and without 
this protocol deviation (data available on request), hence they were included 
in the analysis. 
 
Baseline characteristics 
Baseline characteristics are shown in Table 1.  The mean gestational age at the 
moment of sampling was 28.7 weeks for the intervention group and 29.9 weeks 
for the control group. Fifteen percent of the women in both groups were 
seropositive for C. burnetii. Fifty-two of the 1229 participants had a probable 
acute infection (n=30 (5.6%) in the intervention group and n=22 (3.2%) in the 
control group) and 131 participants had a previous infection (n=52 (9.7%) in the 
intervention group and n=79 (11.4%) in the control group) according to the first 
screening sample. After follow-up seven women in the intervention group 
(1.3%) were diagnosed to have an acute C. burnetii infection and antibiotic 
treatment was started at a median stage of pregnancy of 28 weeks (range 22-
36 weeks) for a duration of 1-5 weeks, depending on the serological follow-up 
and term of pregnancy. In the other patients with a probable acute infection 
(77%, 23/30) follow-up serology ruled out this suspicion and was consistent with 
a previous infection. Follow-up showed no cases of maternal chronic infections 
in either of the two groups, so only obstetric complications in seropositive 
women were recorded as an endpoint. None of the women in the intervention 
or control group were treated with antibiotics during pregnancy for 
symptomatic Q fever. 
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For all the participants the primary outcome measure was available. There was 
no difference in the primary endpoint between the intervention and the 
control group (Table 2). The risk estimate obtained from the clustered analysis 
for an obstetric complication in seropositive women in the intervention group 
compared with the control group was 1.54 (95%CI 0.60-3.96). The un-clustered 
analysis showed a similar OR of 1.56 (95%CI 0.67-3.65). There were six cases of 
perinatal mortality (foetal death n=4, early neonatal mortality n=2). All these 












































Allocation to control strategy  
(28 centres) 
  Received allocated strategy  
  28 centers 
  median size* = 134 (range 32-306) 
  3710 eligible pregnant women 
  Did not receive allocated strategy 
  0 centres 
Allocation to intervention strategy 
(27 centres) 
  Received allocated strategy  
  27 centres  
  median size* = 116 (range 10-250) 
  3150 eligible pregnant women 
  Did not receive allocated strategy 
  0 centres 
Assessed for eligibility  
(99 midwife centres) 
Randomised  
(55 midwife centres) 
Lost to follow-up 
0 centres 
2551 (81%) women not willing to 
participate. 
From 63/599 (11%) participants no 
sample received  no serology. 
 
Analysed 
100% (536/536) of the participants 
with serology performed. 
 




Lost to follow-up 
0 centres 
2961 (80%) women not willing to 
participate. 
From 56/749 (8%) participants no 
sample received  no serology. 
 
Analysed 
100% (693/693) of the participants 
with serology performed. 
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Secondary endpoints 
Analyses of the separate components of the composite measure showed that 
the difference in the primary endpoint in favour of the control group, though 
non-significant, seemed to be the result of a small difference in the risk of 
preterm delivery (Table 2).  
 The fatigue score one month post partum was approximately 1 point 
higher in the intervention group compared with the control group (14.6 versus 
13.5, P<0.001). Quality of life did not differ between the two groups. (Table 3) 
Explorative analysis showed that C. burnetii seropositivity during 
pregnancy, even when the cut-off titre for seropositivity was increased to ≥ 
1:64, was not associated with gestational age at delivery, birth weight or any of 
the defined obstetric complications (Table 4). From the seven women in the 
intervention group with an acute infection two women delivered preterm and 





We showed that large-scale routine serological screening for C. burnetii 
infection during pregnancy starting at 20 weeks of gestation in Q fever high-risk 
areas seems not to be associated with a relevant reduction in obstetric 
complications in seropositive women. Therefore, our data do not support such 
a preventive program. This finding can be explained by the low incidence of 
acute C. burnetii infection (1.3%), the absence of patients with a chronic 
infection and the finding that C. burnetii seropositivity was not associated with 
adverse pregnancy outcomes. Surprisingly, we observed that participants of 
the intervention group had a somewhat higher fatigue score one month post 
partum than controls. Although the clinical relevance may be questionable, 
other screening strategies for infectious diseases during pregnancy have shown 
that screening for and therefore awareness of infectious diseases may induce 
negative psychological effects.21 
Importantly, despite the fact that this study was performed in a Q 
fever high-risk area and participation of midwife centres was high (56%), the 
participation rate of pregnant women was unexpectedly low (20%). Although 
it’s likely that this low percentage reflects a reluctance to take part in a 
randomised controlled trial, this might also indicate that the acceptance of 





Strengths and limitations 
A major strength of this study is that it is the first randomised, prospective, study 
in a community based - non-selected - pregnant population focusing on the 
effectiveness of routine screening for C. burnetii infection. Since the Dutch Q 
fever outbreak between 2007 and 2010 was unique in its magnitude and 
duration, we had the opportunity to perform this study in a high-risk area. 
However, probably due to the drastic veterinary measures taken by the Dutch 
government the incidence of acute C. burnetii infections steeply declined 
since 2010.10 Inclusion of participants after the second half of 2010 would not 
have been informative and was perceived as unethical. Therefore, we did not 
reach our projected number of inclusions, which increases the risk of a type II 
error. However, this risk seems to be minimal, because the lower estimate of the 
95% confidence interval of the primary outcome (OR 0.60) precludes the a 
priori defined 50% risk reduction in relevant outcomes.  
There are also some other limitations to address. In this study screening 
started at 20 weeks of gestation. There are two main reasons why we chose for 
this design. First of all we aimed to avoid treatment with a drug (cotrimoxazole) 
that is not completely investigated in pregnancy, during the most vulnerable 
phase of pregnancy.22 Earlier screening and withholding treatment till 20 weeks 
of gestation was perceived as unethical and therefore not an option. 
Secondly, at 20 weeks of gestation pregnant women could combine the 
venepuncture for this study with a structural ultrasound, which is offered to all 
pregnant women in the Netherlands; a method to increase the participation 
rate. Because of this design screening in the first trimester of pregnancy is still 
untested, and effectiveness of such a strategy can not be excluded. However, 
a recent Danish study showed no association between C. burnetii infection 
and miscarriage up to 22 weeks of gestation23, indicating that screening earlier 
in pregnancy would probably also be ineffective. 
Furthermore, 44% of the eligible midwife centres and 80% of the 
eligible pregnant women were not willing to participate, so generalisability 
might be at stake. However, since major patient characteristics like maternal 
age and proportion of nulliparous women are comparable with other large 
population based cohort studies from The Netherlands we believe our results 
are applicable to this setting.24,25 Nevertheless pregnant women with a non-
Western ethnicity were underrepresented in our study population so our results 
should be interpreted with caution for this group, especially because it is 
known that the seroprevalence in pregnant women with a non-Dutch ethnic 
background is higher.26  
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Serological screening during pregnancy is challenging. A high rate of false-
positivity has been described, especially for IgM assays.27,28 Furthermore, the 
specificity of tests may be low if the incidence of the disease is relatively low 
and the prevalence is relatively high. Of every positive sample the titre was 
determined and we performed serological follow-up of all IgM positive women 
to prevent treatment of false-positive acute cases.  
 
Comparisons with other studies 
In contrast to our results, previous studies reported a strong association 
between undetected and untreated C. burnetii infection during pregnancy 
and complicated pregnancy outcome.7,8,29 One explanation might be that in 
the previous non-randomised studies, selection bias could have led to an 
overestimation of the risks. Otherwise, differences in pathogenicity between 
different C. burnetii strains could exist. Genotyping of Dutch samples is 
ongoing.30 Since in The Netherlands a relatively high number of chronic Q fever 
has been described in patients with aneurysms31, it could be hypothesised that 
the strains involved in the Dutch outbreak are highly virulent for people with 
underlying vascular diseases, while pregnant women are relatively protected.  
There are also studies in line with our results. In two large studies 
conducted in Q fever high-risk areas in The Netherlands and France an 






This clustered randomised controlled trial showed that 15% of the pregnant 
women in Q fever high-risk areas are seropositive, but the incidence of acute 
C. burnetii infection is low. Although the broad confidence interval did not 
exclude a small beneficial effect of screening, routine screening during 
pregnancy starting at 20 weeks of gestation seems in any case not to be 
associated with a relevant reduction of obstetric complications in seropositive 
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Table 1. Baseline characteristics of the clusters and participants  
 Intervention group Control group 
Midwife centre characteristics   
Numbers 27 28 
Size:   
 ≤300 women per year 14 (52) 13 (46) 
 >300 women per year 13 (48) 15 (54) 
Goat farms in municipality:   
 ≤7 13 (48) 14 (50) 
 >7 14 (52) 14 (50) 
Participant characteristics   
Numbers 536 693 
Age (in years) 31.9 ± 3.8 31.7 ± 3.7 
Nulliparous 252 (47) 295 (43) 
Ethnic origin non-Western 14 (2.6) 12 (1.7) 
Educationa   
 Low 29 (5.4) 49 (7.1) 
 Medium 177 (33) 228 (33) 
 High 319 (60) 411 (59) 
 Other/Unknown 11 (2.1) 5 (0.7) 
Maternal smoking during pregnancy 54 (10) 54 (7.8) 
Body mass index (in kg/m2)b 23.8 ± 3.7 24.1 ± 4.0 
Primary hypertension 5 (0.9) 3 (0.4) 
Hypothyroidism 6 (1.1) 11 (1.6) 
History of preterm delivery 20 (3.7) 24 (3.5) 
History of miscarriagec   
 No 411 (77) 550 (79) 
 One 97 (18) 115 (17) 
 Repeated 27 (5.0) 27 (3.9) 
Gestational age at the moment of sampling 28.7 ± 4.7 29.9 ± 4.8 
Coxiella burnetii seropositive 82 (15) 101 (15) 
 
Data are presented as mean ± standard deviation or n (%) of clusters or patients.  
a Low represents: no education, primary school, lower-middle secondary school and   
lower professional school; medium represents: medium professional school and higher 
secondary school; high represents: higher professional school and university.  
b Prior to pregnancy.  
c n=535 for intervention group and n=692 for control group. 
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Table 2. Complications in seropositive participants 
 
 
OR, odds ratio; CI, confidence interval. Data are presented as no. (%) or OR [95% CI]  
a Odds ratio and P-value calculated with generalised linear mixed models, taking into account a clustering effect.  
b Crude odds ratio and P-value calculated with binary logistic regression analysis.  



























12 (2.2) 12 (14.6) 10 (1.4) 10 (9.9) 1.54 [0.60-3.96] 0.37 1.56 [0.67-3.65] 0.30 
Preterm delivery 8 (1.5) 8 (9.8) 5 (0.7) 5 (5.0) 1.80 [0.37-8.72] 0.47 2.09 [0.68-6.41] 0.20 
Small for 
gestational age 
4 (0.7) 4 (4.9) 5 (0.7) 5 (5.0) 1.04 [0.28-3.87] 0.96 1.04 [0.28-3.87] 0.96 




Table 3. Fatigue and Quality of Life one month post partum 
 
OR, odds ratio; CI, confidence interval. Data are presented as mean ± standard deviation, n (%) and OR [95% CI] 
a Odds ratio, mean difference and P-value calculated with generalised linear mixed models, taking into account a clustering effect. 
b n=506 and 662 for the intervention and control group, respectively. Range of the score 4 (not fatigue) to 28 (extreme fatigue). 
c n=488 and 636 for the intervention and control group, respectively. A score of 1 resembles no problems, 2 corresponds with any problems and 3 
with major problems.  
d Self-reported health score on scale from 0 to 100, where a score of 100 represents the ‘Best imaginable health state’ and a score of 0 represents 
the ‘Worst imaginable health state’. Cases with a score lower than 11 were excluded (n=30), since a mistake while filling out was assumed. 
 Intervention group Control group ORa [95% CI] Mean differencea [95% CI] Pa 
Fatigue scoreb 14.6 ± 5.7 13.5 ± 5.5  1.08 [0.43-1.72] <0.001 
Quality of Lifec      
 Mobility ≥ 2 58 (12) 86 (14) 0.86 [0.60-1.23]  0.42 
 Self-care ≥ 2 3 (0.6) 3 (0.5) 1.31 [0.26-6.50]  0.75 
 Usual activities ≥ 2 74 (15) 99 (16) 0.97 [0.70-1.35]  0.85 
 Pain/discomfort ≥ 2 132 (27) 179 (28) 0.94 [0.72-1.24]  0.68 
 Anxiety/depression ≥ 2 27 (5.5) 38 (6.0) 0.92 [0.56-1.53]  0.75 
 EQ VASd 80.1 ± 11.6 81.4 ± 12.1  1.18 [-0.39-2.75] 0.14 
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OR, odds ratio; CI, confidence interval. Data are presented as mean ± standard deviation, no. (%) or OR [95% CI] 
a Using a cut-off titre of ≥ 1:32 
b Odds ratio, mean difference and P-value calculated with generalised linear mixed models, taking into account a clustering effect. 
c Calculated with Fisher’s exact test, since generalised linear mixed models could not provide a P-value. 










Gestational age at delivery (in 
weeks) 
39.6 ± 1.8 39.7 ± 1.7  0.12 [-0.15-0.38] 0.38 
Preterm delivery <37 weeks 13 (7.1) 58 (5.5) 1.30 [0.70-2.43]  0.41 
Very preterm delivery <34 weeks 3 (1.6) 13 (1.2) 1.32 [0.37-4.69]  0.66 
Birth weight (in grams) 3512 ± 527 3507 ± 546  4.8 [-81-90] 0.91 
Small for gestational age 9 (4.9) 78 (7.5) 0.64 [0.32-1.30]  0.22 
Perinatal mortality 0 (0.0) 6 (0.6) not applicable 0.60c 
Overall complicationd 22 (12) 133 (13) 0.94 [0.58-1.52]  0.79 
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Objective Coxiella burnetii infection during pregnancy has been associated 
with adverse obstetric outcome. As part of a randomised controlled trial 
conducted in Q fever high-risk areas in The Netherlands we had the unique 
opportunity to study the predictive value of C. burnetii serological status in 
addition to well-known risk factors for obstetric complications. 
Methods Pregnant women who were not treated with antibiotics for a C. 
burnetii infection were selected from the trial population. These women were 
under supervision of a midwife in primary health care and were followed 
prospectively from approximately 20 weeks of gestation on. We evaluated the 
capacity of maternal characteristics with or without C. burnetii serological 
status to predict adverse obstetric outcome. Adverse obstetric outcome was 
defined as any preterm delivery, child small for gestational age or perinatal 
mortality. The performance of the logistic regression models was assessed with 
receiver-operating-characteristic (ROC) analysis and calibration plots. 
Results In all, of the 1221 included women, 152 (12.4%) had an adverse 
outcome. The prediction model including well-known risk factors such as 
smoking, nulliparity and low education-level was well calibrated, but had low 
predictive value (area under the ROC-curve 0.68; 95% confidence interval 
0.63-0.72) with predicted rates of adverse outcome ranging from 4% to 27%. 
Addition of C. burnetii serological status to the model did not improve its 
predictive value. 
Conclusions In a low-risk obstetric population from high-risk Q fever areas, 
prediction of adverse obstetric outcome is difficult and knowledge of C. 
burnetii serological status does not contribute to a better prediction. 
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INTRODUCTION 
 
Adverse outcome of pregnancy in terms of preterm delivery, a child small for 
gestational age (SGA) or perinatal mortality is still a considerable problem even 
in developed countries.1-3 Several conditions in the woman’s medical history or 
during her pregnancy have been associated with these adverse outcomes 
including maternal infections.4  
The incidence of Q fever, a zoonosis caused by the bacterium 
Coxiella burnetii, has dramatically increased in Europe since 2007.5,6 If infected 
with the bacterium up to 90% of the pregnant women remain asymptomatic.7 
However, both symptomatic and asymptomatic infection during pregnancy 
have been associated with obstetric complications.8-10 Since routine screening 
during pregnancy might prevent complications4, we performed a clustered 
randomised controlled trial (RCT) showing that routine screening for Q fever 
was ineffective in reducing the risk of obstetric complications. Furthermore, C. 
burnetii seropositivity was not associated with obstetric complications in a 
univariable analysis.11 However, it is questionable whether knowledge about 
seropositivity will contribute to a better prediction of adverse obstetric 
outcome in relation to other well-known risk factors. Prediction of adverse 
outcome in obstetrical care is desirable, especially in the unique Dutch 
obstetric care system, where before or at the beginning of pregnancy a 
distinction is made between women with a low risk of pathology (supervision of 
midwifes in primary care) and women with an increased risk (supervision of an 
obstetrician in secondary care).12  
In the present study we assessed the additive predictive value of C. 
burnetii serological status in relation to other well-known risk factors for adverse 
obstetric outcome in a low-risk pregnant population living in an endemic Q 
fever area.       
 
 
PARTICIPANTS AND METHODS 
 
Setting and participants 
We used data from the clustered RCT on screening for C. burnetii infection 
during pregnancy, which was conducted in The Netherlands between March 
2010 and March 2011.11 In short, 55 primary care midwife centres in endemic Q 
fever areas were randomly allocated to a screening or a control strategy. In 
both groups a blood sample was taken from pregnant women who gave 
informed consent, between 20 and 32 weeks of gestation. In the intervention 
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group samples were analysed immediately by indirect immunofluorescence 
assay (IFA) in the laboratory of the Jeroen Bosch Hospital, ‘s-Hertogenbosch, 
The Netherlands. Both immunoglobulin (Ig)M and IgG antibodies against phase 
I and phase II antigens (Nine mile strain) were measured according to the 
manufacturer's instructions (Focus Diagnostics, Cypress, CA, USA). Each run 
included a positive and a negative control. In line with the cut-off values used 
in the clinical setting for the diagnosis of Q fever in symptomatic patients, titres 
≥ 1:32 were considered positive.13 In case of positive serology, intensified 
serological follow up with possible antibiotic treatment of patients with an 
active C. burnetii infection was performed. In the control group samples were 
frozen for analysis after delivery. The study was conducted according to the 
principles of the Declaration of Helsinki and the study protocol was approved 
by the Medical Ethical Review Board of the University Medical Center 
Groningen. 
Only participants who were not treated with antibiotics for a C. 
burnetii infection were included in the current study. Participants in the 
intervention and control group were combined in one cohort.  
 
Outcome measures and predictor selection 
The primary endpoint was a composite measure of obstetric complications, 
which was defined as any preterm delivery, child small for gestational age 
(SGA) or perinatal mortality. Preterm delivery was defined as delivery before 37 
weeks of gestation, SGA was defined as birth weight below the 10th percentile 
according to the birth weight curves of The Netherlands perinatal registry14, 
and perinatal mortality was defined as foetal or neonatal death between 22 
weeks of gestation and one week post partum. 
We evaluated whether the composite endpoint could be predicted using well-
known risk factors including patient’s demographic characteristics (maternal 
age, non-Western ethnicity, low education-level, prepregnancy body mass 
index (BMI)), medical condition (primary hypertension, cardiac disease, 
hypothyroidism), obstetric history (nulliparity, history of miscarriage, history of 
preterm delivery, history of perinatal mortality), lifestyle factors (alcohol use and 
smoking during pregnancy), current clinical characteristics (gestational 
hypertension, gestational diabetes, vaginal blood loss in the second half of 
pregnancy, suspected foetal distress during pregnancy (mainly consisting of 
subjective maternal experience of less foetal movements), male gender of the 
child) and C. burnetii specific serological status. Marginal exploratory analysis 
was performed on the continuous variables maternal age and prepregnancy 
BMI to analyse whether these were best represented in the model as 
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continuous or categorical variables. Based on this analysis, maternal age was 
used as a continuous variable and BMI was categorised in < 25 percentile (BMI 
< 21.3 kg/m2) and ≥ 25 percentile, of which the second category was the 
reference category. 
 
Data analysis   
Baseline demographic information was summarised by outcome group using 
frequencies and proportions for categorical variables and means and 
standard deviations for continuous variables. Binary logistic regression analysis 
was performed to predict the occurrence of the primary endpoint from patient 
characteristics and C. burnetii serological status in a univariable and 
multivariable approach. Only predictors with a frequency of five or higher per 
outcome-group were included in the multivariable analysis. Odds ratio’s (OR) 
and corresponding 95% confidence intervals (CI) were calculated. Two 
methods were used to build the multivariable model. First we applied the full 
model approach, in which only well-known candidate risk factors were 
included in the model irrespective of their P-value, to avoid overfitting of the 
model15: the base model. Secondly, we added C. burnetii serological status, to 
determine the contribution of this variable. The performance of the logistic 
regression models was assessed by calibration and discrimination.16 Calibration 
was evaluated by plotting the observed probabilities against deciles of the 
predictive probabilities and by the Hosmer-Lemeshow test, where a high P-
value (P>0.05) indicates good calibration. The area under the receiver 
operating characteristic (ROC) curve was used to summarise the ability of the 
model to discriminate between individuals with and without the primary 
outcome event. The validity of the two models was evaluated by bootstrap 
analysis. Resampling with replacement from the original dataset was used to 
construct 200 bootstrap models. Calculations were performed using PASW 
Statistics version 18.0 (SPSS inc. Chicago, Illinois, USA) and graphs were 
produces using GraphPad Prism version 4.03 (GraphPad Software inc. La Jolla, 





Of the 6860 eligible pregnant women of the clustered RCT 1348 signed 
informed consent. For this study, 127 participants were excluded because 
serology was not performed (n=119) or the participant was treated with 
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antibiotics for a C. burnetii infection (n=8). Baseline characteristics of the 1221 
participants in relation to the primary endpoint are shown in Table 1.  
 
The primary outcome measure was available for all participants. An obstetric 
complication occurred in 152 of the 1221 (12.4%) participants. Preterm delivery 
occurred in 69 (5.7%) participants, SGA in 86 (7.0%) and perinatal mortality in 6 
(0.5%) women. Eight participants had more than one complication. In a 
univariable analysis participants with an obstetric complication were more 
often nulliparous (P<0.001), smoked cigarettes during pregnancy more often 
(P=0.004), had lower body mass index (P=0.001), gave more often birth to a 
boy (P=0.043) and their pregnancy was more often complicated with vaginal 
blood loss in the second half of pregnancy (P=0.011) and suspected foetal 
distress (P=0.040) (Table 1). In total, 175 of the 1221 participants (14.3%) were C. 
burnetii seropositive (only IgM n=5, only IgG n=131, both IgM and IgG 
antibodies n=39). The presence of C. burnetii antibodies was not associated 
with adverse obstetric outcome in both the univariable and multivariable 
model (OR 0.84, 95% CI 0.50-1.39, P=0.491 and OR 0.90, 95% CI 0.52-1.54, 
P=0.694, respectively). Also when the height of the antibody titres was taken 
into account there was no association with adverse obstetric outcome (Fig. 1).  
 
Figure 1. Probability of obstetric complications in relation to the highest C. 


















The probability of an obstetric omplication (mean with standard error) displayed by the 
highest antibody titre (IgM phase I or II, or IgG phase I or II). Obstetric complication is 
defined as any preterm delivery, SGA or perinatal mortality. 
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Table 1. Baseline characteristics and univariable analysis of the predictors in  
relation to obstetric complications. 
OR, odds ratio; CI, confidence interval; BMI, body mass index. Data are number 
(percentage) or odds ratio [95% confidence intervals] unless otherwise specified. 
a Obstetric complication is defined as any preterm delivery, SGA or perinatal mortality  
b Low represents: no education, primary school, lower-middle secondary school and 
lower professional school; non-low educated represents: medium professional school and 
higher secondary school, higher professional school and university. c Prior to pregnancy. 









Maternal age (mean with 
SD, in years) 
1221 31.7 ± 3.7 31.8 ± 3.8 0.99 [0.95-1.04] 0.794 
Nulliparous 1219 90 (59) 451 (42) 1.98 [1.40-2.80] <0.001 
Ethnic origin non-Western 1212 2 (1.3) 24 (2.3) 0.58 [0.14-2.48] 0.462 
Low educatedb 1211 13 (8.6) 64 (6.0) 1.47 [0.79-2.73] 0.228 
Smoking during 
pregnancy 
1215 23 (15) 84 (7.9) 2.08 [1.27-3.41] 0.004 
Alcohol use during 
pregnancy 
1215 1 (0.7) 24 (2.3) 0.29 [0.04-2.15] 0.225 
BMI (kg/m2) <25th 
percentilec 
1210 55 (36) 246 (23) 1.89 [1.32-2.72] 0.001 
Primary hypertension 1215 1 (0.7) 7 (0.7) 1.01 [0.12-8.24] 0.995 
Hypothyroidism 1215 2 (1.3) 15 (1.4) 0.94 [0.21-4.15] 0.933 
Cardiac disease  1215 1 (0.7) 5 (0.5) 1.41 [0.16-12.17] 0.754 
History of perinatal 
mortality 
1218 0 (0.0) 5 (0.5) not applicable 
History of preterm 
delivery 
1209 6 (3.9) 38 (3.6) 1.10 [0.46-2.65] 0.828 
History of miscarriage 1219 41 (27) 224 (21) 1.39 [0.94-2.05] 0.096 
Male gender child 1219 85 (56) 503 (47) 1.42 [1.01-2.00] 0.043 
Gestational hypertensive 
disorder 
1215 16 (11) 72 (6.8) 1.65 [0.93-2.92] 0.087 
Gestational diabetes 1213 2 (1.3) 9 (0.8) 1.57 [0.34-7.34] 0.566 
Vaginal blood loss 2nd 
half of pregnancy 
1215 10 (6.6) 28 (2.6) 2.62 [1.25-5.52] 0.011 
Suspected foetal distress 
during pregnancy  
1216 11 (7.3) 39 (3.7) 2.07 [1.04-4.13] 0.040 
Coxiella burnetii 
seropositive 
1221 19 (13) 156 (15) 0.84 [0.50-1.39] 0.491 
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Ethnicity, alcohol use, primary hypertension, hypothyroidism, cardiac disease, 
history of perinatal mortality and gestational diabetes were not included in the 
multivariable model since their frequency was below five in de group with an 
obstetric complication. The results of the predictive value of the other variables 
in a multivariable setting are shown in Table 2.  
 
Table 2. Multivariable analysis of the predictorsa in relation to adverse obstetric 
outcome 
RC, regression coefficient; BMI, body mass index. Data are odds ratio (95% confidence 
intervals). a Prior to pregnancy. 
 Base model  
n=1194 
Base model including           
C. burnetii antibody status 
n=1194 
 OR (95% CI) RC P OR (95% CI) RC P 
Maternal age 
(years) 
1.03 (0.98-1.08) 0.030 0.239 1.03 (0.98-1.08) 0.030 0.239 
Nulliparous 2.23 (1.50-3.32) 0.803 <0.001 2.23 (1.50-3.32) 0.801 <0.001 
Low educated 1.33 (0.67-2.64) 0.285 0.414 1.34 (0.68-2.65) 0.291 0.405 
Smoking during 
pregnancy 
1.86 (1.08-3.22) 0.622 0.026 1.85 (1.07-3.20) 0.616 0.027 
BMI (kg/m2) <25th 
percentilea 
1.91 (1.32-2.78) 0.648 0.001 1.90 (1.31-2.77) 0.643 0.001 
History of preterm 
delivery 
1.66 (0.66-4.15) 0.504 0.283 1.65 (0.66-4.15) 0.503 0.283 
History of 
miscarriage 
1.49 (0.98-2.27) 0.398 0.065 1.48 (0.97-2.26) 0.394 0.067 




1.54 (0.85-2.82) 0.434 0.157 1.55 (0.85-2.82) 0.436 0.155 
Vaginal blood loss 
2nd half of 
pregnancy 




1.91 (0.93-3.90) 0.645 0.078 1.92 (0.94-3.92) 0.649 0.076 
Coxiella burnetii 
seropositive 
   0.90 (0.52-1.54) -0.108 0.694 
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The base model gave a moderate discrimination, with an area under the ROC 
curve of 0.68 (95% CI 0.63-0.72, P<0.001) (Fig. 2a). Plotted calibration was 
moderate with predicted rates of obstetric complications ranging from 4% for 
the lowest decile to 27% for the highest decile (Fig. 3a), but the Hosmer-
Lemeshow P-value was high (P=0.49). When we added C. burnetii serological 
status to the model, the area under the ROC curve and the calibration 
remained unchanged (AUC 0.68, 95% CI 0.63-0.72, P<0.001, and Hosmer-
Lemeshow P=0.62) (Fig. 2b and 3b). In both models there was a small 
overestimation of the risk for an obstetric complication in the lowest risk groups 
(<12% predicted probability) and a small underestimation of the risk in the 
higher risk groups (13 to 16% predicted probability) (Fig. 3a and 3b). 
Bootstrapping showed for both models an AUC of 0.65, indicating good validity 
and absence of strong overfitting.   
 
Figure 2. ROC curves of the base model (a) and the model including Coxiella 




















Area under the curve of both curves: 0.68 with confidence interval 0.63-0.72. 
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Figure 3. Calibration plot of the base model (a) and the model including 




















In a low-risk pregnant population from an endemic Q fever area, C. burnetii 
serological status was not of additive value in the prediction of obstetric 
complications. The AUC remained 0.68, which is moderate compared to other 
prediction models in obstetrics.17,18 The reason for this low discriminative 
capacity could be the low-risk population, which we selected on forehand by 
including only women under supervision of a midwife in primary health care. 
Since women with important risk factors, e.g. twin-pregnancies or severe 
underlying morbidities, were therefore already excluded, only weaker risk-
factors remained as input variables for the model. This also explains why the 
variability in predicted probabilities was moderate (4% for the lowest decile to 
27% for the highest decile). In contrast to other studies, we did not identify C. 
burnetii seropositivity as a risk factor for obstetric complications. In a large 
Canadian cohort study, including 7658 parturient women, it was shown that 
IgG seropositivity in umbilical cord blood, which was the case in 3.8% of the 
women, was independently associated with preterm delivery and current and 
prior neonatal death.9 A seroprevalence study performed in Ireland showed 
that IgG phase II seropositive women (11.2% of the 1209 women totally 
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screened) had more often a history of miscarriage or stillbirth.19 An explanation 
for this discrepancy could be in differences in pathogenicity between different 
C. burnetii strains. Genotyping of Dutch samples is ongoing20, but has not 
ended yet. Since in The Netherlands a relatively high number of chronic Q 
fever has been described in patients with aneurysms21, it could be 
hypothesised that the strains involved in the Dutch outbreak are highly virulent 
for people with underlying vascular diseases, while pregnant women are 
relatively protected.  
There are also studies in line with our results. Two large studies conducted in 
Q fever high-risk areas in The Netherlands and France did not find an 
association between seropositivity and complicated pregnancy outcome.22,23 
Furthermore, identifying nulliparity, maternal smoking during pregnancy and 
delivery of a boy as the strongest predictors for adverse obstetric outcome in a 
multivariable approach is similar to the results of previous studies.24-26 The effect 
of BMI on obstetric outcome as described in the literature is, however, two-
sided. On one hand, high BMI has been strongly associated with stillbirth.24 On 
the other hand, low BMI has been associated with low birth weight and SGA.26 
For preterm delivery both low and high BMI have been shown to be risk 
factors.27,28 Since preterm delivery and SGA are much more common than 
perinatal mortality, in our data low BMI turned out to be the risk factor with 
respect to the primary endpoint, which was a composite measure of preterm 
delivery, SGA and perinatal mortality. In our multivariate model vaginal blood 
loss in the second half of pregnancy had the strongest effect on the primary 
endpoint (RC 0.911, OR 2.47), however, this effect is more likely caused by 
clinical intervention than by its natural course.  
The strength of this study is that it was performed on a large cohort of 
pregnant women with a high prevalence of C. burnetii seropositivity due to the 
enormous Q fever outbreak in The Netherlands. Furthermore, data collection 
was very complete. Therefore 1194 of the 1221 cases (98%) could be included 
in the final models. Generalisability to all pregnant women under supervision of 
primary health care in Q fever high-risk areas is expected since we included a 
relatively unselected group, predictors were clearly defined and easy to 
determine. Although large numbers of women were not willing to participate in 
the clustered RCT on C. burnetii screening, random refusal is expected since 
major patient characteristics, like maternal age and proportion of nulliparous 
women, are comparable with other large population based cohort studies 
from The Netherlands.29,30 However, pregnant women with a non-Western 
ethnicity were underrepresented in our study population because only Dutch-
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speaking women were eligible for inclusion. Therefore, the model should be 
interpreted with caution for this specific group. 
In conclusion, prediction of adverse obstetric outcome in women who 
have been assessed as having a low risk for obstetric complications in the 
beginning of pregnancy is difficult using the well-known risk factors like 
nulliparity and smoking during pregnancy. C. burnetii seropositivity was not 
associated with obstetric complications in a multivariate setting and adding 
this variable to the prediction model did not improve the model’s predictive 
capacity. Therefore, knowledge about C. burnetii antibody status is not useful 
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Symptomatic and asymptomatic Coxiella burnetii infection during pregnancy 
have been associated with obstetric complications. We described placental 
histopathology and clinical outcome of five cases with asymptomatic C. 
burnetii infection during pregnancy and compared these cases with four 
symptomatic cases from the literature. In contrast with the symptomatic cases, 
we did not observe necrosis or active inflammation in the placentas of the 
asymptomatic women. Obstetrical outcome was more favourable in the 
asymptomatic cases than in the symptomatic cases. Asymptomatic and 
symptomatic C. burnetii infection during pregnancy are different entities with 
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INTRODUCTION 
 
Several European countries notified increasing numbers of human Q fever 
since 2007.1,2 Q fever is a zoonosis caused by the intracellular bacterium 
Coxiella burnetii. It primarily infects ruminants and rodents, in which the 
infection is mainly associated with miscarriage and stillbirth.3 Humans are 
predominantly infected by inhalation of contaminated aerosols.4   
 Up to 90% of pregnant women with antibodies suggesting recent 
infection with C. burnetii remain asymptomatic.5 However, symptomatic and 
asymptomatic C. burnetii infection during pregnancy have been associated 
with obstetric complications, including miscarriage, preterm delivery and foetal 
death.6,7 Placental infection assessed by polymerase chain reaction (PCR) or 
culture has been strongly related to these complications.6 However, 
information about placental histopathology, in particular in asymptomatic 
cases, is lacking. Therefore, we described placental histopathology from 
women with asymptomatic C. burnetii infection during pregnancy. 
Subsequently, we compared our results with symptomatic cases described in 
the literature.  
 
 
PATIENTS AND METHODS 
 
Setting and participants 
This study was embedded in a clustered randomised controlled trial about the 
effectiveness of a screening program for C. burnetii infection during 
pregnancy. In that study pregnant women living in Q fever high-risk areas in 
The Netherlands were serologically screened for C. burnetii infection. Details 
about the screening study are described elsewhere.8 The study protocol was 
approved by the Medical Ethical Review Board of the University Medical 
Center Groningen (UMCG). All participants included in this study gave written 




From women who participated in the intervention group of the screening trial 
and who had serological evidence for an acute infection, placentas were 
collected. An acute infection was defined as the presence (cut-off titre ≥ 1:32) 
of immunoglobulin (Ig)M accompanied with (rising) IgG during follow-up. 
Serology was performed with indirect immunofluorescence assay (IFA, Focus 
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Diagnostics, Cypress, CA, USA). Placentas were histopathologically analysed 
by one pathologist (AT) from the UMCG. Furthermore, C. burnetii specific real-
time PCR was performed. Primers and probes used have been described 
earlier9, other technical details are available on request.  
 
Systematic review 
A systematic review of the literature was done by searching PubMed and the 
references of the included papers following the PRISMA-guidelines. Our search 
was limited to human studies in English or Dutch. The search strategy was: ‘’Q 
fever OR Coxiella burnetii’’ AND ‘’placenta’’. First we pre-screened the titles 
and the abstracts; afterwards the eligibility of the studies was judged by 
reading the full-texts. Only studies describing human placental histopathology 





Seven of the 536 women in the intervention group of the screening trial had 
serological profiles suggesting an acute C. burnetii infection and were treated 
with antibiotics. Overall, five placentas were stored and send for re-evaluation 
to the UMCG, including two placentas from women with follow-up serology 
suggesting a previous infection. All cases were asymptomatic at the moment 
of screening. Clinical outcome and placental histopathology are summarised 
in the first part of Table 1.  
 The PubMed search resulted in 30 hits. Only 2 papers included data on 
human placental histopathology and were included. Two other reports were 
included based on the references. All included papers concerned case-
reports of symptomatic acute or chronic Q fever cases.10-13 Clinical outcome 
and placental histopathology of these cases are summarised in the second 





We showed that asymptomatic and symptomatic C. burnetii infection during 
pregnancy are different entities with respect to placental pathology and the 
risk of obstetric complications. Placental histology in the asymptomatic cases 
showed, in contrast with the symptomatic cases, no foci of necrosis or active 





  7 
result of interruption of foetal blood flow or destruction of capillaries due to 
previous villitis.14 The presence of low grade chronic villitis is a frequent finding in 
third trimester placentas and probably related to a maternal immune response 
directed against foetal antigens inherited from the father. Until present no 
microbiological pathogens have been linked to chronic villitis.15 Whether 
placenta hypoplasia and pathology consistent with maternal vascular 
underperfusion are linked to C. burnetii infection is to our knowledge unknown.  
In none of the placentas from asymptomatic cases C. burnetii could 
be detected with PCR.  Previously this also has been shown for a larger cohort 
of 153 asymptomatic seropositive women7, suggesting that the rate of 
placental infection during asymptomatic C. burnetii infection is very low. 
Our findings are in line with animal studies. In cows, where Q fever is 
usually not clinically apparent, positive PCR on bulk tank milk is only rarely 
associated with histopathological inflammation of placentas.16 On the other 
hand, in goats and sheep, in which C. burnetii infection is often associated with 
miscarriage and stillbirth, necrotising inflammation of placental tissue is a 
common finding.17,18  
Various factors, including host immune response, cytokines and 
different strains of C. burnetii, have been suggested to play a role in the clinical 
manifestation and outcome of C. burnetii infection in both animals and 
humans, but further research is needed to find target points for prevention and 
treatment.18-20  
 In conclusion, after asymptomatic C. burnetii infection during 
pregnancy placental examination reveals no major pathology related to 
previous villitis, which is associated with a favourable clinical outcome. 
Symptomatic infection is a different entity. Obstetric complications in these 
cases can very well be explained by colonisation with C. burnetii and massive 





The authors gratefully thank all midwives, residents, obstetricians, medical 
microbiologists and pathologists of the participating centres for their help in 
patient recruitment, and data and placenta collection.   
 102 
 






Initial serological valuesa 
Treatment 
IgM II IgM I IgG II IgG I 
Asymptomatic patients 





1:1024 1:32 1:512 <1:32 Erythromycin 






1:256 1:32 1:1024 1:128 Erythromycin 










1:512 1:64 1:256 <1:32 Erythromycin 
4 34 0 None 
 
 
1:512 <1:32 1:128 <1:32 None 





1:256 <1:32 1:128 <1:32 None 




















Unknown; seroconversion Cotrimoxazole 
3 
Friedlan




















1:1600 1:200 1:800 1:25000 Erythromycin/ 
rifampicin 
Legend Table 1. y, years; Ig, immunoglobulin; wks, weeks; g, grams; PCR, polymerase chain reaction; 

























42+0 4030/  
50-80th 
Arrest of second 
stage of labour; 
uncomplicated 
caesarean 
section at term 
PCR negative Unknown No significant 
pathology 








PCR negative 540/75-90th  No significant 
pathology 












stemvillus vessels;  
scattered fibrotic 
villi,  low grade 
chronic villitis  
(Fig. 1) 





PCR negative 425/<10th  Placental 
hypoplasia 






fluid at term 














Unknown Areas of necrosis 
24 Unknown Miscarriage Immunofluorescent 
stain positive 
 
Unknown Multiple foci of 
necrosis 





al strain positive 
Unknown Severe 
necrotising villitis 








transverse lie of 
the foetus 
PCR positive Unknown No areas of 
necrosis or other 
gross pathology 
a Serology of the asymptomatic cases was performed with indirect immunofluorescence assay (IFA, 
Focus Diagnostics, Cypress, CA, USA), measuring both IgM and IgG against phase I and II antigens. 
Serology of the symptomatic cases was performed with in-house assays.  
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Figure 1. Hematoxylin and eosin stain of placental tissue from asymptomatic 
case no 3. 
 
Demonstrating fibrotic chorionvilli, loss of capillaries, stromal karyorrhexi and haemorrhage 
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Since acute Q fever during pregnancy is an indication for long-term antibiotic 
treatment, accurate IgM phase II assays are indispensable. Seroprevalences in 
women from high (n=1229) and low-risk (n=180) Q fever areas were compared 
using indirect immunofluorescence assay (cut-off titre 1:32). The resulting IgM 
phase II seroprevalences of 4.3% and 0% (P=0.001), respectively, indicate 100% 
specificity. 
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INTRODUCTION 
 
The incidence of Q fever, a zoonosis caused by the bacterium Coxiella 
burnetii, has enormously increased in several European countries since 2007.1 
Most of the infected individuals are either asymptomatic or present with a mild 
flu-like illness. However, C. burnetii may pose a serious threat to pregnant 
women because of the increased risk of chronic Q fever which can be 
complicated by endocarditis.2,3 In addition, Q fever during pregnancy has 
been associated with obstetric complications.3,4 Because of these 
complications, accurate diagnosis and knowledge about the significance of 
C. burnetii antibodies during pregnancy is indispensable.  
Because of its simplicity and safety, the diagnosis of Q fever largely 
relies upon serology, of which indirect immunofluorescence assay (IFA) is the 
reference method.5 One of the characteristics of C. burnetii is antigenetic 
phase variation; antibodies against two phases of antigens can be 
distinguished. After exposure to C. burnetii immunoglobulin (Ig)M against phase 
II antigen is the first antibody to appear, followed by IgM phase I, IgG phase II 
and IgG phase I.5 For the diagnosis of acute Q fever demonstrating IgM phase 
II is therefore of great importance. Presence of IgG in the absence of or in 
combination with low titres of IgM suggests a previous infection. Test 
characteristics of IFA during pregnancy are not known. It is a well-known fact 
that serological assays for other infectious diseases during pregnancy, 
especially IgM assays, may produce false-positive results.6,7 Since acute Q fever 
is an indication for long-term antibiotic treatment3, knowledge about the 
specificity of IgM phase II assays is crucial to prevent unnecessary treatment 
during pregnancy. 
A recent Dutch Q fever outbreak was hypothesised to be the result of 
highly infected dairy goat and sheep farms. This outbreak in The Netherlands 
was clearly defined in time and place.8 This gave us the opportunity to 
compare sera drawn from pregnant women in high-risk areas with sera from 
pregnant women in low-risk areas. The objectives of this study were (1) to 
describe the seroprevalences of the different antibodies during pregnancy 
determined by IFA in a low and high-risk area, and (2) to estimate the 








MATERIALS AND METHODS 
 
Participants and setting 
Women from high-risk areas 
Sera from pregnant women living in Q fever high-risk areas were obtained from 
a clustered randomised trial (RCT) on screening for C. burnetii infection during 
pregnancy, which was conducted in The Netherlands between March 2010 
and March 2011.9 Fifty-five primary care midwife centres from regions with the 
highest Q fever incidences in 2009 and 2010 recruited pregnant women for 
participation. From women giving informed consent, a blood sample was 
taken between 20 and 32 weeks of gestation. The study protocol was 
approved by the Medical Ethical Review Board of the University Medical 
Center Groningen.  
 
Women from low-risk areas 
Sera from pregnant women who were not very likely exposed to C. burnetii 
recently, were obtained anonymously from the Centre for Infectious Diseases 
Friesland Izore, The Netherlands. Sera were taken around 12 week of gestation 
as part of a routine screening program for infectious diseases (hepatitis B virus 
(HBV), human immunodeficiency virus (HIV) and syphilis) from women living in 
the Dutch North-western province Friesland. In this province there were no 
dairy goat or sheep farms with C. burnetii-induced abortion waves (>5% 
abortions) and routine tests for the presence of C. burnetii in bulk tank milk, 
which were performed by the Dutch government between October 2009 and 
April 2010 as part of the preventive measures to curb the Q fever epidemic, 
were all negative.8,10 To extra minimise the risk of true-positive samples, all 
selected sera were drawn in 2007, the year before there was a C. burnetii-
associated abortion wave on a farm near the border of the province 
Friesland10 and before the widespread Dutch Q fever outbreak (2008 and 
2009).8  Since none of the included women from the high-risk area were HIV, 
HBV or syphilis positive, only negative sera for those diseases were selected to 
improve comparability between the two groups. Furthermore, in line with the 
women from high-risk areas, we only included women under supervision of a 
primary care midwife. In The Netherlands, midwives working in primary health 
care are only allowed to supervise low-risk, singleton pregnancies in healthy 
women. By excluding sera from women under supervision of an obstetrician 
(secondary health care) we excluded women with auto-immune diseases or 
other underlying illnesses that are known to be associated with aspecific 
antibody formation.7 Since the samples were obtained and screened 
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All sera were analysed with indirect immunofluorescence assay (IFA) in the 
laboratory of the Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands. 
IgM and IgG against phase I and phase II antigens (Nine Mile strain) were 
measured according to the manufacturer's instructions (Focus Diagnostics, 
Cypress, CA, USA). Each run included a positive and a negative control. In line 
with the cut-off values used in the clinical setting for the diagnosis of Q fever in 
symptomatic patients, titres ≥ 1:32 were considered positive.11 Every positive 
sample was fully titrated. Samples with the titre 1:32 were re-analysed and 
judged by two laboratory workers to preclude aspecific reactions. Only if both 
agreed about positivity the sample was assessed as such.  
 
Statistical analysis 
Seroprevalences were calculated for the different antibodies by dividing the 
number of positive cases with the total number tested. Since no IgM phase II 
positive cases were expected in the low-risk areas, specificity of the assay was 
estimated using the formula: 100% – (IgM phase II seroprevalence of the low-
risk group). Fisher’s exact test was used to test the differences between the two 
groups. A two-sided P value of less than 0.05 indicated statistical significance. 
Statistical analyses were performed using PASW Statistics version 18.0 (SPSS inc. 





Within the clustered RCT (women from high-risk areas) 1229 women were 
routinely screened for the presence of C. burnetii antibodies. From the areas 
with a low risk of C. burnetii exposure 180 samples were randomly selected and 
tested. Seroprevalences are shown in Table 1. Specificity of the IgM phase II 









Table 1. Seroprevalences of the different antibodies per group 
Data are no. (%) of women. Ig, immunoglobulin.  





As expected from a region without recent C. burnetii exposure we did not find 
IgM phase II positive cases in the low-risk area, in contrast to a 4.3% 
seroprevalence in the high-risk area (P=0.001). This finding suggests that C. 
burnetii IgM phase II IFA during pregnancy, using a cut-off of 1:32, is 100% 
specific. Still, the presence of IgM phase II should always be judged in relation 
to IgG, because both isotypes of antibodies will appear following an acute 
infection.5 After combining the results for all four antibodies, only two positive 
IgM phase II results in the high-risk group (0.2%) were judged to be aspecific 
reactions by a medical microbiologist with much experience in this field 
(ACAPL), indicating a specificity slightly less than 100% with a positive 
predictive value over 96%.  
Antibodies presenta  
 
Women from 
high-risk areas  
(n=1229) 




Seropositiveb 187 (15.2) 20 (11.1) 0.176 
 Any IgM 56 (4.6) 0 (0) 0.001 
 IgM phase I 10 (0.8) 0 (0) 0.626 
 IgM phase II 53 (4.3) 0 (0) 0.001 
 Any IgG 179 (14.6) 20 (11.1) 0.252 
 IgG phase I 34 (2.8) 4 (2.2) 0.810 
 IgG phase II 178 (14.5) 20 (11.1) 0.252 
IgG phase II titre    
 1:32 60 (4.9) 7 (3.9) 0.708 
 1:64 37 (3.0) 2 (1.1) 0.220 
 1:128 25 (2.0) 5 (2.8) 0.576 
 1:256 29 (2.4) 4 (2.2) 1.000 
 >1:256 27 (2.2) 2 (1.1) 0.571 
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The overall C. burnetii seroprevalence in both groups of pregnant women from 
a low-risk and a high-risk area was high, being 11.1% and 15.2% respectively, 
mainly caused by a high prevalence of IgG phase II. These seroprevalences 
seems to be higher than in non-pregnant Dutch populations.12,13 Before the 
epidemic a seroprevalence of 2.4% was estimated for the general population12 
and during the outbreak in 2009 a seroprevalence of 12.2% was measured 
among blood donors.13  
 There are several reasons for the difference in seroprevalence 
between our pregnant women and the non-pregnant population. First of all C. 
burnetii exposure risk could be different, especially with respect to our low-risk 
group. We selected these women from an area without known infected dairy 
goat or sheep farms, but the province Friesland has many sheep farms. 
Previously in southwestern Germany, the seroprevalence showed a linear 
increase with sheep density.14 Since IgG phase II can be positive over 10 years 
after the primary infection15, possible undetected C. burnetii infected farms in 
the past could have led to an increased seroprevalence in human living in this 
area.  
Another explanation could be the different characteristics of the 
hosts. During pregnancy sex hormones cause shifts of immunity from cell 
mediated to humoral, which could lead to higher immunoglobulin levels at 
baseline and in response to infection.16,17 Whether the term of pregnancy, 
which differed between our low and high-risk group, is important in this setting 
is unknown. Furthermore, cut-off values in general and in specific during 
pregnancy are subjects of ongoing debate. Since we pursued a high 
sensitivity, we used a cut-off titre of 1:32 for all antibodies. The manufacturer 
noted that levels of phase II IgG <1:256 may be considered non-specific. If we 
would apply this to our test results the seroprevalences of phase II IgG in our 
high-risk and low-risk group would drop to 4.6% and 3.3%, respectively. Because 
C. burnetii is widespread in the environment and infected animals are mostly 
asymptomatic8 we are unable to guarantee absence of previous exposure to 
C. burnetii in the low-risk group. Therefore specificity of the IgG assay using 





The findings of our study indicate a very high specificity of the IgM phase II IFA 
during pregnancy, using a cut-off titre of 1:32, both when solitary judged as 
well as in combination with other isotypes. The overall C. burnetii 
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seroprevalence in pregnant women from both the high and low-risk area was 
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Objective Contracting Q fever during pregnancy carries a risk of developing 
obstetric complications. The aim of this study was to gain insight into pregnant 
women’s decisions regarding participation in a future Q fever screening and 
treatment program. 
Methods Pregnant women (n=148) in Q fever high-risk areas in The Netherlands 
were recruited via midwives’ practices and via an online panel for a cross-
sectional questionnaire survey. The outcome measures included intention to 
participate in the program, Q fever exposure risk, perceived Q fever risk, trust in 
health professionals and authorities, disease-related knowledge and additional 
outcome measures. 
Results Fifty-six percent of the respondents intended to participate in the 
screening and treatment program. The sole determinant of a higher intended 
program uptake was a more positive appraisal of program efficacy and 
convenience. This appraisal was in turn associated with perceived risk and 
knowledge. 
Conclusion Women’s appraisal of program efficacy and convenience, their 
disease-related knowledge and perceived Q fever risk seem to be crucial for 
their intended program uptake. A successful implementation of a Q fever 
screening and treatment program may thus depend on the benefits and 
downsides of the program, and on securing that women are aware of the risks 
of the disease. 
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INTRODUCTION 
 
Q fever, a zoonosis caused by the bacterium Coxiella burnetii1,2, has recently 
caused a large epidemic in a specific region in The Netherlands.3 A total of 
2357 human cases were notified in 2009.3 Pregnant women have been 
described to be a risk group for Q fever.4-6 Acute and chronic Q fever 
increases the risk of developing obstetric complications, such as foetal growth 
restriction, low birth weight, premature delivery, oligohydramnios, stillbirth and 
spontaneous abortion.4-6 Veterinary measures have been implemented to 
control the Q fever epidemic in The Netherlands. However, it has been 
suggested that these veterinary measures may not decrease Q fever 
incidence levels.3 Public health preventive measures may therefore be 
essential to prevent potential adverse obstetric outcomes. Accordingly, a 
large study has been undertaken to assess the costs and effectiveness of 
implementing a specific Q fever screening program for pregnant women in 
The Netherlands.7 Such program in which pregnant women are offered 
maternal blood serum screening for C. burnetii has been advised under 
epidemic conditions, as Q fever during pregnancy is commonly 
asymptomatic.8 Administering appropriate cotrimoxazole treatment to women 
who test positive for Q fever would then prevent Q fever-induced obstetric 
complications.5  
The effectiveness of any screening and treatment program for Q fever 
depends on the pregnant women’s uptake and compliance. Although some 
studies have examined the influence of various determinants on the uptake of 
prenatal screening aimed at detecting genetic diseases9, few studies have 
looked at the decisions of pregnant women regarding serum screening for 
infectious diseases. To our knowledge, no studies have been conducted on 
pregnant women’s decisions regarding screening for emerging infectious 
diseases under epidemic conditions. The present study aimed to gain insight 
into the decisions of pregnant women regarding participation in a future 
screening and treatment program for Q fever. The study focused on Q fever 
exposure risk, perceived Q fever risk, knowledge about the disease, and trust in 
health professionals and authorities. Given the relatively new, emerging nature 
of this infectious disease, we expect that risks and knowledge are particularly 
relevant determinants of pregnant women’s decisions regarding participation 
in the program. Q fever exposure risk had our attention, as this real risk might 
have an influence on perceived risk. As Sjoberg stated, ‘several factors have 
been proposed for the explanation of perceived risk’.10 A primary candidate is, 
of course, real risk. Subsequently, perceived risk may have an influence on 
 122 
 
pregnant women’s decisions regarding participation in the program, as it is a 
central determinant of intentions in many health-behaviour-predicting 
theories.11 Moreover, perceived risk has been found to be associated, 
although weakly, with pregnant women’s attitude towards undergoing 
prenatal screening for Down syndrome.12 Knowledge of Q fever may also be 
relevant, as pregnant women might be unfamiliar with this disease. Knowledge 
about the condition being screened for has been described to influence the 
uptake of prenatal screening for Down syndrome.13 Moreover, trust in health 
professionals and authorities was considered to be relevant, given their vital 
role in implementing central screening programs. The level of trust in public 
health authorities and health care professionals has, for instance, been 
described to positively influence parental protective behaviour in studies on 
parental uptake of traditional MMR vaccination.14,15 Furthermore, the current 
study looked at the influence of some other determinants obtained from 
general health behaviour predicting theories (e.g. protection motivation 
theory16). This study identified the key determinants of a successful 
implementation of a maternal serum screening and treatment program for Q 





Study sample and procedure 
The study comprised a cross-sectional questionnaire survey among pregnant 
women who lived in Q fever high-risk areas in The Netherlands (Noord-Brabant, 
Gelderland and Limburg). Women were recruited in two ways, either via their 
midwifes’ practice or via an existing online panel. Ten midwives’ practices 
were selected in municipalities where Q fever incidence in 2009 was over 5 per 
100,000 inhabitants.17 These midwives’ practices were asked for their 
cooperation by the National Institute for Public Health and the Environment. 
Eight practices recruited respondents by handing out invitation leaflets to 
pregnant women who came to the practice for a routine visit. The invitation 
leaflet gave details about the study and included a web address where a link 
to the web-based questionnaire could be found (www.examine.nl). Two other 
midwives’ practices directly distributed paper-form questionnaires during 
consulting hours. Subsequently, the respondents recruited via the midwives’ 
practices consisted of a web-based group and a paper-based group. 
Separately, a group of pregnant women received a questionnaire via an 
existing online research panel [Flycatcher (http://www.flycatcher.eu/)]. This 
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research panel is representative of the general Dutch population. For this 
study, a sample of panel respondents was selected based on postal codes to 
match the areas where respondents were recruited via midwives’ practices. 
The resulting three groups of pregnant women will be denoted as ‘web-
based,’ ‘paper-form’ and ‘panel’ groups. A screening strategy study for Q 
fever, simultaneously with the present study, which was conducted between 
April and May 2010, during pregnancy, was held in the same region.7 It was 




The questionnaire used in the study contained the sections with questions 
pertaining to background characteristics and outcome measures as well as a 
section dedicated to providing information about the Q fever screening and 
treatment program that was offered. As this program is not yet implemented, 
the offer in this study was hypothetical. The information that respondents 
received about the program was formulated in correspondence with the 
authors of the ongoing screening strategy study for Q fever.7 This information 
included the screening and treatment procedure, and the duration, benefits 
and potential side effects of antibiotic treatment. The questionnaire addressed 
the following outcome measures (in order of appearance in the 
questionnaire). 
Knowledge about Q fever and Q fever during pregnancy was tested by six 
questions (answer categories ‘true,’ ‘false’ and ‘don’t know’). 
Affected acquaintance Respondents were asked if they knew someone who 
had contracted Q fever (one item). 
General perceived risk of conditions during pregnancy which are generally 
known to affect baby’s health (i.e. alcohol, smoking, toxoplasmosis) was 
measured by six items. Addition of the responses on these items resulted in a 
combined scale with Cronbach’s α=0.862. Cronbach’s α is a measure that 
reflects the reliability of outcome measures that are constructed by adding the 
scores of the answers of multiple items. It is generally agreed that a Cronbach’s 
α of approximately 0.7 or higher indicates a satisfactory internal consistency on 
a group level.18 
Perceived Risk of Q fever during pregnancy was measured by four items 
(Cronbach’s α=0.632) which assessed the perceived foetal vulnerability, 
perceived severity of Q fever-induced obstetric complications, perceived own 
vulnerability of contracting Q fever during pregnancy, and perceived own 
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vulnerability compared to other pregnant women of the same age (perceived 
relative risk). 
General anxiety was assessed by two items (Cronbach’s α=0.785) regarding 
anxiety of stillbirth or of physical defects of the baby, derived from a 
pregnancy related anxiety questionnaire.19 
Anxiety was measured by two questions (Cronbach’s α=0.985) about the 
respondent’s worries about Q fever-induced obstetric complications and the 
influence of Q fever on their baby’s health. 
Preventive measures Respondents were asked if they had already adopted 
measures to prevent Q fever during pregnancy (one item, e.g. avoidance of 
contact with goats and sheep during pregnancy). 
Decisions regarding participation Respondents were asked if they intended to 
participate in the screening and treatment program, if this program would be 
organised and recommended by public authorities at present (one item) or 
would be organised and recommended in future (one item). In one open-
ended question, respondents were then asked for the main reasons of their 
decision regarding participation in the program. Furthermore, respondents 
were asked how certain they were of this decision (one item). 
Appraised efficacy and convenience Respondents were asked by six items 
(Cronbach’s α=0.715) how they appraised the efficacy of the Q fever 
screening test (e.g. regarding prevention of Q fever-induced obstetric 
complications), of the antibiotics treatment and of the screening and 
treatment program in total, and whether they thought the treatment would be 
inconvenient. Appraised efficacy and inconvenience have been described to 
be predictors for health protective behaviour in terms of response efficacy and 
response costs in the protection motivation theory.16 
Trust in the communication and competence of first line health care 
professionals and public authorities regarding Q fever during pregnancy was 
assessed by ten items (Cronbach’s α=0.908), in analogy with trust items 
described for environmental risks.20 
Exposure risk was estimated based on six items which assessed known risk 
factors for contracting Q fever: the proximity of a Q fever-affected dairy goat 
farm,21 occupational risk22-24 and direct contact with Q fever-infected 
ruminants25 or with materials originating from these animals.26 A risk profile was 
calculated based on the number of risk factors (no vs one or more).  
 
The information about the screening and treatment program was presented 
after the question about other preventive measures. The questionnaire was 
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pilot-tested among pregnant women in Q fever high-risk areas and 
subsequently slightly revised to enhance comprehensibility. 
 
Analysis 
Descriptive analyses were performed for each variable. As the distributions of 
the variables anxiety and exposure risk were skewed to the right, these 
variables were dichotomised. The main reasons of participants’ intentions for 
participation in the screening and treatment program or for no participation 
were classified and categorised by the first and third author separately. The 
determinants of intention to participate at present were identified by simple 
and multiple logistic regression analyses (backward and forward selection). To 
establish the determinants of appraised efficacy and convenience, general 
linear model multiple regression analysis (backward selection) was used. 
Demographic, obstetric, general anxiety and general perceived risk variables 
were included one-by-one in these logistic and general linear model analyses. 
The association between exposure risk and perceived risk items was examined 
by independent sample t -tests and linear-by-linear chi-square tests. For all 
outcomes (responses or found associations) differences between the three 
groups of respondents (web-based, paper-form or panel data) were checked 
by analysis of variance (ANOVA) and chi-square analysis. All significance tests 
performed in this study were two-sided (α=0.05) and analyses were conducted 






In total, 148 respondents completed the questionnaire, of which 61 were web-
based (response rate 9%), 36 paper-form (response rate 36%), and 51 panel 
respondents (response rate 73%). The majority of the outcome measures did 
not differ between the web-based, paper-form and panel group (ANOVAs 
and chi-square analyses, P>0.05). These three groups solely differed in 
knowledge and gestational age. The paper-form group had a lower 
knowledge score (ANOVA, F=8.89, P<0.001) compared to the other groups, 
and had eight weeks’ higher gestational age than had the panel group 
(ANOVA, F=7.79, P=0.001). The data source had no influence on the 
significance of the relationship between knowledge and intention to 
participate, or that of the association between knowledge and appraised 
efficacy and convenience. Table 1 presents demographic and obstetric 
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characteristics of the total sample. The majority of the respondents (94%) had 
heard about Q fever. Although most respondents (71%) were aware that 
pregnant women are a risk group for Q fever, a minority (35%) had heard 
about the effects of Q fever on the pregnancy outcome. Only 4% was aware 
that Q fever during pregnancy could be asymptomatic, whilst 35% incorrectly 
assumed that Q fever is invariably symptomatic and the other respondents 
indicated that they did not know the correct answer. The descriptive results of 
exposure risk, perceived Q fever risk, knowledge, trust, and additional 
determinants are shown in Table 2. The mean score of general anxiety was 3.3 
(range 0–10, SD=0.15). General perceived risk had a mean score of 26.0 (range 
0–32, SD=0.41). 
 
Table 1. Demographic and obstetric data of the respondents 
Demographic and obstetric variables Total samplea 
Age (years) 31.3 (4.5) 
Gestational age (weeks) 25.1 (10.1) 
Educational level, n (%)  
Low 9 (6.6) 
Middle 50 (36.8) 
High 77 (56.6) 
Religion, n (%)  
None 56 (40.9) 
(Roman) Catholic 64 (46.7) 
Protestant 8 (5.8) 
Other 9 (6.6) 
Parity, n (%)  
Primiparous 69 (50.4) 
Multiparous 68 (49.6) 
Data are mean (standard deviation) unless otherwise specified. 
a Because of missing values, the total number of respondents (n) differs for each variable. 
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Table 2. The descriptive results for perceived risk, trust, knowledge, exposure 
risk, and other determinants 
Determinants Total samplea Rangeb 
Perceived risk 12.2 (0.24) 0–21 
Trust 39.0 (0.50) 10–50 
Knowledge 14.8 (1.7) 6–18 
Exposure risk, n (%)   
No risk factors 93 (68)  
One or more risk factors 44 (32)  
Appraised efficacy and convenience 11.8 (0.21) 0–20 
Affected acquaintance, n (%)   
No 117 (84)  
Yes 23 (16)  
Preventive measures, n (%)   
No 124 (87)  
Yes 18 (13)  
Anxiety, n (%)   
None/little 113 (80)  
Considerable/much 28 (20)  
Data are mean (standard deviation) unless otherwise specified. 
a Because of missing values, the total number of respondents (n) differs for each  
   determinant. 
b Ranges are presented for continuous determinants. 
 
Pregnant women’s decisions regarding participation 
More than half of the respondents intended to participate in a Q fever 
screening and treatment program at present (Table 3). The answers about the 
intention to participate in the future and the intention to participate at present 
were strongly associated Pearson’s χ2=77.1, P<0.001). Respondents were quite 
certain about their decision to participate in the program (Table 3). The most 
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frequently mentioned reasons of having no intention to participate (answer 
categories ‘absolutely not’ and ‘probably not’) were ‘exposure risk perceived 
to be low’ (22%); ‘side effects of antibiotics not known or not yet known’ (19%); 
‘own and baby’s status perceived as healthy’ (15%) and ‘anxiety of the 
consequences of participation’ (7%). The major reasons of the intention to 
participate (answer categories ‘probably’ and absolutely’) were ‘baby’s 
health’ (36%), ‘certainty of not having Q fever’ (13%), ‘excluding health risk’ 
(10%) and ‘own health’ (10%). 
 
Table 3. Decisions of respondents regarding their participation in a Q fever 
screening and treatment program 
Decisions regarding participation Total samplea 
Intended to participate in future, n (%)  
Absolutely not 7 (5.1) 
Probably not 23 (16.7) 
May be 29 (21.0) 
Probably 57 (41.3) 
Absolutely 22 (15.9) 
Intended to participate at present, n (%)  
No 62 (44) 
Yes 79 (56) 
Certainty of decisions regarding participation 4.2 (1.4)b 
Data are mean (standard deviation) unless otherwise specified. 
a Because of missing values, the total number of respondents (n) differs for each variable. 
b Range 0–6. 
 
Determinants of intention to participate 
Respondents’ trust in health professionals and authorities regarding Q fever 
during pregnancy had no influence on their intention to participate at present 
(Table 4). Exposure to Q fever risk factors and perceived risk of Q fever during 
pregnancy were also not related to the intention to participate (Table 4). 
Appraised efficacy and convenience was the sole determinant of the 
intention to participate (Table 4). Respondents’ intention to participate was 




  9 
higher when they appraised the screening and treatment program as more 
efficacious and less inconvenient (Table 4). Demographic, obstetric, general 
anxiety and general perceived risk variables had no influence on the 
relationship between intention and appraised efficacy and convenience. 
 
Table 4. Multiple logistic regression analysis results of the associations between 
the determinants and the intention to participate in the Q fever screening and 
treatment program at present 
Determinants β-value SE P 
Perceived risk 0.001 0.10 0.99 
Trust 0.06 0.04 0.14 
Exposure risk 0.12 0.54 0.37 
Knowledge − 0.13 0.15 0.87 
Appraised efficacy and convenience 0.86 0.16 <0.001 
Affected acquaintance 0.95 0.73 0.19 
Preventive measures 1.18 0.86 0.17 
Anxiety − 0.37 0.76 0.63 
SE, standard error. 
 
Determinants of appraised efficacy and convenience 
The independent determinants of appraised efficacy and convenience were 
perceived risk and knowledge. Respondents, who perceived the risk of Q fever 
as high, appraised the program as more efficacious and less inconvenient 
(general linear model, β=0.229, SE=0.074, P=0.002). A higher knowledge about 
Q fever in general and Q fever during pregnancy was associated with a higher 
appraised efficacy and convenience (general linear model, β=0.284, SE=0.119, 
P=0.018). Demographic, obstetric, general anxiety and general perceived risk 
variables had no influence on the significance of these associations. 
 
Exposure risk and perceived risk 
Linear-by-linear chi-square tests revealed that respondents who had a higher 
exposure risk perceived the relative risk of contracting Q fever during 
pregnancy compared to other pregnant women of the same age as higher 
(χ2=6.72, P=0.012). However, an increased exposure to risk factors had no 
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influence on the perceived risk of contracting Q fever during pregnancy 





More than half of the pregnant women in Q fever high-risk areas included in 
the present study intended to participate in a Q fever screening and treatment 
program, if this program would have been implemented at present. The most 
important direct determinant of this intention was found in the pregnant 
women’s appraisal of efficacy and of practical convenience of the screening 
and treatment program. This appraisal, in turn, differed among women 
depending on the perceived risk of Q fever and on the level of knowledge 
about Q fever. Trust in health professionals and authorities and actual exposure 
to Q fever risk factors were not associated with pregnant women’s intention to 
participate in the program.  
A positive appraisal of efficacy and convenience of the maternal Q 
fever screening and treatment program seems to be crucial for a women’s 
intention to participate. This is in line with the finding that response efficacy 
influences adherence to medical treatment regimens in general.27 In our study, 
about one quarter of the women who did not intend to participate had 
doubts about the side effects of the antibiotic treatment or was afraid of the 
consequences of participation. The importance of such appraised efficacy 
and convenience would dictate that information materials about Q fever 
screening should be very clear about the likelihood of the expected benefits 
and possible downsides of screening and treatment.  
While the women’s level of knowledge about Q fever had no 
independent influence on their decision regarding participation in the 
screening and treatment program, it had an indirect impact on this decision 
by influencing the appraisal of the program efficacy and convenience. 
Pregnant women who knew more about Q fever appraised the efficacy and 
convenience of the screening and treatment program more positively. This 
finding may reflect that awareness about Q fever and the potential of 
obstetric complications is generally limited. This is particularly illustrated by the 
commonly found incorrect assumption that Q fever during pregnancy would 
be invariably symptomatic. Such misconception would likely reduce the 
perceived need for serum screening unless a women experiences symptoms.  
The intention of pregnant women to participate in the screening and 
treatment program was not directly influenced by perceived risk, which is in 
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contrast with the positive effect of perceived risk on intentions and behaviours 
in numerous studies based on the protection motivation theory.27 However, 
women who perceived the risks of Q fever as higher had a more positive 
appraisal of the efficacy and convenience of the screening and treatment 
program. The finding that perceived Q fever risk and knowledge about Q fever 
in general and Q fever during pregnancy influenced the appraisal of these 
program characteristics, may suggest that for a new and somewhat unfamiliar 
disease pregnant women’s appraisal of the efficacy and convenience of 
screening and treatment may particularly be influenced by either having some 
basic knowledge about the disease or by perceiving it as relatively risky.  
The influences of other determinants on the intention to participate 
failed to reach statistical significance. Pregnant women’s trust in the 
communication and competence of health professionals and authorities did 
not affect the intention to participate in the program. This finding is in contrast 
with previous studies on trust and parental protective behaviour, for example in 
studies on MMR immunisation.14,15,28,29 In the present study, the pregnant 
women overall expressed a considerable level of trust about the topic in health 
professionals and authorities. Trust may therefore either play only a minor role in 
these decisions, or the trust may vary more when screening and treatment 
involve more well-known diseases.  
Pregnant women’s intention to participate in the screening and 
treatment program was also not influenced by Q fever exposure risk (based 
on, for instance, the proximity to an affected farm). This finding is in 
accordance with research on HIV maternal screening, as pregnant women 
exposed to few HIV risk factors did not differ in acceptance of screening with 
pregnant women exposed to multiple risk factors.30 Moreover, it has been 
argued that, compared to actual risk, perceived risk has more influence on the 
uptake of prenatal tests.9  
At this, our findings suggest that the relation between exposure risk 
and perceived risk is primarily a relative one. While women who were exposed 
to multiple risk factors perceived their risk of contracting Q fever as relatively 
higher compared to other pregnant women of the same age, their general risk 
perception about Q fever was similar. Although pregnant women thus seem 
well aware of their increased exposure risk, they may still perceive their total risk 
of subsequent obstetric complications in absolute terms as low.  
This study has some potential limitations. First, while the regional Q 
fever epidemic provided a unique opportunity for our study, the locally 
confined nature of this epidemic meant that a relatively small number of the 
respondents were available for recruitment in the study. In addition, the 
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response rates for the groups that were recruited via the midwives’ practices 
were fairly low compared with some other studies about attitudes towards 
prenatal screening.12,31 An important reason for this may lie in the passive 
recruitment approach of our study, which consisted merely of distributing 
information leaflets and involved no active recruitment or discussion about Q 
fever or the screening and treatment program during the actual consultation 
with the midwife. While the low response rate may limit the generalisability of 
our findings, the results show that the outcome measures were similar across 
the different response groups, suggesting that the web-based and paper-form 
group were comparable to the panel group which had a relatively high 
response rate. Moreover, the demographic and obstetric characteristics of the 
total sample are comparable to that of previous large and representative 
studies among pregnant women in The Netherlands12,32, although slightly more 
higher educated respondents were included in the study. This does not suggest 
that participation in this study was restricted to a specific subgroup of women. 
A second limitation may come from the fact that the respondents had to 
make a decision about participation in a hypothetical screening and 
treatment program. While this hypothetical nature could affect decision-
making, the high certainty that women expressed about their choice suggests 





This study demonstrates that the decision to participate in a new screening 
and treatment program for Q fever is firstly determined by the pregnant 
women’s appraisal of efficacy and convenience of the program. In turn, this 
appraisal is highly influenced by the prior knowledge that women have of the 
disease and by the risk they perceive it to carry for them and their child. 
Decisions were not influenced by actual exposure risk or by trust in health 
professionals and authorities. The success of implementing a screening and 
treatment program for Q fever may thus hinge on first the practical downsides 
and benefits of the program and second on securing that women are aware 
of the risks of the disease. 
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In The Netherlands, the number of notified human Q fever cases showed a 
steep increase over the last three years and is not expected to disappear in 
the next few years. Since vaccination might be an option to prevent Q fever 
cases in the general population, evidence is needed about its effectiveness. 
We therefore conducted a meta-analysis to determine the evidence base for 
effectiveness for Q fever vaccination in human populations. We calculated 
Mantel-Haenszel risk ratios and we used the following formula to calculate the 
vaccines effectiveness: (1 − mhRR) × 100%. Although individual and the pooled 
estimates showed a high effectiveness of Q fever vaccine, conclusions for the 
general population cannot be confidently drawn about vaccine effectiveness 
due to potential flaws in the design of the studies and the selected group of 
study participants. 
 







In The Netherlands, the number of notified human Q fever cases, caused by 
Coxiella burnetii, showed a steep increase over the last three years, with 168 
versus 2357 new cases in 2007 and 2009, respectively.1 Despite many measures 
being taken to prevent further transmission in The Netherlands, it can be 
expected that Q fever cases will occur in the next few years.1 This is a serious 
hazard not only for those at high occupational risk to get the disease, but also 
to other vulnerable groups, such as pregnant women, immunocompromised 
persons and those with pre-existing cardiac valve- or vessel-defects.2 
Currently only one Q fever vaccine (Q-Vax, Commonwealth Serum 
Laboratories Limited) is available for humans. This vaccine is registered in 
Australia and is there used in the population that has the highest occupational 
risk (mainly abattoir workers). Since vaccination with Q fever vaccine might be 
an option to prevent symptomatic and asymptomatic cases of Q fever in the 
general population, evidence is needed about its effectiveness. In 2007, a 
paper discussing the effectiveness of human Q fever vaccine was published.3 
However, although this study gave a good overview of literature, it did not aim 
to conduct a systematic analysis of current evidence for Q fever vaccine 
effectiveness. 
We therefore conducted a meta-analysis to determine the evidence 
for the effectiveness of Q fever vaccination in humans in a systematic way. 
Furthermore, as studies on the effectiveness of Q fever vaccination were often 
small and probably biased, we aimed to assess bias by using the assessment 





A review of literature was done by searching PubMed and the references of 
included papers. Our search was limited to human studies in the English 
language. The search strategy was: ((Q fever OR Coxiella burnetii OR C. 
burnetii) AND (vaccination OR vaccine OR immunised OR immunisation)). First 
we pre-screened the titles and the abstracts; afterwards the eligibility of the 
studies was judged by reading the full-text. Only the studies that used Q fever 
vaccine in human and gave information about the clinical outcome and 
reported the raw data were included in the analysis. The final analysis was 
performed on the effectiveness of Q-Vax (CSL Limited) vaccine. 
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The design and possible limitations of the studies were assessed using criteria for 
randomised controlled trials4 and longitudinal non-randomised observational 
studies.5 As the main possible limitations we considered bias because of 
information, selection or confounding, which may lead to the over- or 
underestimation of the vaccine effectiveness. 
The Mantel-Haenszel risk ratio (mhRR) was calculated after pooling the 
raw data by using Episheet by Rothman.6,7 Vaccine effectiveness was 





Results of the search 
The first search resulted in more than a hundred hits. Only five articles met our 
inclusion criteria, and three extra papers were included after screening the 
references (Fig. 1). We had to exclude one paper8 that described an interim 
analysis as we included the complete study in our meta-analysis.9 Finally, our 
search resulted in seven studies containing the raw data about the 
effectiveness of the Q fever vaccine.9-15 Four of them contained the raw data 
about the effectiveness of Q-Vax (CSL Limited).9,10,13,15 
We included three retrospective cohort studies10,13,14, one prospective cohort 
study9, one randomised controlled trial15 and two experimental studies.11,12 
Except for the volunteers in the experimental studies, the study population 
consisted of persons who are at risk to get Q fever due to their profession, 
mostly abattoir workers and laboratory staff. 
 
The summary of the included studies can be found in Table 1.  
 
Assessment of vaccine effectiveness 
All of the studies showed a protective effect of the vaccine against Q fever 
(ranged between 91 and 100%). The overall effectiveness of the vaccine as 
calculated after pooling the raw data was 97% (95% confidence interval 94–
99%). 
The incubation time of Q fever is around 15 days. Therefore, those who 
developed clinical signs and symptoms of Q fever within 15 days after 
vaccination could be considered to be vaccinated within the incubation time 
of a natural infection. After excluding those cases, the vaccine effectiveness 
increased to 99% (95% confidence interval 96–99.7%). 





The effectiveness of Q-Vax (CSL Limited) vaccine was 98% (95% confidence 
interval 94–99%), and reached 100% after excluding the cases that occurred 
within 15 days after vaccination. 
 





























Assessment of bias 
One of the problems in the reviewed studies was possible bias due to the 
inclusion and exclusion criteria of vaccinees and nonvaccinees. In six of the 
reviewed studies the subjects were excluded from receiving Q fever 
vaccination when they had a positive antibody titre (CF titre ≥ 2.5) and/or 
positive skin test9,10,12,13,14,15; however there were exceptions and in some cases 
Records identified through 
database searching  
(n=118) 
Records screened for the title 
and the abstract 
(n=5) 
 




Studies included in quantitative 




through references  
(n=3) 
Full-text articles excluded  
(n=1) 
 
Studies included in quantitative 




the thresholds of serological and/or skin tests were not given.10,11,12,14 In three 
studies the inclusion and exclusion criteria for nonvaccinees were not given or 
it was different from the criteria used for vaccines.10,11,13 The inclusion of skin- 
and/or seropositive nonvaccinees might have led to underestimation of 
vaccine effectiveness as persons with positive markers are thought not to be at 
risk for Q fever infection. 
Furthermore, vague or even absent case definition might have led to 
both under- and overestimation of vaccine effectiveness due to lack of 
objective assessment. Only in one of the reviewed studies Q fever case 
definition was properly described and included both a list of clinical symptoms 
and the cut-off values for serological markers.13 Three studies also used 
serological markers to confirm suspected Q fever cases10,11,15; however the 
detailed description, including the list of symptoms and the cut-off points of 
serological markers was missing. A couple of studies did not provide any case 
definition. Only one of the reviewed studies was a blinded study.13 
The absence of the description of the baseline characteristics of both 
vaccinees and nonvaccinees might have led to bias as well. The description of 
baseline characteristics, such as gender or age, of vaccinees and 
nonvaccinees was poor or absent in six studies.10-15 For example, according to 
the National Q fever management program in Australia, the incidence and 
vaccination against Q fever is higher in males than in females.16 There is 
already some evidence from animal studies that females are less susceptible to 
Q fever infection than males due to female hormones.17 Such differences in the 
distribution of gender between vaccinees and nonvaccinees at baseline 
therefore might lead to bias. Only one of the reviewed studies provided a 





Individual studies showed that the effectiveness of the vaccine against Q fever 
is very high, without exceptions.9-15 The same high vaccine effectiveness was 
found after pooling the raw data. Even when cases that occurred within 15 
days after vaccination were included, the vaccine effectiveness was very 
high. However, the designs of the included studies had some potential flaws. 
Different inclusion and exclusion criteria for vaccines and 
nonvaccinees, inclusion of seropositive nonvaccinees, vague or absent Q 
fever case definition, and differences in baseline characteristics of vaccinees 





and nonvaccinees might have led to biased results of Q fever vaccine 
effectiveness. 
Another major problem was the selected study sample: there were 
two studies performed on volunteers, four of the studies focused on abattoir 
workers and one study focused on laboratory staff. Although information about 
the demographic characteristics was limited, the study sample was relatively 
young. At least in three of the reviewed studies the mean age was around 30 
years.9,10,13. Furthermore, the authors of the reviewed studies did not give 
information about the health status of the study participants. Still, as the study 
subjects were abattoir workers, laboratory staff and volunteers, it seems likely 
that they were relatively healthy. This creates problems to generalise the results 
in different populations. Additionally, it is unclear for how long the vaccine is 
protective against Q fever, and whether this protection is the result of 
vaccination in combination with a constant exposure to Coxiella burnetii. It 
was shown that the number of Q fever cases decreased with longer 





In all, the vaccine effectiveness in groups with a high risk for Q fever seems to 
be very high. However, due to the selected study population and the absence 
of a proper description of the studied samples and study procedures, it is not 
possible to generalise our results and draw conclusion about the effectiveness 
of Q fever vaccine in the general population or in specific groups of patients. 
One of the important goals for the future should be decreasing Q fever 
incidence and prevention of related complications in persons who are not at 
constant exposure, but might be more vulnerable, such as pregnant women, 
immunocompromised persons or those with pre-existing cardiac valve- or 
vessel-defects. 
It seems likely that the vaccine against Q fever might decrease the 
incidence of Q fever in these specific groups and in the general population as 
well. However more blinded, randomised and unbiased research about its 








CFT, Complement Fixation Test; IFT, Immunofluorescence Test.  
a These studies are described in review papers by other authors.12,14   
b After excluding those who got ill within 15 days after receiving Q fever vaccine. 






Table 1.  Description of studies included into meta-analysis.  





(3 batches of 30 µg and 1 
batch of 20 µg ) 
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Experimental study Retrospective cohort study 
Intervention for 
control group 
- - - 
Setting, study 
population 
3 Australian abattoirs, 
workers 




for  vaccinees  
Exclusion: positive 
serology (CF titre >=2.5)  
or skin test positive 
(presence of induration 
at 5-7 days); with a few 
exceptions 
None Inclusion: negative serology 
(CF titer <2.5) and skin test 







Not given, but most likely 
both, who have positive 
and negative markers for 
Q-fever  
None None 
Case definition  “the pattern of 
symptoms and signs 
conformed to the 
description of clinical Q 
fever” and “serological 
evidence indicating 
current or quite recent 
infection with C. burnetii” 




Confirmed case: ≥4 increase 
in antibody titre to phase II 
antigen (AG) by CFT or a 
positive IgM titer (≥80) to 
phase II AG by IFT. 
Suspected case: At least 4 
of the following symptoms: 
fever, sweats, rigorous, 
fatigue, headache, 
myalgia, arthralgia, cough; 
serological tests negative or 
not available. 







Number of cases 
among 
nonvaccinees 
55/1365 8/10 7/68 
 
Effectiveness 
(RR, CI 95%) 
98% (92%-99%) 91% (64%-98%) 100% 
Effectivenessb 100% - - 
Limitations 1. Vague definition of 
cases 
2. Exceptions in 
inclusion/exclusion of 
cases 
3. No sufficient description 
of  the baseline 
characteristics  of 
vaccinees and 
nonvaccinees 
1. Vague definition of cases 
2. No sufficient description of 
the baseline characteristics 
of vaccinees and 
nonvaccinees 
3. No randomisation or 
allocation procedures 
described 
4. No pre-vaccination 
screening 
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 Both; but possibility to 
see the raw data with 
the same inclusion 
criteria as for cases 
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 97% (88%-99%) 100% 97% (88%-99%) 100% 
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1. Insufficient case 
definition 
2. No information 




3. No thresholds for 
skin tests 
1. Insufficient case 
definition 
2. No information about 
the baseline 
characteristics  of 
vaccinees and 
nonvaccinees 
3. Inclusion criteria  are 
not sufficiently 
described  
1. No information about 
the baseline 
characteristics 
2. Allocation procedure is 
not described 
3. Case definition is not 
sufficiently described 
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GENERAL DISCUSSION - LESSONS FROM THE DUTCH EPIDEMIC 
 
Between 2007 and 2010 The Netherlands faced an enormous outbreak of Q 
fever, a zoonosis caused by the bacterium Coxiella burnetii.1 This outbreak was 
a catastrophe for both human and veterinary health. Within a period of only 
four years over 4000 human symptomatic acute Q fever cases were notified, of 
whom at least 25 died.2 Furthermore, long-term consequences of acute illness 
proved to be significant, as shown by a study among 515 acute Q fever 
patients. Two third of these patients suffered from functional impairment 
(mainly because of fatigue) and impaired quality of life 12 to 26 months after 
the onset of illness.3 Furthermore, hospitals in the epicentrum of the epidemic 
are increasingly confronted with patients with highly probable and proven 
chronic Q fever. In the veterinary field culling of thousands of pregnant goats 
and sheep in the first half of 2010 had an extreme impact on the psychological 
and financial situation of farmers and their families.4 Good surveillance and 
cooperation between the Ministry of Health, Welfare and Sport and the Ministry 
of Agriculture was crucial to curb the epidemic. Apart from these challenges, 
the unique Dutch situation gave researchers the opportunity to gain 
knowledge about different aspects of this relatively rare infectious disease. 
Since 2008 over twenty PhD programs were started covering many of these 
aspects. However, research during an epidemic is challenging. On one hand 
time is scarce because policy makers and clinicians need evidence to support 
their practices. On the other hand a high level of evidence should be pursued 
by performing time-consuming prospective trials, so that recommendations 
can be immediately implemented in practice. Besides this, during the Dutch 
epidemic, public pressure asked officials to take several immediate actions 
that were not evidence based at that moment. These actions had a great 
impact on the epidemic and therefore also on several studies running in 2009 
and 2010, the years in which the epidemic was curbed. Finally, besides 
answers, most of the time research also produces many new questions; a 
‘’flywheel’’. This is also what we experienced; we learned a lot about the 
consequences of Q fever during pregnancy. We got some answers but 
remained with many new questions too. 
 
The problem – risks of Q fever during pregnancy 
Almost all knowledge concerning the effects of Q fever during pregnancy that 
was available at the start of the Dutch epidemic derived from several case-
reports and case series written by the French group of Raoult.5,6 Their 
retrospective landmark study, performed between 1991 and 2005, showed a 





devastating association between insufficiently treated Q fever during 
pregnancy – both symptomatic and asymptomatic -  and several obstetric 
and maternal complications.5 Furthermore in a Canadian cohort study in 
collaboration with the French group, an association was found between C. 
burnetii seropositivity in parturient women and adverse pregnancy outcomes, 
further underscoring the risks of asymptomatic infection.7 Although the results of 
especially the retrospective study needed to be cautiously interpreted as the 
study design has probably led to an overestimation of risks, from the start of the 
Dutch Q fever epidemic pregnant women were considered as a risk group by 
health authorities and policy makers.8 When the outbreak still seemed to be 
located in a very restricted area in 2007, already all pregnant women were 
informed and offered serological screening.9 However, based on the available 
reports at that time, the Health Council of The Netherlands concluded that 
evidence was insufficient to promote large-scale routine screening when the 
epidemic spread to adjacent areas the next year. Instead, they ordered that 
rigorous studies to assess the effectiveness of such serological screening 
programs amongst pregnant women were required.8 We subscribed this 
conclusion in Chapter 3 of this thesis after scrutinising the available evidence 
with criteria developed by the World Health Organization. 
 
The Dutch outbreak has given several new insights into the C. burnetii-
associated risks during pregnancy. The first Dutch publication focusing on this 
subject was published in March 2009. Women in high, middle and low-risk areas 
for Q fever were serologically screened for the presence of C. burnetii 
antibodies to estimate seroprevalences. Since the majority was screened 
anonymously, in only three cases with an acute infection data on clinical 
outcome were available.  Two of these three women were treated with 
cotrimoxazole during the remainder of the pregnancy. All women were 
asymptomatic, had uncomplicated pregnancies and deliveries. Furthermore, 
polymerase chain reaction (PCR) for C. burnetii DNA on birth products were all 
negative.9 Two other case reports of pregnant women with an active infection 
were published almost two years later. The first concerned an asymptomatic 
woman who was routinely screened at 38 weeks of gestation because of a Q 
fever outbreak near her work. Acute C. burnetii infection was diagnosed and 
therefore delivery was induced to prevent possible complications. A healthy 
infant was born and PCR on birth products was negative.10 The second case 
concerned a woman in whom the pregnancy was complicated by a 
symptomatic chronic Q fever infection, for which she was extensively treated. 
Finally, also this pregnancy led to the birth of a healthy child (Chapter 2). A 
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larger study was performed by Van der Hoek et al., who retrospectively 
screened 1646 sera from pregnant women in Q fever high-risk areas for the 
presence of immunoglobulin (Ig)M and IgG phase II. Seropositivity, suggesting 
either previous or recent infection, was not associated with any adverse 
pregnancy outcome.11 The results of our clustered randomised controlled trial, 
presented in Chapter 4, 5 and 6, confirm these results. Absence of significant 
placental pathology in asymptomatic seropositive cases (Chapter 7) might 
explain this favourable clinical outcome.   
 
In conclusion, the first lesson we can learn from the Dutch Q fever epidemic is 
that asymptomatic C. burnetii seropositivity during pregnancy turned out not 
to be as hazardous as was thought based on previous literature. There are 
three main explanations for the discrepancy between our findings and the 
available literature. First of all it is hypothesised that differences in virulence 
between C. burnetii strains involved in the different outbreaks exist.12 
Genotyping of Dutch samples is ongoing and shows that at least five strains 
were involved in the Dutch outbreak, which implies that environmental 
circumstances (such as high density of farms and people, dry periods in spring) 
favoured the Dutch Q fever spread rather than that one highly virulent C. 
burnetii strain was responsible.13 However, since in The Netherlands a relatively 
high number of chronic Q fever has been described in patients with 
aneurysms14, it can be hypothesised that the strains involved  are highly virulent 
for people with underlying vascular diseases at least. On the other hand, it 
might be hypothesised that pregnant women are relatively protected, 
although we do not have an explanation for this observation. Secondly, 
available studies in the literature used several different, mostly non-
commercial, serodiagnostic methods and cut-off values, probably influencing 
sensitivity and specificity (see further). While these first two explanations for the 
difference in study outcomes are mainly suggestive, a third reason seems most 
likely. This reason concerns a difference in study design between the landmark 
study of the group of Raoult5 and the recent prospective Dutch studies. The 
retrospective design of the French study may have led to selection bias by 
testing for C. burnetii infection after obstetric complications had occurred. This 
will have led to an overestimation of risks.  
The risks of symptomatic acute or chronic Q fever during pregnancy 
remain unclear, particularly because symptomatic pregnant cases are scarce, 
even after an enormous outbreak like the one in The Netherlands. The 
assumption that symptomatic Q fever during pregnancy may pose a risk to the 
pregnant women involved is underscored by the fact that the woman we 





describe in Chapter 2 is, to our knowledge, the youngest patient with chronic 
Q fever described in this epidemic. The published case reports and series 
focussing on symptomatic cases remain the best available protocols for 
management of these cases.     
  
The screening population 
Since the incidence of Q fever varies largely between regions and within a 
region varies between different time periods, the number of pregnant women 
needed to screen, to prevent one complication possibly caused by an 
infection with C. burnetii, fluctuates significantly. Our clustered randomised 
controlled trial (Chapter 4, 5 and 6) was performed in Q fever high-risk areas 
based on the incidence of notified Q fever cases in those regions in 2009 and 
the beginning of 2010. The high percentage of seropositive women (15%) 
agreed with the high level of endemicity in the study regions. Still, the 
prevalence of acute infection during the actual study period was very low and 
probably therefore the screening strategy was ineffective in reducing the risk of 
obstetric complications in seropositive women within this region. Logically, 
screening in an even lower-risk population would not be effective at all. 
Effectiveness in a higher risk population, e.g. pregnant women living within a 2 
to 5 kilometre zone around an infected farm1, with occupational hazard for Q 
fever or with complicated pregnancies, can not be excluded. Furthermore, we 
can also not exclude a benefical effect of routine screening of women in their 
first trimester of pregnancy, since in the clustered RCT (Chapter 4, 5, and 6) 
screening started at 20 weeks of gestation. However, a recent Danish study 
showed no association between C. burnetii infection and spontaneous 
abortion up to 22 weeks of gestation15, indicating that screening earlier in 
pregnancy would probably also be ineffective.  
 
The test and the treatment 
As already mentioned research provides some answers, but also generates 
many new questions. This proved certainly to be the case in the field of 
serological assays. The performance (sensitivity and specificity) of serological 
assays to diagnose acute disease is highly influenced by the incidence of the 
disease.16 With respect to the Dutch Q fever epidemic we can differentiate two 
time periods: the beginning of the outbreak and the end of the outbreak. At 
the beginning of the epidemic the performance of serological assays proved 
to be high, because the background seroprevalence was low in combination 
with a relatively high incidence.16 At the end of the epidemic, however, the 
background seroprevalence increased, as shown by de studies in Chapter 5 
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and 8 of this thesis and by several other studies.17,18 At the same time the 
incidence of acute infections decreased. These circumstances in combination 
with the fact that antibodies against C. burnetii remain present for months or 
even years, impeded interpretation of serological test results, with a possible 
increase of false-positive results. Besides these facts, the Dutch Q fever 
outbreak was felt a threat to several groups at risk and led to more awareness 
for Q fever among health care workers and the public. Therefore, many more 
(screening)tests were performed by patients with less specific or even without 
any symptoms. Due to these changes, cut-off values and interpretation of 
antibody profiles remain subject for debate. Many studies have been 
published in this field16,19-23 and its plausible that many more will follow. During 
pregnancy interpretation of serology is even more complicated, since two 
opposite theories exist with respect to (the extent of) antibody formation. The 
first theory includes the hypothesis that during pregnancy sex hormones cause 
shifts of immunity from cell mediated to humoral, which could lead to higher 
immunoglobulin levels at baseline and in response to infection.24,25 The 
opposite theory assumes that pregnancy causes a relative state of 
immunosuppression, since an attenuated antibody response against infectious 
diseases has been described.26 Possibly, these lower antibodies levels are 
caused by a higher distribution volume during pregnancy. Overall, it is clear 
that antibody responses in pregnancy require further investigation. 
 Randomised studies on the treatment of pregnant women with a C. 
burnetii infection have not been performed yet and probably never will. Since 
our clustered randomised trial (Chapter 4, 5 and 6) was a pragmatic study, 
decisions regarding the type and duration of antibiotic treatment in cases with 
an acute infection were made by the medical specialists involved. Treatment 
with cotrimoxazole for at least five weeks had been suggested to be the 
treatment of choice during pregnancy5 and was given to women in their 
second trimester of pregnancy (n=3). Women who were diagnosed in their 
third trimester received erythromycin (n=4), since cotrimoxazole is relatively 
contraindicated prior to delivery because of neonatal hyperbilirubinemia. 
Since the number of treated women in our study was small we are unable to 
draw conclusions about effectiveness and safety of these drugs. Rigorous 
studies on treatment during pregnancy are needed, mainly focusing on 
treatment of symptomatic Q fever.        
 
The costs 
Since, with the current economic situation, costs of healthcare are of 
increasing importance, we aimed to assess the cost-effectiveness of routine 





screening during pregnancy as well (Chapter 4). However, because there was 
no relevant clinical beneficial effect of screening, there was refrained of a 
rigorous cost-effectiveness study. Still, uncertainty in the result of the clinical 
outcome existed since the 95% confidence interval (CI) of the odds ratio 
included a risk reduction due to screening up to 40%. Therefore we performed 
an explorative cost-utility analysis in which we focused on preterm delivery.27 
Input data on the costs of healthcare were based on the Dutch 
reimbursement system, including the costs of screening, treatment of infected 
women and costs associated with a hospital delivery.28,29 Since Dutch data 
were lacking, costs of preterm delivery at different terms of pregnancy and the 
risk for severe outcome as well as the corresponding utilities of these outcomes 
were based on studies from the USA.30,31 Three outcome conditions were 
distinguished: normal health (utility=1), severe disability (utility=0.61) and dead 
(utility=0). The risks for very preterm delivery (<34 weeks of gestation), preterm 
delivery (<37 weeks of gestation) and at term delivery (≥37 weeks of gestation) 
per strategy were based on our trial data (1.5%, 3.9% and 94.6% for the 
intervention group and 1.2%, 4.9% and 93.9% for the control group, 
respectively). We used a decision-tree model to compare the screening and 
no-screening (control) strategy, developed and analysed with TreeAge Pro 
2011 (TreeAge Software, Williamstown, MA, USA). The intervention strategy 
turned out to be more costly (+€275.75) and slightly less effective (-0.000043 
quality adjusted life years (QALY)); screening was dominated by the no-
screening strategy. Probabilistic sensitivity analysis, using Monte Carlo Markov 
Chain (MCMC) with 10,000 iterations and a willingness to pay (WTP) of €50,000 
per QALY, showed a delta net monetary benefit (∆NMB) of - €274.51 (95% CI - 
€283.44 to - €265.57). The negative ∆NMB indicates that the screening strategy, 
under these circumstances and assumptions, is not cost-effective. 
No other studies have been reported on the cost-effectiveness of 
routine screening for C. burnetii infection during pregnancy so far. The lessons 
we can learn from the Dutch epidemic are therefore entirely based on the 
studies in this thesis. Although, in our cost-utility analysis a part of the input data 
on costs was based on American data and therefore possibly not entirely 
applicable to the Dutch situation, we may conclude that the screening 
strategy was obviously not cost-effective, based on the finding that the 






Since the success of a screening program is not only based on medical 
effectiveness but also on a successful implementation, willingness of pregnant 
women to participate is indispensable. In Chapter 5 we observed that despite 
the fact that the screening study was performed in a Q fever high-risk area the 
participation rate of pregnant women was low (20%). In Chapter 9 we 
identified the determinants of pregnant women’s decisions regarding 
participation in a (possible future) Q fever screening and treatment program. 
Although the intention to participate was already somewhat higher than in the 
screening trial, still almost 50% of the respondents did not intend to participate 
in such a program, which is low in comparison with the existing screening 
program for other infectious diseases during pregnancy.32 The sole determinant 
of a higher intended program uptake was a more positive appraisal of 
program efficacy and convenience. This appraisal in turn was associated with 
perceived risk and knowledge about Q fever during pregnancy. Since before 
the recent Dutch epidemic Q fever used to be a rare disease, lack of 
knowledge about possible consequences of Q fever during pregnancy could 
have played a major role in refusal of participation in the screening trial 
(Chapter 4, 5 and 6) or future screening programs (Chapter 9). In conclusion, 
these findings indicate that, at this moment, the acceptance of a preventive 
screening program among pregnant women might not be straightforward. 
 
Alternative methods 
While discussing the effectiveness of screening it is also important to pay 
attention to alternative methods to minimise C. burnetii associated 
complications. One of these methods, besides the most important veterinary 
measures to curb the epidemic4, could be human vaccination. In Chapter 10 
we performed a meta-analysis to assess the effectiveness of human Q fever 
vaccination. Partly based on this analysis the Health Council of The 
Netherlands advised the Ministry of Health, Welfare and Sport to start 
vaccination among patients at risk for chronic Q fever – including patients with 
cardiac valve diseases, congenital heart diseases, and vascular defects – as 
part of individual patient care. Vaccination of pregnant women however, was 
not advised because the producer of the vaccine dissuaded use during 
pregnancy since safety in this group had never been tested and could not be 
guaranteed.33  
In spring 2011 a vaccination campaign among the high-risk cardiac 
patients was started in the areas with the highest Q fever incidence. General 





practitioners and medical specialists identified 2688 patients at risk of whom 
907 refused vaccination or turned out to have no proper indication. The 
remaining 1781 patients received a skin test and were screened for the 
presence of antibodies against C. burnetii, since vaccination of persons who 
have previously been exposed to C. burnetii may lead to serious adverse 
reactions. Of those patients 394 (22%) had a positive pre-vaccination test and 
were excluded, again pointing to the massive seroprevalence in this area. 
Another 21 patients declined. Finally, a total of 1366 patients were vaccinated 
with the Australian Q-vax® vaccine.34 Research is ongoing to determine 
vaccine efficacy and safety.34,35 
Overall, the human Q fever vaccination campaign is a clear example 
of immediate implementation of recommendations generated by research 
performed during the epidemic. Further research is required to determine 







Q fever and pregnancy 
This thesis predominantly focussed on the diagnosis and consequences of 
asymptomatic C. burnetii infection during pregnancy. Still, data on 
symptomatic Q fever during pregnancy remain scarce. Further research, 
preferably randomised controlled trials, should focus on the risks (both 
obstetrical and maternal), pathophysiology and treatment of symptomatic Q 
fever during pregnancy. Since these cases will be scarce, cooperation 
between different countries facing Q fever outbreaks is indispensible to create 
a large cohort of affected pregnant women. Central notification of Q fever 
affected pregnant women could also be useful. Animal models might be 
helpful in understanding pathophysiological mechanisms. If the risks of 
symptomatic Q fever during pregnancy turn out to be very high, research 
about preventive strategies like vaccinating of this specific group should be 
performed. 
 
Genotyping of Coxiella burnetii 
To gain insight into the differences in the magnitude and clinical 
consequences of C. burnetii infection between different outbreaks, 
genotyping of C. burnetii strains involved in the Dutch outbreak should be 
continued. The results should be compared with the genotypes of the strains 
involved in the previous outbreaks in other countries. When it can be proved 
that different genotypes have different clinical consequences, this probably 




Since the number of notified acute Q fever cases steeply decreased in The 
Netherlands since 2010, the focus will change from acute illness to long-term 
consequences of the disease. Reactivation of primary infections during 
pregnancy has been described in subsequent pregnancies.5 The incidence, 
risk factors and pathophysiological mechanisms of these reactivations are 
unknown. Also data on the follow-up of children from women with Q fever 
before or during pregnancy is lacking and should be subject of future 
research. Furthermore, chronic Q fever is estimated to become an enormous 
health problem, especially in patients with underlying cardiac valve or vascular 
diseases. Besides that, with the protocolised follow-up of acute Q fever 
patients, many serological profiles suggesting chronic infection will be found 





also in the absence of clinical signs and symptoms. The significance of these 
antibodies is unclear36 and requires further investigation. Finally, also other long-
term consequences, like chronic fatigue syndrome, need attention. Trials 
about the effectiveness of different types of treatment of patients with 
debilitating fatigue are already ongoing.37  
 
Prediction models 
To optimise individual patient care, prognostic models have to be developed 
to predict the response to treatment and the risk of complicated outcome 
after an acute (symptomatic) Q fever infection in both the general population 
and in risk groups like pregnant women. Prognostic modelling might also be 
helpful in predicting the magnitude of an outbreak, which is of great 
importance to policy makers worldwide. Input data for such prediction models 
are needed but require comprehensive and intensive research because large 











CONCLUSIONS AND RECOMMENDATIONS 
 
Although the Q fever epidemic was a disaster for both human and veterinary 
health, the unique Dutch situation gave researchers the opportunity to gain 
knowledge about different aspects of this relatively rare infectious disease. 
Asymptomatic C. burnetii seropositivity during pregnancy turned out not to be 
as hazardous as shown by previous research. Routine screening starting at 20 
weeks of gestation was not associated with a relevant reduction in obstetric 
complications in seropositive women and was not cost-effective. Furthermore, 
the intention of pregnant women to participate in a (future) screening 
program was low, which indicates that the acceptance of such a preventive 
program might not be straightforward and supports our notion that screening 
will probably be an ineffective strategy. Therefore, in the current setting, 
routine screening for C. burnetii infection of pregnant women living in Q fever 
high-risk areas should not be advised. The risks, treatment and pathophysiology 
of symptomatic acute or chronic Q fever require further investigation. 
Serodiagnosis of acute and chronic Q fever, especially during pregnancy, is 
challenging because the performance of serological assays is highly 
influenced by the a priori chances, cut-off values vary between settings and 
pregnancy is accompanied by immunological changes. Minimising C. burnetii 
associated complications is possible by human Q fever vaccination. However, 
in the Dutch vaccination campaign pregnant women were excluded due to 
lack of knowledge about safety. Although in The Netherlands the number of 
notified acute Q fever cases steeply decreased since 2010, the Q fever 
problem still deserves attention in the future, because large-scale long-term 
consequences including chronic Q fever and chronic fatigue syndrome are 
expected and other European countries are facing Q fever outbreaks as well. 
Consequences for women infected with C. burnetii during previous 
pregnancies may become clear during the coming years. Good surveillance 
and awareness remain of great important to signal possible unexpected 
consequences – both during pregnancy and in the general population – and 
new outbreaks.   
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Between 2007 and 2010 The Netherlands suffered from on enormous human Q 
fever outbreak with over 4000 notified cases. Q fever is a zoonosis, caused by 
the intracellular bacterium Coxiella burnetii. In the Dutch situation, especially 
infections in dairy goat and sheep are hypothesised to be the main sources of 
human infection. Peron-to-person spread is rare. Acute C. burnetii infection is 
characterised by fever, hepatitis or pneumonia, but remains asymptomatic in 
60% of the cases. The incubation period is one to three weeks. Since C. burnetii 
is highly infectious and cut-off values for serodiagnosis are inconsistent, 
diagnosing Q fever is difficult. Additive in serodiagnosis is the characteristic of 
C. burnetii of antigenetic phase variation. Depending on the duration of 
infection, antibodies against two phases of antigens are produced (first against 
phase II antigen, later against phase I). Therefore a distinction can be made 
between an acute, previous or chronic infection. Treatment of acute Q fever 
consists of doxycycline for at least two weeks. After an acute infection 1-5% of 
the patients develop chronic Q fever which is often complicated by 
endocarditis or infection of vascular structures. The risk of chronic Q fever has 
been reported to be increased in immunocompromised patients, patients with 
underlying cardiac valve or vascular diseases and pregnant women. In case of 
chronic Q fever long-term treatment with doxycycline in combination with 





Besides the possible increased risk of developing chronic Q fever, infection 
during pregnancy has been associated with obstetric complications including 
miscarriage, preterm delivery, intrauterine growth restriction, oligohydramnios 
and foetal death. Long-term treatment with cotrimoxazole (doxycycline and 
hydroxychloroquine are contraindicated from the second trimester of 
pregnancy) has been shown to decrease the risk of complicated outcome. 
Since up to 90% of the pregnant women with a C. burnetii infection remain 
asymptomatic, routine screening during pregnancy in endemic areas for Q 
fever could be of great value to prevent complications in this high-risk group, 
but evidence from randomised trials is lacking. The studies presented in this 
thesis aimed to provide evidence on this topic. Furthermore, related issues 
were discussed, including specificity of serodiagnosis, placental pathology, risk-






After a general introduction in Chapter 1, this thesis started with a case report 
concerning a 42-year old pregnant woman with chronic Q fever (Chapter 2). 
The patient suffered from a pneumonia caused by C. burnetii shortly before her 
third pregnancy. During regular serological follow-up 6 months after the 
primary infection chronic Q fever is diagnosed based on increasing titers of IgG 
phase I and II and a positive C. burnetii PCR in serum. Since there exists a 
contraindication for treatment with doxycycline, hydroxychloroquine and 
cotrimoxazole due to pregnancy and an allergy respectively, the patient is 
treated with erythromycin. She experiences many complaints of dyspnoea, 
fatigue and weight loss. Therefore at 38 weeks and two days of gestation labor 
is induced and a healthy boy with a normal birth weight is born. Evidence for 
endocarditis or infections of vascular structures is not found. 
 The literature shows that pregnant women have an increased risk to 
develop chronic Q fever after an acute infection. This is most likely due to the 
decreased cell-mediated immune response influenced by sex hormones. 
Furthermore, the placenta seems to be one of the target organs of C. burnetii, 
which might contribute to the increased risk during pregnancy.  
In conclusion, because of the increased risk of chronic Q fever, we 
advise to intensivate serological follow-up of pregnant women with acute Q 
fever shortly before or during pregnancy to create the possibility for early 
treatment. C. burnetii related obstetric complications do not have to occur, 
probably as a result of adequate antibiotic treatment. 
 
In Chapter 3 the Dutch Q fever outbreak and the concerns that raises among 
pregnant women and their caregivers has been put in a wider perspective. 
We applied the updated Wilson and Jungner criteria to systematically review 
the available evidence in the literature for routine screening for C. burnetii 
infection during pregnancy in Q fever high-risk areas. These criteria included, 
amongst others, judgment of relevance, quality of the screening methods, 
options for treatment and costs. Because of potential bias in the available 
studies too much uncertainty remained about the relevance and clinical 
consequences of C. burnetii infection during pregnancy. Furthermore, there 
was lack of consensus concerning screening methods and treatment options.  
Overall, more evidence about the effectiveness of a C. burnetii 
screening program, in addition to other Q fever preventative and controlling 
measures taken by the European countries, is needed before C. burnetii will 




In Chapter 4 the study protocol of the clustered randomised controlled trial 
(RCT) on the (cost)effectiveness of routine Q fever screening during pregnancy 
has been presented. Primary care midwife centres in Q fever high-risk areas 
were randomised to recruit pregnant women for either the intervention or for 
the control group. Randomisation was stratified for the number of goat farms in 
the municipality and by the size of the midwife centre. Pregnant women, 18 
years of age or older, with an estimated date of delivery between June 1st and 
December 31st 2010 were eligible for inclusion. Women who did not have 
access to internet and / or an email address, were unable to understand 
Dutch, unable to give informed consent, or had previously been tested positive 
for Q fever were excluded. All participating women were asked for a blood 
sampling between 20 and 32 weeks of gestation. In the intervention group 
these samples were analysed immediately for antibodies against C. burnetii 
(IgM and IgG, phase I and II) by indirect immunofluorescence assay (IFA). Titres 
≥ 1:32 were considered positive. In case of an acute or chronic C. burnetii 
infection, women were referred to an obstetrician, and intensified serological 
and obstetric follow-up with possible antibiotic treatment according to the 
local hospital protocol was given. In case of a previous infection serological 
analysis was repeated in the third trimester of pregnancy to exclude 
reactivation as part of a chronic infection. Serum samples of the control group 
were frozen for analysis after delivery similar to the intervention group. In case 
of a positive test, the participant’s general practitioner was advised to perform 
an extra serological analysis to exclude a chronic infection. 
 The primary endpoint was a composite measure of maternal (chronic 
infection) or obstetric complications (a child small for gestational age (SGA), 
preterm delivery or perinatal mortality) in seropositive women. Secondary 
outcome measures included fatigue and quality of life one month post partum 
and costs. In total, we needed 3400 participants to detect a risk reduction of at 
least 50%, which was defined as being clinically relevant (2-sided, α 0.05, β 
0.80). Analyses were performed according to the intention-to-screen principle. 
 
Chapter 5 reported the results of this clustered RCT. Between March and July 
2010 55 of the 99 eligible midwife centres were randomised; 27 were allocated 
to the intervention strategy and 28 to the control strategy. They supervised 6860 
eligible pregnant women, of which 1348 (20%) gave informed consent for 
participation. Of 536 women in the intervention group and 693 in the control 
group a blood sample was analysed. Fifteen percent in both groups was 
seropositive (previous or acute infection). Follow-up serology in the intervention 






(IgM present in the first screening sample) antibody titres did not increase and 
IgM was present as part of a previous infection. In 7 women in the intervention 
group an acute infection was diagnosed and antibiotic treatment during 
pregnancy was started. None of the participants in either of the two groups 
developed a chronic infection. 
 Screening during pregnancy starting at 20 weeks of gestation did not 
reduce the risk of obstetric complications in seropositive women (2.2% in the 
intervention and 1.4% in the control group, odds ratio (OR) 1.54 (95% 
confidence interval (CI) 0.60-3.96)). Furthermore, there was no difference in the 
risk of obstetric complications between seropositive and seronegative 
participants (12% (22/183) and 13% (133/1046) respectively, OR 0.94, 95% CI 
0.58-1.52). Participants of the intervention group scored significantly higher on 
the fatigue score one month post partum compared with the control group 
(14.6 ± 5.7 versus 13.5 ± 5.5, P<0.001).  
 The incidence of acute Q fever infections steeply declined since 2010. 
Inclusion of participants in the second half of 2010 would not have been 
informative and was perceived as unethical. Therefore, we did not reach our 
projected number of inclusions, but the lower estimate of the 95% CI (OR 0.60) 
of the primary outcome precludes the a priori defined 50% risk reduction in 
relevant outcomes.  
 In conclusion, screening during pregnancy starting at 20 weeks of 
gestation did not contribute to a relevant reduction of obstetric complications 
in seropositive women. Therefore, in the current setting, this study does not 
support routine screening for C. burnetii infection of pregnant women living in 
Q fever high-risk areas. 
 
Chapter 6 went more into depth by focusing on the role of positive C. burnetii 
serology in the prediction of obstetric complications. We aimed to assess the 
predictive value of C. burnetii serological status in addition to well-known risk 
factors for the development of obstetric complications. Women who 
participated in the clustered RCT discussed in Chapter 4 and 5 and who were 
not treated with antibiotics for a C. burnetii infection were included. An 
obstetric complication was defined as any SGA, preterm delivery and/or 
perinatal mortality. We used multiple logistic regression analysis to build two 
prediction models; in the base model we only included well-known risk factors 
like smoking, maternal age and obstetric history; secondly, we added C. 
burnetii serological status, to determine the contribution of this variable. The 
performance of the prediction models was assessed using receiver operating 
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characteristic (ROC) analysis and calibration. The validity of the two models 
was evaluated by bootstrap analysis. 
Overall, 1221 women were included, of which 152 (12.4%) developed 
an obstetric complication. The base model including well-known risk factors 
had good calibration (Hosmer-Lemeshow test P=0.49), but low predictive 
capacity (area under the ROC-curve (AUC) 0.68; 95% CI 0.63-0.72). 
Bootstrapping showed an AUC of 0.65, indicating good validity and absence 
of strong overfitting. Addition of C. burnetii serological status to the model did 
not improve its predictive value. 
 In conclusion, prediction of adverse obstetric outcomes in a first line, 
low-risk, healthy population is difficult. Knowledge of C. burnetii serological 
status does not contribute to a better prediction. 
 
The aim of Chapter 7 was to describe placental histopathology and clinical 
outcome in women with asymptomatic C. burnetii infection during pregnancy 
and to compare these cases with cases described in the literature. Five 
women with asymptomatic C. burnetii infection during pregnancy could be 
selected from the clustered RCT (Chapter 4 and 5). Placental examination 
showed a few scattered fibrotic villi, which could be a result of interruption of 
foetal blood flow or destruction of capillaries due to previous villitis. In none of 
the placentas C. burnetii could be detected with PCR. Four out of five women 
delivered at term from living children. The literature search resulted in four 
cases; all symptomatic. Severe placenta pathology including necrosis and 
active inflammation was described. Furthermore, in all four placenta’s C. 
burnetii could be detected. All pregnancies ended preterm and in two cases 
perinatal mortality occurred. 
In conclusion, asymptomatic and symptomatic C. burnetii infection 
during pregnancy are different entities with respect to placental 
histopathology and the risk of obstetric complications.  
 
Since acute Q fever during pregnancy is an indication for long-term antibiotic 
treatment, accurate IgM phase II assays are indispensable. The objectives of 
the study presented in Chapter 8 were therefore to describe the 
seroprevalences of the different antibodies (IgM and IgG, phase I and II) 
during pregnancy determined with IFA in a low and high-risk area for Q fever, 
and to estimate the specificity of the IgM phase II IFA during pregnancy. 
Samples from women from high-risk areas (n=1229) were selected from the 
clustered RCT (Chapter 4 and 5). Samples from women from low-risk areas 






Friesland Izore, The Netherlands, which stores sera of pregnant women drawn 
routinely as part of a screening program for infectious diseases. IFA was 
performed in one laboratory using a cut-off titre of 1:32.  
The overall C. burnetii seroprevalence in both groups of pregnant 
women from a high-risk and a low-risk area was high, being 15.2% and 11.1% 
respectively, mainly caused by a high prevalence of IgG phase II. All cases 
from low-risk areas were IgM phase II negative in contrast to a 4.3% prevalence 
in the high-risk areas (P=0.001), which indicates 100% specificity of IFA in the 
detection of IgM phase II, using a cut-off titre of 1:32. 
 
The aim of Chapter 9 was to identify the determinants of pregnant women’s 
decisions regarding participation in a possible future Q fever screening and 
treatment program. Therefore, 148 pregnant women living in Q fever high-risk 
areas filled out a questionnaire containing items concerning health behavior. 
Questions included, amongst others, intention to participate, Q fever exposure 
risk, perceived Q fever risk, trust in health professionals and authorities and 
disease-related knowledge. Fifty-six percent of the respondents intended to 
participate in the future screening and treatment program. The sole 
determinant of a higher intended program uptake was a more positive 
appraisal of program efficacy and convenience. This appraisal was in turn 
associated with perceived risk and knowledge.  
 In conclusion, women’s appraisal of program efficacy and 
convenience, their disease-related knowledge and perceived Q fever risk 
seem to be crucial for their intended program uptake. A successful 
implementation of a possible future Q fever screening and treatment program 
may thus depend on these determinants. 
 
In Chapter 10 we performed a meta-analysis to determine the effectiveness of 
human Q fever vaccination. Seven studies could be included, describing in 
total 3752 vaccinees and 1649 nonvaccinees, of which 9 and 81, respectively, 
developed Q fever. We calculated separate relative risks, the pooled Mantel-
Haenszel risk ratio (mhRR) and vaccines effectiveness ((1 − mhRR) × 100%). 
Furthermore, we assessed the amount of bias. Although the separate and the 
pooled estimates showed a very high vaccine effectiveness (91-100% and 97%, 
respectively), conclusions for the general population or of specific groups at 
risk, like pregnant women, cannot be confidently drawn due to the selected 
group of participants (mainly abattoir workers) and the potential flaws in the 















Van 2007 tot 2010 kampte Nederland met een Q-koortsuitbraak van 
ongekende omvang, met meer dan 4000 humane gevallen. Q-koorts is een 
infectieziekte die wordt veroorzaakt door de bacterie Coxiella burnetii. Het is 
een zoönose, wat betekent dat de bacterie verspreid wordt van dieren op 
mensen. Met name melkgeiten en –schapen zijn de bron van de humane 
besmettingen in Nederland. Besmetting van mens-op-mens is zeer zeldzaam. 
Een acute C. burnetii infectie wordt gekenmerkt door koorts, hepatitis of 
pneumonie, maar verloopt in 60% van de gevallen asymptomatisch. De 
incubatietijd is één tot drie weken. Het stellen van de diagnose Q-koorts is 
lastig, temeer omdat C. burnetii hooginfectieus is en afkapwaarden voor 
serodiagnostiek niet vaststaan. Bijdragend in de diagnostiek is de antigene 
variatie die C. burnetii vertoont. Afhankelijk van de duur van infectie 
produceert het lichaam antistoffen tegen antigenen in een bepaalde fase 
(eerst tegen fase II antigenen, vervolgens tegen fase I). Hierdoor is er een 
onderscheid te maken tussen een doorgemaakte infectie, acute infectie of 
chronische infectie. Na het stellen van de diagnose acute Q-koorts, bestaat 
de eerste keuze behandeling uit een kuur doxycycline voor minimaal twee 
weken. Een acute infectie leidt in 1-5% van de gevallen tot een chronisch 
ziektebeeld, waarbij endocarditis of infecties van vasculaire structuren kunnen 
ontstaan. De kans op het ontwikkelen van chronische Q-koorts wordt groter 
geacht bij immuungecompromitteerden, patiënten met pre-existent klep- of 
vaatlijden en zwangeren. Een langdurige behandeling met doxycycline 






Naast het waarschijnlijk verhoogde risico op chronische Q-koorts, veroorzaakt 
een C. burnetii infectie bij zwangeren mogelijk ook risico’s voor de foetus, 
voornamelijk bij infecties vroeg in de zwangerschap. Er zijn aanwijzingen in de 
internationale literatuur dat onbehandelde besmette zwangeren een 
verhoogd risico hebben op een miskraam, vroeggeboorte, groeivertraging, 
oligohydramnion en intra-uteriene vruchtdood. Een langdurige behandeling 
met co-trimoxazol (doxycycline en hydroxychloroquine zijn gecontraïndiceerd 
vanaf het tweede trimester van de zwangerschap) zou mogelijk dit risico 






Aangezien een C. burnetii infectie bij zwangeren in tot wel 90% van de 
gevallen asymptomatisch verloopt, zou routinematig screenen van zwangeren 
in risicogebieden voor Q-koorts mogelijk bij kunnen dragen aan een afname 
van Q-koorts gerelateerde complicaties. Gerandomiseerd onderzoek naar de 
effectiviteit van een dergelijke screening ontbreekt echter. Met de studies in 
dit proefschrift hebben we getracht dit vraagstuk op te lossen. Daarnaast 
kwamen er gelieerde facetten aanbod, waaronder de betrouwbaarheid van 
diagnostiek, placentapathologie, risicoperceptie en humane Q-koorts 
vaccinatie. 
 
Na een algemene introductie in Hoofdstuk 1, beschreven we in Hoofdstuk 2 
een casus betreffende een 42-jarige zwangere vrouw met chronische Q-koorts. 
Deze patiënte maakte vlak voor haar derde zwangerschap een pneumonie 
door veroorzaakt door C. burnetii. Bij de reguliere serologische follow-up 6 
maanden na de primaire infectie werd de diagnose chronische Q-koorts 
gesteld op basis van sterk stijgende IgG titers en een positieve C. burnetii PCR 
in serum. In verband met een contra-indicatie voor doxycycline, 
hydroxychloroquine en co-trimoxazol wegens de zwangerschap en een 
allergie, respectievelijk, werd de patiënte behandeld met erytromycine. 
Patiënte ervoer veel klachten van dyspnoe, vermoeidheid en gewichtsverlies. 
Op maternale indicatie werd de bevalling daarom bij een amenorroeduur van 
38 weken en 2 dagen ingeleid. Patiënte beviel uiteindelijk middels sectio 
caesarea van een gezonde zoon van 3850 gram. Aanwijzingen voor 
endocarditis of vasculaire infecties werden niet gevonden. 
Literatuuronderzoek laat zien dat het risico op een chronische Q-
koorts infectie tijdens de zwangerschap waarschijnlijk verhoogd is in verband 
met een afname van de celgemedieerde immuunrespons onder invloed van 
oestrogenen en progestagenen. Daarnaast is de placenta één van de 
doelwitorganen van C. burnetii, wat mogelijk bijdraagt aan het verhoogde 
risico bij zwangeren.  
Concluderend adviseren wij in verband met een verhoogd risico op 
chronische Q-koorts tijdens de zwangerschap, ook na een acute infectie vlak 
vóór de zwangerschap, de serologische controles te intensiveren, zodat indien 
noodzakelijk tijdig gestart kan worden met antibiotica. C. burnetii gerelateerde 
zwangerschapscomplicaties, zoals vroeggeboorte en groeivertraging, hoeven 
niet op te treden, mogelijk ten gevolge van adequate therapie. 
 
In Hoofdstuk 3 werd het onderwerp Q-koorts tijdens de zwangerschap in een 
breder perspectief geplaatst. We probeerden, onderbouwd met literatuur, de 
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vraag te beantwoorden of het zinvol is om zwangeren woonachtig in 
risicogebieden voor Q-koorts routinematig serologisch te screenen op een 
infectie met C. burnetii. Dit deden we aan de hand van de Wilson en Jungner 
criteria. Deze criteria werden in 1968 opgesteld om screeningsmethoden 
systematisch te kunnen beoordelen op onder andere relevantie, kwaliteit van 
opsporingsmethode, behandelbaarheid en kosten-baten. In de afgelopen 
jaren verschenen aanvullingen op deze criteria waarbij onder andere de 
geïnformeerde eigen keuze tot deelname en programma-evaluatie 
toegevoegd werden. Ook deze aanvullende criteria namen we mee in onze 
beoordeling.  
Vanwege potentiële bias in de beschikbare studies bestond er teveel 
onzekerheid over de incidentie en de gevolgen van onbehandelde C. burnetii 
infectie tijdens de zwangerschap. Daarnaast was er geen consensus over (de 
interpretatie van) de optimale screeningsmethode en behandeling.  
Concluderend is er meer onderzoek nodig naar de effectiviteit van 
een C. burnetii screeningsprogramma voordat deze infectieziekte een 
onderdeel zou kunnen worden van het huidige infectieziektescreenings- 
programma tijdens de zwangerschap.  
 
In Hoofdstuk 4 beschreven we het studieprotocol van de geclusterde 
gerandomiseerde gecontroleerde studie (RCT) naar de (kosten)effectiviteit 
van screenen op C. burnetii infectie tijdens de zwangerschap. Eerstelijns 
verloskundigenpraktijken in hoogrisicogebieden voor Q-koorts werden 
gerandomiseerd toegewezen aan de interventie of controle strategie. De 
randomisatie was gestratificeerd voor het aantal geitenbedrijven in de 
omgeving en de grootte van de verloskundigenpraktijk. Zwangere vrouwen 
onder controle van de deelnemende praktijken, van 18 jaar of ouder en met 
een a terme datum tussen 1 juni 2010 en 31 december 2010 waren geschikt 
voor inclusie. Vrouwen zonder toegang tot internet / e-mail, die eerder Q-
koorts positief waren getest, geen begrip hadden van de Nederlandse taal of 
geen geïnformeerde toestemming konden geven, werden geëxcludeerd.  
Alle deelnemende zwangeren werd verzocht om een buisje bloed af 
te laten nemen bij een amenorroeduur tussen 20 en 32 weken. Bij zwangeren 
onder controle bij een interventiepraktijk werd het serum direct geanalyseerd 
op te aanwezigheid van C. burnetii antistoffen (IgM fase I en II en IgG fase I en 
II) door middel van indirecte immunofluorescentie assay (IFA). Titers ≥ 1:32 
werden beschouwd als positief. In het geval van een acute of chronische 
infectie werd de zwangere vrouw verwezen naar een obstetricus voor 






ziekenhuisprotocol en geïntensiveerde zwangerschapscontroles. In het geval 
van een doorgemaakte infectie verrichtte de verloskundige een extra 
serologische controle in het derde trimester van de zwangerschap ter uitsluiting 
van een chronische infectie. De sera van zwangeren die onder controle waren 
bij een controlepraktijk werden ingevroren en post partum geanalyseerd, 
conform de methode van de interventiegroep. In geval van een positieve test 
werd de huisarts geadviseerd om een extra serologische controle te verrichten 
ter uitsluiting van een chronische infectie. 
De primaire uitkomstmaat was een samengestelde uitkomstmaat van 
een maternale (chronische infectie) of obstetrische complicatie 
(vroeggeboorte, dysmaturiteit of perinatale sterfte) bij C. burnetii seropositieve 
zwangeren. Secundaire uitkomstmaten betroffen moeheid en kwaliteit van 
leven één maand post partum en kosten. In totaal waren er 3400 zwangeren 
nodig om een reductie van de primaire uitkomstmaat van 50% aan te tonen, 
het op voorhand vastgestelde klinisch relevantie verschil (2-zijdige test, α 0,05, 
β 0,80). Analyses werden uitgevoerd volgens het intention-to-screen principe. 
 
In Hoofdstuk 5 werden vervolgens de resultaten besproken van deze 
geclusterde RCT. Tussen maart en juli 2010 werden er 55 van de 99 
verloskundigenpraktijken in risicogebieden voor Q-koorts gerandomiseerd 
toegewezen; 27 lootten voor de interventiestrategie en 28 voor de 
controlestrategie. Alle praktijken tezamen superviseerden 6860 zwangeren die 
voldeden aan de inclusiecriteria, van wie er 1348 (20%) wilden deelnemen. 
Vijfhonderdzesendertig zwangeren in de interventiegroep en 693 in de 
controlegroep lieten een bloedmonster afnemen, waarvan er in beide 
groepen 15% C. burnetii seropositief waren (doorgemaakte of acute infectie). 
Serologische follow-up in de interventiegroep toonde aan dat bij 77% (23/30) 
van de zwangeren met een verdenking op een acute infectie (IgM aanwezig 
in het eerste screeningsmonster) antistoftiters niet doorstegen en IgM aanwezig 
was in het kader van een doorgemaakte infectie. Bij 7 zwangeren in de 
interventiegroep (1,3%) werd de diagnose acute C. burnetii infectie gesteld en 
volgde een behandeling met antibiotica tijdens de zwangerschap. Geen van 
de zwangeren in beide groepen ontwikkelde een chronische infectie.  
Screenen tijdens de zwangerschap startend bij een amenorroeduur 
van 20 weken verlaagde het risico op obstetrische complicaties bij 
seropositieve zwangeren niet (2,2% in de interventiegroep en 1,4% in de 
controlegroep, odds ratio (OR) 1,54, 95% betrouwbaarheidinterval (BI) 0,60-
3,96). Daarnaast verschilde het percentage obstetrische complicaties tussen 
seropositieve en seronegatieve zwangeren niet (12% (22/183) en 13% 
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(133/1046) respectievelijk, OR 0,94, 95% BI 0,58-1,52). Zwangeren in de 
interventiegroep waren significant vermoeider één maand post partum dan 
de zwangeren in de controlegroep (score 14,6 ± 5,7 versus 13,5 ± 5,5, P<0,001). 
In 2010 daalde de incidentie van acute Q-koorts aanzienlijk. Inclusie 
van zwangeren in de tweede helft van 2010 zou daarom niet informatief zijn en 
werd als onethisch verondersteld. Daarom werd het beraamde aantal inclusies 
niet gehaald. Echter de laagste schatting van het 95% BI (OR 0,60) van de 
primaire uitkomstmaat sluit de op voorhand gedefinieerde klinisch relevante 
complicatiereductie van 50% uit. 
Concluderend leidt screenen tijdens de zwangerschap, startend bij 
een amenorroeduur van 20 weken, niet tot een relevante complicatiereductie 
bij seropositieve zwangeren. In de huidige situatie adviseren wij daarom om 
niet routinematig te screenen op de aanwezigheid van C. burnetii antistoffen 
bij zwangeren woonachtig in hoog risicogebieden voor Q-koorts.  
 
In Hoofdstuk 6 werd de betekenis van positieve C. burnetii serologie tijdens de 
zwangerschap verder uitgediept. Het doel van de studie was om te bepalen 
wat de additief voorspellende waarde was van de aanwezigheid van C. 
burnetii antistoffen tijdens de zwangerschap, naast bekende risicofactoren, op 
het ontwikkelen van obstetrische complicaties. Zwangeren die deelnamen 
aan de geclusterde RCT (Hoofdstuk 4 en 5) die niet behandeld waren met 
antibiotica voor een C. burnetii infectie, werden geïncludeerd. Een 
obstetrische complicatie was gedefinieerd als het optreden van 
vroeggeboorte en / of dysmaturiteit en / of perinatale sterfte. Er werden twee 
modellen gemaakt met behulp van meervoudige logistische regressie; in het 
eerste model werden alleen bekende risicofactoren zoals roken, maternale 
leeftijd en obstetrische voorgeschiedenis meegenomen; in het tweede model 
voegden we C. burnetii serologische status toe om de bijdrage van deze 
variabele te bepalen. De prestatie van de prognostische modellen werd 
beoordeeld door middel van receiver-operating-characteristic (ROC) analyse 
en een kalibratie. Interne validatie werd verricht door middel van 
bootstrapping.  
In totaal werden er 1221 vrouwen geïncludeerd, van wie er 152 
(12,4%) een obstetrische complicatie kregen. Het model met de bekende 
risicofactoren had een goede kalibratie (Hosmer-Lemeshow test P=0,49), maar 
de voorspellende capaciteit was laag (oppervlakte onder de ROC-curve 
(AUC) 0,68, 95% BI 0,63-0,72). Bootstrapping toonde met een AUC van 0,65, dat 






was. Het toevoegen van C. burnetii serologische status verbeterde de 
voorspellende capaciteit niet. 
Concluderend is het voorspellen van obstetrische complicaties in een 
cohort relatief gezonde eerstelijns zwangeren in hoogrisicogebieden voor Q-
koorts lastig. Kennis over C. burnetii antistofstatus draagt niet bij aan een 
betere voorspelling. 
 
Het doel van de studie beschreven in Hoofdstuk 7 was om de placenta 
histopathologie en de klinische uitkomsten te beschrijven van zwangeren die 
een asymptomatische C. burnetii infectie tijdens de zwangerschap hadden 
doorgemaakt en om deze resultaten te vergelijken met casus uit de literatuur. 
Vijf zwangeren met een asymptomatische C. burnetii infectie tijdens de 
zwangerschap konden worden geselecteerd uit de geclusterde RCT 
(Hoofdstuk 4 en 5). Histopathologisch onderzoek van de placenta’s toonde 
enkele fibrotische villi, wat een gevolg kan zijn van interruptie van de foetale 
doorbloeding of van destructie van capillairen ten gevolge van een 
doorgemaakte villitis. In geen van de placenta’s kon C. burnetii worden 
aangetoond middels PCR. Vier van de vijf zwangeren bevielen a term van een 
levend kind. Literatuuronderzoek resulteerde in vier casus; allen symptomatisch. 
Ernstige placentapathologie waaronder necrose en actieve inflammatie werd 
beschreven. Tevens kon in alle vier de placenta’s de aanwezigheid van C. 
burnetii worden aangetoond. Alle zwangerschappen eindigden preterm, 
waarbij er in twee gevallen sprake was van perinatale sterfte. 
 Concluderend zijn asymptomatische en symptomatische C. burnetii 
infectie tijdens de zwangerschap twee verschillende entiteiten ten aanzien 
van placentapathologie en het risico op obstetrische complicaties.  
  
Aangezien acute Q-koorts tijdens de zwangerschap een indicatie is voor 
langdurige antibiotische therapie, zijn betrouwbare diagnostische methoden, 
met name voor het aantonen van IgM fase II, onmisbaar. De doelen van de 
studie gepresenteerd in Hoofdstuk 8 waren daarom om de seroprevalenties 
van de verschillende antistoffen (IgM fase I en II en IgG fase I en II) bij 
zwangeren woonachtig in een hoog- en laagrisicogebied voor Q-koorts te 
bepalen met IFA en om een indruk te krijgen over de specificiteit van de IgM 
fase II IFA. Serum van zwangeren uit hoogrisicogebieden (n=1229) werd 
verkregen vanuit de geclusterde RCT (Hoofdstuk 4 en 5). Serum van 
zwangeren woonachtig in laagrisicogebieden (n=180) werd anoniem 
verkregen van Izore Centrum Infectieziekten Friesland. Dit centrum bewaart 
serum van zwangeren dat routinematig is verkregen als onderdeel van het 
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landelijke screenings-programma naar infectieziekten tijdens de 
zwangerschap. IFA werd verricht in één laboratorium gebruikmakende van 
een cut-off titer van 1:32. 
De totale C. burnetii seroprevalentie in zowel de zwangeren uit 
hoogrisicogebieden als in de zwangeren uit laagrisicogebieden was hoog - 
15,2% en 11,1%, respectievelijk – en werd voornamelijk veroorzaakt door een 
hoge prevalentie van IgG fase II. Alle zwangeren uit het laagrisicogebied 
waren IgM fase II negatief, in tegenstelling tot een 4,3% IgM fase II prevalentie 
in de hoogrisicogebieden (P=0,001). Hieruit blijkt dat IFA 100% specifiek is in de 
detectie van IgM fase II, indien er gebruik wordt gemaakt van een cut-off titer 
van 1:32.  
 
Het doel van Hoofdstuk 9 was om determinanten te identificeren die bepalend 
zijn in de beslissing van zwangere vrouwen om wel of niet deel te nemen aan 
een mogelijk toekomstig screen-en-behandel programma voor Q-koorts. 
Hiertoe vulden 148 zwangere vrouwen woonachtig in hoogrisicogebieden voor 
Q-koorts een vragenlijst in met items, geselecteerd op basis van de literatuur, 
aangaande gezondheidsgedrag. De vragen betroffen onder andere intentie 
tot participatie, het blootstellingsrisico, risicoperceptie, vertrouwen in 
zorgprofessionals en de overheid en ziekte-gerelateerde kennis. Zesenvijftig 
procent van de respondenten gaf aan deel te willen nemen aan het mogelijk 
toekomstige screen-en-behandel programma. De sleuteldeterminant voor 
intentie tot deelname was een positieve beoordeling van het programma 
aangaande werkzaamheid en gemak. Deze positieve beoordeling was 
geassocieerd met risicoperceptie en kennis. 
 Concluderend zijn een positieve beoordeling van programma-
werkzaamheid en –gemak, ziektegerelateerde kennis en Q-koorts specifieke 
risicoperceptie van zwangeren cruciaal voor de intentie tot deelname aan 
een screen-en-behandel programma. Om een succesvolle implementatie van 
een dergelijk programma te bewerkstelligen, dient daarom rekening te 
worden gehouden met deze determinanten.  
 
In Hoofdstuk 10 werd door middel van een meta-analyse de effectiviteit van 
humane Q-koorts vaccinatie onderzocht. Zeven studies konden worden 
geselecteerd, waarin in totaal 3752 mensen werden gevaccineerd en 1649 
mensen ongevaccineerd waren. Acht gevaccineerden ontwikkelde Q-koorts 
ten opzichte van 91 ongevaccineerden. We berekende afzonderlijke relatieve 
risico’s, de gepoolde ‘Mantel-Haenszel risk ratio (mhRR)’ en vaccineffectiviteit 






de afzonderlijke en gepoolde vaccineffectiviteit zeer hoog waren (91-100% en 
97%, respectievelijk), kunnen er geen conclusies over de vaccineffectiviteit in 
de algemene bevolking of in specifieke risicogroepen, zoals zwangere 
vrouwen, getrokken worden. Dit in verband met de zeer selecte 
onderzoekspopulatie (met name slachthuismedewerkers) en de gebreken in 
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Dit proefschrift was nooit tot stand gekomen zonder de hulp van velen. Nu 
eindelijk de kans om iedereen te bedanken voor de geleverde bijdrage, in wat 
voor vorm dan ook. 
 
Allereerst gaat mijn dank uit naar alle deelnemende verloskundigenpraktijken, 
verloskundig actieve huisartsenpraktijken, hun zwangeren en de ziekenhuizen 
waarnaar verwezen werd. Zonder jullie belangeloze deelname en inzet was 
het nooit gelukt om in korte tijd, onder druk van de Q-koorts epidemie, zoveel 
data te verzamelen en zoveel antwoorden te geven op grote vraagstukken. 
Tevens heb ik genoten van de Zuidelijke gastvrijheid en mooie tochten langs 
de Brabantse dorpen. Ik zie de bezoeken aan de eerstelijns praktijken als ware 
aanvulling op mijn carrière in de gynaecologie. Heel erg bedankt hiervoor! 
 
En dan achter de schermen: 
 
Prof. dr. E. Hak, beste Eelko, wat een geluk dat jij besloten had om de files van 
de randstad te verruilen voor het Noordelijke landschap. Ik ben met mijn neus 
in de boter gevallen met dit project, waarvoor jij de eerste opzet al gemaakt 
had tijdens jouw vorige werkzaamheden in Utrecht. Wel heb ik vaak de vraag 
gekregen waarom een arts-onderzoeker uit Groningen (!) een dergelijk project 
in het Zuiden coördineerde; zie hier de verklaring. Hartelijk dank voor jouw 
doorzettingsvermogen, met name bij het verkrijgen van goedkeuring van de 
METc. Tevens bedankt voor je vertrouwen een dergelijk project in alle vrijheid 
te mogen runnen en voor de korte lijnen tijdens de uitwerkfase van de 
manuscripten. Met trots ben ik jouw eerste promovenda. 
 
Prof. dr. J.G. Aarnoudse, beste Jan, jij belde mij tijdens mijn semi-arts stage bij 
de gynaecologie met de boodschap dat jij iets zeer belangrijks te melden 
had. Toch wel enigszins met knikkende knietjes begaf ik mij naar jouw kamer. 
Een aanbod voor dit onderzoek had ik nooit verwacht. Ik was op dat moment 
als een vis in het water in de kliniek en had het plan om na mijn co-schappen 
ANIOS te worden. Ik heb er echter geen moment spijt van gehad dat ik op je 
aanbod ben ingegaan. Bedankt voor deze unieke kans! Tevens wil ik je 
bedanken voor je frisse blik op momenten dat ik even door de bomen het bos 
niet meer zag en voor je hulp bij het oplossen van kleine crises in den lande. 
Met trost ben ik één van jouw laatste promovendi. 
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Dr. A.C.A.P. Leenders, beste Sander, met open armen ben ik ontvangen bij 
jullie op het lab in Den Bosch. Ondanks de enorme drukte vanwege de Q-
koorts epidemie wist jij altijd een gaatje te vinden om mij uitleg te geven over 
alle ingewikkelde vormen van diagnostiek en om manuscripten van gedegen 
commentaar te voorzien. Erg prettig om jou als expert in het team te hebben. 
Daarnaast wil ik je bedanken voor alle gezellige momenten, bij jullie op het 
lab, via de telefoon en tijdens het congres van de ECDC in Lissabon. Ik heb 
veel van je geleerd, waarvoor heel veel dank!  
 
Dr. C.J.C.M. Hamilton, beste Carl, wat fijn om jou als echte clinicus erbij te 
hebben, zowel in de opzetfase als in de uitwerkfase van de studie. Ik heb 
dankbaar gebruik gemaakt van jouw kennis op het gebied van de obstetrie 
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de toekomst nog eens op klinisch vlak zouden kruisen. 
  
Dr. W. van der Hoek, beste Wim, bedankt voor het feit dat dankzij jou de lijnen 
met het RIVM heel kort waren. Tevens bedankt voor de prettige samenwerking 
aan het project bij de Perinatale Registratie Nederland. Ik wens jou, Chantal 
en Marit heeft veel succes met de afronding. 
 
J.C.E. Meekelenkamp en L. van Lieverloo, beste Jamie en Linsey, zonder jullie 
inspanningen rondom de logistiek van alle diagnostiek in onze studies was er 
niets terecht gekomen van dit proefschrift. Ik heb erg veel bewondering voor 
het feit dat jullie ondanks de enorme drukte op jullie lab, altijd tijd wist te 
vinden om onze samples te analyseren en adequaat de uitkomst terug wist te 
rapporteren. Bedankt hiervoor! 
 
Ook wil ik de overige co-auteurs van de manuscripten in dit proefschrift 
bedanken, met name ook de mensen die in de vroege fase van studieopzet 
betrokken zijn geweest: Ingeborg Bart, Marc Bijl, Anne-Marie van Elsacker-
Niele, Giedre Gefenaite, Henk Groen, Lolkje de Jong-van den Berg, Janna 
Klein Breteler, Peter Lestrade, Jerome Lo Ten Foe, Glen Mithoe, Maarten 
Postma, Ariene Rietveld, Josien Riphagen-Dalhuisen, Peter Schneeberger, 
Liesbeth Schölvinck, Ronald Stolk, Bert Timmer en Esther de Vries. 
 
Alle logistiek rondom de RCT had ik niet kunnen doen zonder de hulp van het 
Trial Coordination Centre (TCC). Onderzoek doen in een epidemie betekent 





in goede banen te leiden. Mijn speciale dank gaat uit naar Namkje, Souaad, 
Ans, Bas, Jef, Bart, Klaas en Nick. 
 
En dan de meiden van de zwangeren-helpdesk: Barbara, Anja en Ilona. Wat 
waren jullie gedreven en wat was het leuk om jullie te begeleiden! Na een 
stoomcursus over Q-koorts, zwangerschap en alle aanverwante logistieke 
zaken functioneerden jullie als ware experts. Bedankt! Ik wens jullie heel veel 
succes met het afronden van jullie geneeskunde-studie. 
 
Het feit dat er verschillende instellingen bij de studies in dit proefschrift 
betrokken waren, vroeg om een eigen huisstijl. Ellen Spanjaard, ik wil je heel 
erg bedanken voor het gezicht dat jij ons gegeven hebt. Ik heb altijd erg 
prettig met je samengewerkt én heb veel van je geleerd over grafisch 
vormgeven, een vakgebied waarvan ik me nooit had gerealiseerd dat het zo 
veelzijdig en boeiend zou zijn. 
 
In de betrokkenheid bij een drietal afdelingen – Obstetrie en Gynaecologie en 
Epidemiologie van het UMCG en Farmacie, Farmaco-Epidemiology & 
Farmaco-Economie van de Rijksuniversiteit Groningen – schuilt het gevaar dat 
je bij geen van de afdeling echt hoort. Echter, dankzij de prettige 
samenwerking met alle medewerkers en de verschillende secretariaten voelde 
ik mij overal thuis en welkom. Bedankt hiervoor! In het bijzonder wil ik Gert 
Dijkstra bedanken voor het regelen van de financiële zaken. Declaraties van 
gemaakte kosten door mijzelf maar ook door deelneemsters en derden 
werden altijd zeer vlot verwerkt. Super!  
  
Mijn dagen in het ‘’onderzoekshok Y4.240’’ werden gekleurd door mijn 
(gang)collega’s van de gynaecologie: Aniek, Annet, Anne Marijn, Catharina, 
Elsbeth, Ineke, Ingrid, Irene, Jelmer, Kim, Maartje, Marjon, Marloes, Meike, 
Merel, Natalia, Renée, Renske, Teelkien, Titia en Welmoed. Bedankt voor de 
gezelligheid, hulp, interesse, liters thee en koffie en vrijdagmiddagborrels! En 
ook mijn onderzoekscollega’s van de epidemiologie en farmacie, Giedre, Hoa, 
Josien, Lilian, Petros en Stefan, bedankt! 
 
Ik was nooit aan een promotietraject begonnen zonder de enthousiaste 
begeleiding tijdens mijn wetenschappelijke stage bij de nefrologie en 
longtransplantatie. Prof. G.J. Navis, Prof. W.J. van Son, Dr. M.A.J. Seelen en Dr. 
W. van der Bij, beste Gerjan, Willem, Marc en Wim, heel erg bedankt voor het 
naar boven halen van mijn wetenschappelijke interesse. Ondanks dat mijn hart 
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bij de gynaecologie ligt en niet bij de interne geneeskunde, had ik de 
leerzame tijd bij jullie niet willen missen. Daarnaast heb ik oneindig veel 
gezellige momenten met de ‘’Nefronerds’’ mogen beleven: Femke, Folkert, 
Mieneke, Jan, Hilde, Titia, Leendert, Rutger, Else, Arjan, Steef, Maartje, Solmaz, 
Ferdau, Esther, Lieneke en Wendy bedankt! 
 
Ook mijn twintigtal ‘’Q-koorts collega-promovendi’’ in de rest van het land wil 
ik bedanken voor de nuttige bijeenkomsten en gezellige momenten op het 
RIVM. Succes met de afronding van jullie projecten! 
 
Ondanks dat met het schrijven van dit dankwoord mijn promotieonderzoek 
weer even helemaal tot leven komt, staat op dit moment mijn werkende leven 
in het teken van de kliniek. Prof. M.J.E. Mourits en prof. P.P. van den Berg, beste 
Marian en Paul, hartelijk dank dat jullie mij op het juiste moment de juiste 
stappen hebben laten zetten. Tevens wil ik al mijn huidige collega’s in het 
Medisch Spectrum Twente bedanken voor dit geweldige eerste jaar als AIOS 
gynaecologie. 
 
Lieve vrienden, ik mag dan soms een workaholic zijn, zonder jullie gezelligheid, 
sportieve en ontspannende momenten, etentjes, borrels en logeerpartijen in 
Zuidelijk Nederland was er niets terecht gekomen van dit proefschrift. Van jullie 
wordt ik blij! Anne Chris, Agnes, Marjolein, Nine, Janke, Pembegul, Iris, Maike, 
Imke, Annemarie, Kim, Anneke, Dorien, Maartje, Margriet, Janien, Welmoed, 
Femke, Saskia, Janieke, Judith, Karen, Monique, Sabine, Anouk, Hilda en de 
roeidames en coach Klaas van NSNM: dank jullie wel hiervoor! In het bijzonder 
wil ik Tsjitske bedanken voor het feit dat jij op deze speciale dag aan mijn zij wil 
staan als paranimf.  
 
Lieve schoonfamilie, Raymond, Margriet, Lizette, Hanneke, Francis, Peter Paul 
en de kids Pieter en Jacob. Ik heb het enorm met jullie getroffen. Hartelijk dank 
voor jullie gastvrijheid, gezelligheid, interesse én hulp met de bouw. Fijn om nu 
ook familie in het Noorden van het land te hebben! 
 
Lieve familie, te groot om alle namen te noemen. Ik heb dankbaar gebruik 
gemaakt van jullie woonplaatsen en gastvrijheid overal in Nederland én in de 
rest van de wereld. Van Rotterdam, tot Lissabon en Perth; altijd was een 
congresbezoek wel te combineren met een familiebezoek. Mijn speciale dank 
gaat uit naar Opa en Oma Rouwet en Paul en José op de Lindehoeve in 





overnachtingen in het Zuiden van het land. Ondanks dat Oma deze 
bijzondere dag niet meer mee zal maken, weet ik dat u erbij zult zijn. Ik ben erg 
blij dat ik mede door het onderzoek zoveel van uw laatste jaren heb kunnen 
en mogen genieten.  
 
Lieve pap, mam, Twan, Renée en Pieter. Opgegroeid in een gezin waarbij 
dierziekten zoals mond- en klauwzeer en de varkenspest al vanaf jongs af aan 
soms het gesprek van de dag waren. Niet voor niets was dit onderzoek 
daarom op mijn lijf geschreven. Hartelijk dank voor jullie hulp, interesse, het 
warme nest, het heerlijke gevoel van thuis komen en de kansen om dromen 
waar te maken. En lieve zus Renée, ik ben erg blij dat ook jij mijn paranimf 
bent!   
 
Liefste Pieter, wat een onbeschrijflijk gevoel: gewoon weten dat het werkt, dat 
het klopt. Bedankt voor jouw onuitputtelijke steun, relativeringsvermogen, 
vriendschap en liefde. Door de week bouwen aan mijn proefschrift, in de 
avonden en weekenden aan jouw (ons!) huis. Samen met jou zou ik deze 
uitdaging nog wel 10 keer aan durven gaan. Waar zullen we mee beginnen? 
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